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ATR-FT-IR (attenuated total reflection-Fourier transform infra-red); 
APR (aprotinin); 
BSA (bovine serum albumin);  
CD (circular dichroism); 
DSC (differential scanning calorimetry);  
DTT (dithiothreitol); 
EDAC (N-(3-Dimethylaminopropyl)-N-ethyl carbodiimide hydrochloride); 
EI (enzyme inhibitor); 
GPC (gel permeation chromatography); 
GSH (reduced glutathione); 
HPLC (high-performance liquid chromatography); 
ICH (International Conference on Harmonisation); 
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NaAc (sodium acetate); 
NMR (nuclear magnetic resonance); 
PAF (peak adhesive force);  
PBS (phosphate buffered saline);  
PE (permeation enhancer); 
RH (relative humidity); 
SEM (scanning electron microscopy);  
TA (texture analyser);  
TGA (thermo-gravimetric analysis);  
TG (thioglycolic acid); 
TWA (total work of adhesion);  
XRPD (X-ray powder diffraction) 
  
ABSTRACT 
Stable mucoadhesive lyophilised chitosan and thiolated chitosan xerogels have been 
developed for potential delivery of proteins via the buccal mucosa. Membrane dialysis to 
eliminate sodium acetate (NaAc) and annealing during lyophilisation cycle (developed by 
differential scanning calorimetry; DSC) were critical for obtaining optimised porous xerogels. 
Based on characteristic performance and structural integrity, xerogels containing 10 % (per 
polymer weight) each of plasticizer (glycerol) and cryoprotectant (D-mannitol) were loaded 
with bovine serum albumin (BSA) and insulin (INS) as model drugs for further development. 
The optimised xerogels were loaded with enzyme inhibitor (EI) and permeation enhancer 
(PE) to enhance permeability of the buccal mucosa and backed with impervious ethylcellulose 
(EC) laminate to ensure unidirectional release. Characterisation of xerogels using 1HNMR 
and ATR-FT-IR spectroscopy confirmed the functional groups in chitosan and TG-chitosan. 
The amount of thiol groups on TG-FKLWRVDQZDVTXDQWLILHGE\(OOPDQ¶VUHDFWLRQ with polymer 
molecular weight monitoring by gel permeation chromatography (GPC). The stability of the 
secondary structures of BSA and INS were by ATR-FT-IR and circular dichroism (CD) while 
xerogel crystallinity was examined by XRPD. SEM micrographs showed highly porous 
xerogels due to annealing which allowed for high drug loading and hydration capacities of the 
dialysed and annealed xerogels which also exhibited optimal moisture content for maintaining 
protein stability. Disulphide bond formation in thiolated xerogels however limited the 
hydration capacity. Storage at 25 °C/ 60 % RH for six months led to protein instability while 
storage at 5 °C maintained protein stability. 2% mucin concentration was found optimum for 
mucoadhesion studies of the chitosan based xerogels. EI (glutathione; GSH and aprotinin; 
APR) effect on mucoadhesion was concentration dependent and inhibitor specific. In vitro 
BSA release profiles from annealed xerogels were similar and significantly higher than non-
annealed xerogels but were not affected by thiolation. Crystalline NaAc in the undialysed 
xerogel led to a three-fold reduction in BSA release. Significant reductions in BSA and INS 
release were also observed with the addition of EIs to TG-chitosan-BSA and TG-chitosan-
INS xerogel respectively. The drug dissolution data from xerogels fitted best with model 
dependent First order, Hixson-Crowell and Korsmeyer-Peppas equations. PeUPHDWLRQVWXGLHV¶
using EpiOralTM showed 12- to 14-fold increase in BSA permeation but was reduced by GSH 
for both BSA and INS loaded xerogels. APR containing xerogel enhanced INS permeation 
through sheep buccal membrane and demonstrated a good linear correlation with EpiOralTM. 
These results demonstrate the potential application of lyophilised chitosan and thiolated 
chitosan xerogels for buccal mucosa delivery of proteins with improved mucoadhesion, 
penetration enhancing and enzyme inhibition characteristics. 
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CHAPTER ONE 
INTRODUCTION AND LITERATURE REVIEW 
1.1 Overview 
 The buccal mucosa has received increased attention in recent years for the delivery of 
proteins and peptides as an alternative to the currently used parenteral route (Sudhakar et a l., 
2006). Although the buccal mucosa is limited by drug molecular size, hydrophobicity and low 
membrane permeability, chitosan and its thiolated derivatives have been identified to deliver 
proteins and peptides via this route because of their mucoadhesive, penetration enhancing and 
peptidase inhibition properties. Chitosan is a weak cationic polyaminosaccharide derived from 
deacetylation of the native polymer chitin (Wu et al., 2009), present in shellfish and was 
discovered 200 years ago (Muzzarelli et al., 2012). Chitosan is composed mainly of (1, 4) 
linked 2-amino-2- deoxy-ȕ-D-glucan (Xu et al., 2007), and has been developed as a suitable 
matrix for the controlled release of protein or peptide drugs over the last two decades (Janes et 
al., 2001). Formulations with bioadhesive properties have been reported to offer certain 
advantages for mucosal drug delivery including prolonged residence time, ease of application 
(Lawlor et al., 1999; Jones et al., 2003) and controlled release of loaded drug.  
 The concept of mucoadhesion has gained significant interest in pharmaceutical 
technology over the past two decades and might provide opportunities for novel dosage 
forms, particularly useful for buccal drug delivery (Thanou et al., 2001). Chitosan exhibits 
mucoadhesive properties and is often used to enhance the residence time of drugs in the 
mucosal membrane thereby increasing drug bioavailability. The presence of hydrophilicity, 
functional amino groups, and a net cationic charge has made chitosan a suitable polymer for 
the µintelligent¶ delivery of macromolecular compounds, such as proteins and genes. Large 
changes in functional properties such as swelling in response to small changes in 
environmental stimuli such as temperature, ionic strength, pH or light explain the intelligent 
properties of polymers. The ability of a polymer to respond to surrounding environment 
makes it attractive for use in controlling parameters such as mechanical properties, drug 
delivery and permeability (Martins et al., 2010).  
Such intelligent properties of chitosan have been studied by Wu et al., (2006) when 
they developed a novel hydrogel composed of N-[(2-hydroxy-3-trimethylammonium) propyl] 
chitosan chloride (HTCC) and glycerophosphate (GP) with a thermo- sensitive sol-gel 
transition property at body temperature. The chitosan derivative incorporated drug as a stable 
solution at room temperature but transformed to a transparent hydrogel at body temperature 
  
with pH-dependent swelling and drug release characteristics. At low pH, chitosan containing 
HTCC/GP hydrogel displayed increased hydrophilicity leading to polymer dissolution and 
consequent release of the entrapped drug. Furthermore, it has been shown that polymers (e.g. 
chitosan) with thiol groups (thiomers) exhibit much higher adhesive properties than other 
known mucoadhesive polymers. Sulfhydryl bearing agents can be covalently attached to their 
primary amino group via the formation of amide bonds where the carboxylic acid group of the 
ligand, such as thioglycolic acid (TGA) is conjugated with chitosan via the primary amino 
group, mediated by a water soluble carbodiimide (Kast & Bernkop-Schnürch, 2001). The 
improved mucoadhesive properties of thiolated chitosans are explained by the formation of 
stronger covalent bonds between thiol groups of the polymer and cysteine rich sub-domains 
of glycoproteins present in the mucus layer (Snyder et al., 1983; Leitner et al., 2003). Various 
factors that can alter the interaction between the polymer and the mucosal layer can affect the 
mucoadhesive property of a polymer. These include polymer molecular weight (Andrew et 
al., 2009; Tiwari et al., 1999), polymer concentration (Solomonidou et al., 2001) and method 
of drying.  
 Lyophilisation (freeze-drying) as a method of drying is preferred over others as it 
overcomes most of the limitations associated with formulation of protein-based products. 
Freeze-drying of formulations offers stable products, extends shelf-life, allows storage of 
products at room temperature instead of - 20 °C, avoids the complications of cold chain 
supply management, facilitates transportation of the products and increases patient 
compliance (Bunte et al., 2010). During freezing, or even storage however, a number of small 
molecule drugs and excipients tend to undergo incomplete or delayed crystallization resulting 
in the formation of mixtures of different polymorphic forms or vial breakage as in the case of 
the cryoprotectant mannitol (Kim et al., 1998; Liao et al., 2007). Such processes may cause 
reproducibility and product characterization problems. It is therefore critically important that 
the selection of conditions during the freezing step in a lyophilisation cycle be informed by 
knowledge from investigating potential for freeze induced damage, product characteristics 
and the attainment of product stability. Annealing as a process step may be employed to 
maintain samples at a particular temperature below the equilibrium freezing point but above 
the glass transition temperature for a specified period of time. The goal is to facilitate 
crystallization of the active ingredients and the cryoprotectant and to improve the pore size 
distribution of ice crystals as in Ostwald ripening (Schwegman, 2009a). Jiang et al., (2007) 
observed that mannitol based formulations sometimes caused vial breakage during early 
primary drying due mainly to moderate to fast freezing rates (when the mannitol remains 
amorphous), high fill volume and high total solid content of mannitol in the formulation. The 
  
freezing rate at the start of a lyophilisation cycle can be critical with respect to phase 
separation and concentration gradients in the mould because it can yield more dense layers at 
the top of the cake, forming a barrier for water transport. However, fast freezing does result in 
significant morphological changes such as smaller pore diameter and altered surface structure 
of the cake (Seales, 2000; Gieseler, 2004) and could impose higher resistance to mass flow 
during primary drying of samples. In addition, knowledge of such properties is of value in 
predicting the final properties of the formulation including physical appearance and drug 
release characteristics.   
This thesis reports on the formulation design, optimisation and characterisation of the 
physico-chemical properties of freeze dried chitosan and thiolated chitosan xerogels as 
potential protein drug delivery systems to the buccal mucosa membrane. Background to 
mucosal drug delivery and their advantages and challenges as well as the prospects of protein 
delivery via the buccal route has been critically reviewed. The weight average molecular 
weights (MW) of natural (chitosan) and synthesized (TG-chitosan) polymers were monitored 
with gel permeation chromatography (GPC) and chemical structures confirmed with proton 
nuclear magnetic resonance (1HNMR) and attenuated total reflection Fourier transform-
infrared spectroscopy (ATR-FT-IR). Differential scanning calorimetry (DSC) has been used 
in the preliminary formulation studies to develop an appropriate lyophilisation cycle 
incorporating an annealing step. The physical characterisation data obtained were used to 
compare formulations containing different amounts of glycerol (GLY) (plasticizer) and 
mannitol (MANN) (cryoprotectant) and also to select the most appropriate formulation for 
further development. The optimised xerogels have been characterised for moisture content, 
drug loading capacity, mucoadhesion properties, crystallinity and microscopic structure using 
thermo-gravimetric analysis, BUDGIRUG¶V DVVD\ texture analysis, x-ray powder diffraction 
(XRPD) and scanning electron microscopy (SEM) respectively. The effect of the process of 
annealing on the hydration capacity, mucoadhesion properties, microscopic structure and the 
release profile of Bovine serum albumin (BSA) loaded in the optimised freeze-dried chitosan 
and thiolated chitosan formulations were studied. The effect of membrane dialysis on the 
characteristics of chitosan based lyophilised xerogels, as well as the hydration capacity with 
or without a reducing agent dithiothreitol, was investigated. In addition, the effect of different 
enzyme inhibitors as well as a permeation enhancer on xerogel characteristics was studied.  
Permeability and accelerated/real -time stability profile of BSA were studied with Epi-oralTM 
tissue construct and UV spectrophometry respectively. Furthermore the optimised novel 
delivery system was loaded with human insulin (INS) as a model therapeutic protein, an 
enzyme inhibitor and permeation enhancer and characterised for in vitro release and ex vivo 
  
permeability using sheep buccal tissue which was correlated with Epi-oralTM characterisation.  
Accelerated and real-time stability evaluation of the INS containing xerogels was determined 
by high-performance liquid chromatography (HPLC). The conformational stability of the 
protein drugs was studied with circular dichroism (CD) and attenuated total reflection Fourier 
transform infrared (ATR-FT-IR) spectrophotometry. 
 
1.2 Protein structure and aggregation 
Every protein molecule has a characteristic three-dimensional shape (Jankowska et al., 
2012), or conformation. For example, fibrous proteins, such as collagen and keratin, consist of 
polypeptide chains arranged in roughly parallel fashion along a single linear axis, thus 
forming tough, usually water-insoluble, fibres or sheets. Because the physiological activity of 
most proteins is closely linked to their three-dimensional architecture, specific terms are used 
to refer to different aspects of protein structure. The term primary structure denotes the 
precise linear sequence of amino acids that constitutes the polypeptide chain of the protein 
molecule. The physical interaction of sequential amino-acid subunits results in a so-called 
secondary structure (Song et al., 2012), which can either be a twisting of the polypeptide 
FKDLQ DSSUR[LPDWLQJ D OLQHDU KHOL[ Į-FRQILJXUDWLRQ RU D ]LJ]DJ SDWWHUQ ȕ-configuration). 
Most globular proteins also undergo extensive folding of the chain into a complex three-
dimensional geometry designated as tertiary structure (Eyrich et al., 1999). Two or more 
polypeptide chains that behave in many ways as a single structural and functional entity are 
said to exhibit quaternary structure. The separate chains are not linked through covalent 
chemical bonds but by weak forces of association. The native state describes the precise three-
dimensional structure of a protein molecule and appears, in almost all cases, to be required for 
proper biological function. If the tertiary or quaternary structure of a protein is altered, e.g., by 
such physical factors as extremes of temperature, changes in pH, or variations in salt 
concentration, the protein is said to be denatured and usually exhibits reduction or loss of 
biological activity. 
Aggregation is a general term that encompasses several types of interactions or 
characteristics (Cromwell et al., 2006). Protein aggregates can arise from several mechanisms 
and may be classified in numerous ways, including soluble/insoluble, covalent/noncovalent, 
reversible/irreversible, and native/denatured. For protein therapeutics, the presence of 
aggregates of any type is considered to be undesirable because of concerns that such 
  
aggregates may lead to an immunogenic reaction (small aggregates) or may cause adverse 
events on administration (Cromwell et al., 2006). There are clear guidelines and limitations 
on the nXPEHURISDUWLFOHVPDQG 25 µm in size that may be present in pharmaceutical 
preparations (US Pharmacopeia, 2006). However, the levels of soluble aggregates such as 
dimers and trimers that are acceptable are not well defined. There are many types of 
interactions and environmental factors that can lead to protein aggregation, (Chi et al., 2003). 
Solution conditions such as temperature, protein concentration, pH, and ionic strength may 
affect the amount of aggregates observed. In addition, the presence of certain ligands, 
including specific ions such as calcium and magnesium (Zhu & Damodaran, 1994) may 
enhance aggregation. Further, stresses to the protein such as freezing, exposure to air, or 
interactions with metallic surfaces and mechanical stresses may result in surface denaturation 
which then leads to the formation of aggregates. Each of these environmental factors is 
typically encountered during bio-processing and formulation. Wang, (2000) observed that 
stresses associated with freezing can damage sensitive molecules including proteins. It is 
therefore critically important that the thermal treatment during a freeze drying cycle should be 
understood by preliminary investigations to determine the potential for freeze induced 
damage. 
 
1.2.1 Use of proteins as therapeutic agents 
The high prevalence of chronic non communicable diseases such as cardiovascular 
related conditions, diabetes, cancer and the rising number of ageing adults in the population 
have resulted in significant increase in protein therapeutics due to their important role in the 
development of current treatment options. Consequently, protein based pharmaceuticals has 
attracted many large and small biopharmaceutical and biotechnological industries, making 
protein therapeutics one of the fastest growing global emerging markets. According to the 
Global Protein Therapeutics Market Analysis, for 2011-2013, the pharmaceutical 
biotechnology market is expected to grow at an astounding Compound Annual Growth Rate 
(CAGR) of about 12 % (Szlachcic, et al., 2011) as a result of improved investment, 
production and subsequent marketing of novel protein therapeutics. Furthermore, the 
expiration of patents of many top biotech industries will strengthen the growth of the global 
protein market as they would now turn to the expected large number of generic biotech 
products, estimated to be a multi-billion dollar market. 
 
  
1.2.2 Model protein drugs 
 Two model drugs representing small to medium sized endogenous proteins naturally 
present in the body were selected for this research; the well-studied and characterised albumin 
and insulin, one of the first biotechnologically derived protein therapeutic drugs and 
commonly used clinically. 
 
1.2.2.1 Bovine serum albumin (BSA) 
 Serum albumins are the most abundant blood plasma proteins, corresponding to a 
concentration of 4.2 % w/v and accounts IRUXSWRRIWKHERG\¶VWRWDOSURWHLQ. Albumins 
also SURYLGHDSSUR[LPDWHO\RIWKHEORRG¶s osmotic pressure (Carter & Ho, 1994 cited in 
Gelamo et al., 2002). A number of diverse biochemical, biophysical and physicochemical 
studies have employed albumins as model proteins due to their ability to bind to a variety of 
hydrophobic substrates including anaesthetics, bilirubin, lysolecithin, steroids, tryptophan and 
several dyes (Curry et al.,1998; Narazaki et al., 1997; Chadborn et al., 1999; Reynolds et al., 
cited in Gelamo et al., 2002). A single chain of about 580 amino acid residues constitute the 
primary structure while the secondary structure is composed of 67 % Į-helix with 6 turns and 
17 disulphide bridges which are located nearly exclusively between the helical segments 
(Carter & Ho., 1994; Narazaki et al., 1997, cited in Gelamo et al., 2002).  
 These disulphide bonds are inaccessible to reducing agents in the pH range of 5-7, but 
become progressively available at lower or higher pH. The three-dimensional structure of 
serum albumin is composed of three homologous domains namely; I, II and III based on 
crystallographic determination, conferring a heart shaped molecular form to the protein (He & 
Carter, 1992, cited in Gelamo et al., 2002). The domains are further divided into sub-
domains: IAB, IC; IIAB, IIC; IIIAB and IIIC respectively (Figure. 1.1).  
 
 
  
 
Figure 1.1: Molecular model of serum albumin. Available at 
<http://www.friedli.com/research/PhD/bsa/fig53.gif> [Accessed; 25/04/12] 
 
 A number of features such as basic amino acid residues, hydrophobic phase and 
proline residues at the tips of the loops, are shared by the sub-domains, however, each sub-
domain is unique and may show a certain degree of specificity. Bovine serum albumin (BSA) 
shares 76 % sequence identity and same molecular weight (67 kDa) with human serum 
albumin (HSA) (Peters, 1985; Carter & Ho, 1994, cited in Gelamo et al., 2002). Two 
tryptophan residues (W131 and W214) are found in BSA while only one (W124) is found in 
HSA. Spectroscopically, the additional tryptophan has been proposed to lie close to the 
VXUIDFHRIWKHĮ-helix of the first domain of the BSA molecule (Carter & Ho, 1994, cited in 
Gelamo et al., 2002). Changes in pH result in reversible conformational isomerization as 
summarised in Table 1.1 below.  
 
Table 1.1: Relationship of isomeric forms of bovine serum albumin (Forster, 1977).  
 E <----> F <----> N <----> B <----> A 
pH of 
transition 
 2.7  4.3  8  10  
Name Expanded  Fast  Normal  Basic  Aged 
% helix 35  45  55  48  48 
<----> shows the transition from one isomeric form of BSA to the other based on pH. 
  
BSA foams by diffusing into the air-water interface in solution with subsequent 
reduction in surface tension. Partial unfolding and association occurs resulting in an 
intermolecular cohesive film. Improvement in foam expansion and stability is achieved by 
BSA interaction with clupeine (Poole et al., 1984). Gelation of the protein follows a two step 
process of initial unfolding or dissociation and a subsequent aggregation step resulting in gel 
formation under suitable conditions. The heating of BSA results in the formation of soluble 
aggregates, through non-covalent and disulphide bonds, which leads to the formation of a gel. 
Albumin binds reversibly with a wide range of ligands serving as the principal carrier for 
insoluble fatty acids in plasma circulation. Oxidation of approximately 30 % of free 
sulphydryl Cys-34 in circulating plasma is by glutathione and cysteine (Peters, 1985). 
 
1.2.2.2 Insulin (INS)  
Insulin (INS) is a polypeptide hormone which regulates carbohydrate metabolism and 
produced in the Islets of Langerhans in the pancreas. As a primary effector in carbohydrate 
homeostasis, INS also partakes in fat and protein metabolism. Clinically, INS is used in some 
forms of diabetes mellitus. While Type 1 diabetes mellitus patients depend on injected 
exogenous INS for survival, Type 2 diabetes patients occasionally require INS administration 
in addition to adequate medication to control blood glucose level. 
Chemical structure: The chemical structure of INS varies slightly between species however, 
porcine INS is similar in composition to human INS. The empirical formula of the protein is 
C254H377N65O75S6 with a molecular weight of approximately 6,000. INS is synthesised from a 
single chain precursor, proinsulin. Proteolysis removes 4 basic amino acids and the remaining 
connector or C peptide to convert human proinsulin to INS which consists of two chains of A 
(acidic, consisting of 21 amino acids with glycine at the amino terminal residue) and B (basic, 
consisting of 30 amino acids with phenylalanine at the amino terminus) amino acids linked 
together by two disulphide bonds (Figure 1.2 (i) and (ii)). INS may exist as a monomer 
(biologically active), dimer or hexamer. The hexamer has two molecules of coordinated Zn2+ 
and is stored as granules in the beta cell. Porcine INS differs from that of humans only by the 
substitution of threonine by alanine residue in the B chain at the carboxyl terminus. Bovine 
INS, however, differs by three amino acid residues, making it more antigenic. 
  
 One of the greatest milestones in medical history was the discovery of INS which has 
revolutionised proteins and peptides as useful therapeutic agents. Until the recent 
breakthrough in biotechnology for the production of human INS in satisfactory quantities, 
INS products from different animal sources such as bovine and porcine were used for over six 
decades. 
 
Figure 1.2: Structure and amino acid sequence of INS; (i) Sequence of human insulin with 
the A chain above and the B chain beneath. Cysteines forming disulphide linkages are 
indicated with bars. (ii) Ribbon model of INS. The A-chain is indicated in red, and the B-
chain with blue. Disulphide bridges are shown by gold spheres (sulphur atoms); pairings are 
indicated in black boxes. %ODFNVSKHUHVVKRZ&ĮFDUERQVRI the residues (Adapted from T-
state protomer; Protein Data bank access ion code 4 INS; Baker et al., 1988, cited in Hua et 
al., 2011). 
 
 Currently, research is focussed on developing non-invasive INS delivery systems with 
various technologies (see Table 1.2) at different stages of development. With over 22,000 
published articles and 300 patents on non-invasive INS delivery, clinical application still 
remains an elusive goal despite the exploration of different approaches (Mukhopadhyay et al., 
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2012). Treatment and management of diabetics using INS still relies on subcutaneous 
injections with the added complexities of needles, syringes and vial system that hinder patient 
compliance.  
Table 1.2: Transmucosal routes of insulin delivery systems. Adapted from Khafagy et al., 
(2007). 
Administration 
route 
Delivery system  Model Results 
Buccal 
 
Insulin solution/lysalbinic acid Hamster 
cheek pouch  
Significantly increased 
insulin permeability 
Deformable lipid vesicles  
 
Rabbits BR was 19.78 % 
Nasal 
  
 
Nasal powder formulation Rabbits BA was 11.1 %±22.4 % 
Insulin±chitosan powder  Sheep BR was 17 % 
Chitosan±TBA±insulin 
microparticles  
Rats BA was 7.24 % 
Pulmonary 
 
Insulin microcrystals/Zn2+ Rats  17 % reduction in blood 
glucose levels 
Insulin PLGA nanospheres  Guinea pigs Long-lasting 
hypoglycaemic response 
Ocular 
 
Insulin 
solution/alkylglucosides 
Rats Significantly stimulated 
systemic insulin 
absorption 
Gelfoam® ocular device Rabbits 60 % reduction in blood 
glucose levels over 8h 
Rectal 
  
Insulin suppositories/Witepsol 
W35, SDC, SC, STDC or STC 
Dogs PA was 50 % 
Insulin glycerol±gelatin 
suppositories/snail mucin 
Rats 44 % reduction in blood 
glucose levels within 2h 
 
Abbreviations: BR, relative bioavailability; BA, absolute bioavailability; SDC, sodium deoxycholate; chitosan±
TBA±insulin, chitosan±4-thiobutylamidine insulin conjugate; PA, pharmacological availability; PLGA, 
poly(lactide-co-glycolide); STC, sodium taurocholate; SC, sodium cholate; STDC, sodium taurodeoxycholate 
 
Delivery systems such as liposomes, liquid emulsions, pro-drugs, polymer-inhibitor 
conjugates and nanocapsules have been investigated for non-invasive INS delivery with 
  
limited success. INS released in a pulsatile manner in response to blood glucose levels from 
intelligent stimuli-responsive delivery systems such as hydrogels have also been investigated. 
The development of poly(methacrylic acid-g-ethylene glycol) hydrogels with Ca2+ deprivation 
ability, mucoadhesive characteristics and sensitve pH-dependent (Wood et al., 2010) release 
led to approximately 10% pharmacological availability of orally administered INS (Morishita 
et al., 2006). 
 Insulin delivery via the buccal mucosa is an interesting approach that will be explored 
in this research, where the drug delivery system has been designed to achieve increased 
mucoadhesion, permeation enhancement and enzyme inhibition using chitosan and thiolated 
chitosan lyophilised xerogels, to overcome the limitations of protein transport across the 
buccal mucosa.  
 
1.2.3 Protein delivery and challenges   
The parenteral route (injection) has for decades been the major means for the systemic 
delivery of protein and peptide drugs but is limited by the problem of pain associated with 
injections. Although current technological advancements has led to the use of micro-needles 
that are virtually pain-free, there still remains the challenge of high injection frequency, site 
reactions (irritiations) (Kenndy, 1991, cited in Khafagy et al., 2007) and consequent patient 
non-compliance. These have necessitated the need to focus research on alternative non-
invasive routes for the delivery of protein and peptide drugs (Figure 1.3).  
However, these potential routes are fraught with their own challenges. Most proteins 
and peptides have shown poor bioavailability of the order of less than 1 % when delivered via 
the nasal route (Deurloo et al., 1989). Limiting factors such as enzymatic inhibition in the 
GIT and at mucosal sites, hepatic first pass metabolism, size exclusion at epithelial barriers 
and cellular transport pathways are still a huge challenge for the pharmaceutical industry. In 
addition, these hydrophilic biopharmaceuticals may also be unstable and prone to 
modification or degradation due to extreme changes in the pH of the local environment as 
encountered in nasal delivery (Lee, 1988). In developing alternative protein/peptide delivery 
systems with high bioavailability, modification of the physicochemical properties of 
macromolecules, addition of novel functions to these macromolecules and the use of 
improved delivery carriers have been found essential for the maintenance of the biological 
activity of the proteins (Morishita & Peppas 2006). 
  
 
Figure 1.3: A schematic diagram showing clinical and potential protein delivery routes 
Abbreviation: absorption enhancers (AE) enzyme inhibitors (EI) and electroporation (EP), 
Adapted from Agu et al., 2001.   
 
1.3 Improving protein absorption  
The use of permeation enhancers (PE), enzyme inhibitors (EI) and the exploitation of 
bioadhesive delivery systems have been investigated to overcome protein delivery challenges. 
 
1.3.1 Permeation enhancers  
 Permeation enhancers have been extensively studied to overcome the barriers to 
buccal protein and peptide delivery. Penetration enhancers act on the epithelium and increase 
the permeability of the membrane by either the paracellular or the transcellular pathway. 
Other mechanisms proposed for the improvement of mucosal peptide absorption by 
penetration enhancers include reduction of mucus layer elasticity and/or viscosity and 
increasing the thermodynamic activity of protein drugs which may be affected by the 
  
composition of the delivery system with subsequent influence on micellization and solubility 
and by degree of drug and enhancer ion-pair formation (Veuillez et al., 2001). Examples of 
this class of compounds include surfactants, fatty acids, bile salts, and chelators such as 
ethylene diamine tetra acetate (EDTA). Many gel-forming polymers such as polycarbophil, 
chitosan and thiolated chitosans also act as permeation enhancers by binding to the 
extracellular Ca2+. Fatty acids, bile salts and surfactants mostly enhance permeability by 
increasing the fluidity of the lipid bilayer of the cell membranes. Local toxicity to the 
epithelium in the gastrointestinal tract is a major concern in using these systems in 
pharmaceutical products. Intracellular Ca2+ plays an important role in regulating the 
permeability of the tight junction (Kan & Coleman, 1988). Thus, compounds such as EDTA 
that can bind the extracellular Ca2+, lowering the intracellular Ca2+ concentration, can act as 
permeation enhancers by rendering the paracellular pathway more permeable (Khafagy et al., 
2007). Some of these enhancers, however, can cause local damage to the mucosal membrane 
and even enter the systemic circulation, leading to systemic toxic effects. The potential 
damage to the epithelium and changes in the mucosal morphology, especially in long term 
multi-dosing regimen, as would be required in diabetes treatment, are major concerns in the 
clinical use of these agents. Another disadvantage of these compounds is their non-specificity 
in permeation enhancement. Increased permeability of the epithelium may also allow toxins 
and microbial pathogens in the buccal cavity to pass more easily into the systemic circulation, 
an event which negates the very function of the buccal mucosa (Sudhakar et al., 2006). 
Factors such as characteristics of permeant, composition of the delivery system and the 
previous treatment of tissue with or without enhancer, affect the degree of enhancement. 
Enhancers may therefore be selected based on safety, chemical and biological inertness, 
effectiveness and rapid but reversible effect (Nicolazzo et al., 2005). 
 
1.3.2 Enzyme inhibitors 
The stability of protein and peptide drugs may be improved by the addition of enzyme 
inhibitors to formulations intended for absorption through the buccal mucosa (Khafagy et al., 
2007). Concomitant administration of INS with aprotinin and soybean trypsin inhibitors has 
been shown to induce better hypoglycemic effect (Bernkop-Schnürch, 1998; Morishita, 1993).  
Polyacrylates such as Carbopol 934P and polycarbophil, which are typically used as 
bioadhesives, are also known to inhibit the activity of trypsin and chymotrypsin in a calcium-
dependent manner (Madsen & Peppas, 1999; Lueben et al., 1997). Bai et al., (1996) showed 
that in-situ absorption of INS was improved by carbomer polymers and also induced a 
  
significant decline in blood glucose levels. However, these enzyme inhibitors (Figure 1.4) 
have a toxic potential caused by the inhibition of digestive enzymes, which can further cause 
incomplete digestion of the nutrient proteins. In addition, the inhibitory action can cause 
increased secretion of these enzymes by a feed-back regulatory mechanism (Bernkop-
Schnürch, 1998; Reseland et al., 1996). Studies have shown that this feed-back regulation 
leads to both hypertrophy and hyperplasia of the pancreas and prolonged administration of 
soybean trypsin inhibitor may lead to invasive carcinoma (Bernkop-Schnürch, 1998). One of 
the recent additions to the class of absorption enhancers is zonula occludens toxin (Zot), a 
protein secreted by Vibrio cholerae (Baudry et al., 1992). This toxin induces modifications of 
cytoskeletal organization, specifically at the actin filament of the zonula occludens which 
leads to opening of the tight junctions causing increased permeability. This increase in 
permeability is reversible, time and dose-dependent and is restricted to the jejunal and ileal 
sections of the small intestine owing to the presence of receptors for the protein in those 
sections (Fasano & Uzzau, 1997). 
 
 
Figure 1.4: Schematic diagram showing the mechanism of enzyme inhibition. Available at 
<http://www.saburchill.com/IBbiology/chapters01/034.html> [Accessed; 20/03/2011] 
 
 Studies with diabetic animals have shown that INS DGPLQLVWHUHG ZLWK ȝJ =RW DQG
NaHCO3 to neutralize the gastric acidity, induced a hypoglycaemic effect comparable to that 
caused by subcutaneously administered INS. This is a promising approach to improving oral 
bioavailability of INS, but it suffers from the same safety and specificity issues that limit the 
use of permeation enhancers discussed above. Thus, attempts to increase the oral 
  
bioavailability of proteins using permeation enhancers and protease inhibitors have not 
resulted in an acceptable delivery system as the potential side effects of these approaches have 
limited clinical application (Lee et al., 1991). 
 
1.3.3 Mucoadhesive delivery systems 
Application of mucosal drug delivery systems has increased exponentially for every 
conceivable route of administration because of the potential therapeutic benefits this delivery 
technology brings, particularly in the area of protein therapeutics. These include less frequent 
dosing, site-specific targeting and maintaining effective plasma concentrations without 
increased consumption.  
  Bioadhesive polymers can be broadly classified into two groups, namely specific and 
non-specific (Woodley, 2001). Specific bioadhesive polymers such as lectins and fimbrin 
have the ability to adhere to particular chemical structures within biological molecules while 
the nonspecific bioadhesive polymers such as polyacrylic acid, cyanoacrylates, chitosan and 
chitosan derivatives, have the ability to bind with both the cell surfaces and the mucosal layer 
(Sudhakar et al., 2006). A polymer will exhibit sufficient mucoadhesive property if it can 
form strong intermolecular hydrogen bonds with the mucosal layer, penetrate the mucus 
network or tissue crevices, easily wetted by the mucosal layer and the polymer chain has a 
high molecular weight.  
The ideal characteristics of a mucoadhesive polymer matrix include (Sudhakar et al., 2006) 
x rapid adherence to the mucosal layer without any change in the physical property of 
the delivery matrix, 
x  minimum interference with the release of the active agent,  
x biodegradable without producing any toxic by-products,  
x inhibit the enzymes present at the delivery site and  
x enhance the penetration of the active agent (if the active agent is meant to be absorbed 
from the delivery site).  
 
 
1.3.3.1 Theories of mucoadhesion  
Many theories have been proposed to explain the complex mechanism involved with 
the phenomenon of bioadhesion. However, these six recently proposed theories enhance the 
understanding of the phenomenon of adhesion which might also be extended to explain the 
  
mechanism of bioadhesion. The theories include: (a) the electronic theory; which proposes 
transfer of electrons among the surfaces resulting in the formation of an electrical double 
layer thereby giving rise to attractive forces; (b) the wetting theory; postulates that if the 
contact angle of liquids on the substrate surface is lower, then there is a greater affinity of the 
liquid to the substrate surface. If two such substrate surfaces are brought into contact with 
each other in the presence of the liquid, the liquid may act as an adhesive between the 
substrate surfaces; (c) the adsorption theory; proposes that the presence of intermolecular 
forces (hydrogen bonding and van der wDDO¶VIRUFHV), serve as adhesive interaction between 
the substrate surfaces; (d) the diffusion theory; which assumes the diffusion of the polymer 
chains present on the substrate surfaces, across the adhesive interface thereby forming a 
networked structure; (e) the mechanical theory; explains the diffusion of the liquid adhesives 
into the micro-cracks and irregularities present on the substrate surface thereby forming an 
interlocked structure which gives rise to adhesion and (f) the cohesive theory; proposes that 
the phenomena of bioadhesion is mainly due to the intermolecular interactions between like-
molecules (Smart, 2005; Andrew et al., 2009).  
Based on these theories, the process of bioadhesion can be generally classified into 
two subsets, namely chemical (electronic and adsorption theories) and physical (wetting, 
diffusion and cohesive theory) methods (Hubbell, 1995; Peppas & Sahlin 1996). Two stages 
may be involved in the process of muco-adhesion. During the first stage (also known as 
contact stage), wetting of the mucoadhesive polymer and mucous membrane occurs followed 
by the consolidation stage (Figure 1.5), where the physicochemical interactions prevail (Wu, 
1982; Smart, 1999). 
 
 
 
 
 
 
 
 
Figure 1.5: Mechanism of dosage form and mucosal layer interaction (Carvalho et al., 2010) 
  
 
  
1.3.3.2 Factors affecting mucoadhesion 
A number of variables which have the capacity to alter the interaction between the 
polymer and the mucosal layer can affect the mucoadhesive property of a polymer and are 
discussed below. These include; 
(a) Molecular weight; an increase in molecular weight (MW) of a polymer has been found to 
have a direct correlation with increasing muco-adhesivity of the polymer. Polymers with MW 
greater than 100,000 generally exhibit sufficient mucoadhesive properties for biomedical 
applications. A classical example is demonstrated by the negligible mucoadhesiveness of PEG 
20,000, enhanced mucoadhesiveness of PEG 200,000 and the excellent mucoadhesiveness of 
PEG 400,000 (Middleton, 1990). Likewise, Dextrans of 200,000 MW, poly(acrylic) acid of 
~750,000 MW and  polyethylene oxide of 4,000,000 MW have demonstrated good 
bioadhesive properties with polyoxyethylene of 7,000,000 MW exhibiting excellent 
mucoadhesive properties in addition to being a candidate for buccal delivery system 
development (Andrew et al., 2009; Tiwari et al., 1999).  
(b) Hydrogen bonding; formation of strong hydrogen bonds between polymeric functional 
groups such as hydroxyl, carboxyl and amino groups and the mucosal layer leads to stronger 
adhesion. In addition, the presence of these functional groups within the polymer structure 
may result in the polymer chains behaving as polyelectrolytes. The functional groups in the 
polymer chain have a marked effect on the strength of bioadhesion via hydrogen bonding 
between nonionised carboxylic acid and mucin (Sudhakar, 2006). Poly(vinyl alcohol), acrylic 
derivatives, celluloses (Lee et al., 2000) and chitosan have the ability to form hydrogen 
bonds.  
 
(c) Polymer concentration; the process of mucoadhesion is significantly affected by the 
concentration of the polymer. An unstable and insufficient interaction occurs between the 
polymer and the mucosal layer at low polymer chain concentration which results in poor 
mucoadhesive properties. For biomedical applications, polymer concentration in the range of 
1-2.5 % w/w exhibit adequate mucoadhesive properties (Roy et al., 2009). There is however a 
limited interpenetration of polymer and mucin chains at very high concentrations for 
polymers such as poly(vinyl pyrrolidone) and poly(vinyl alcohol) which subsequently results 
in  a reduction of mucoadhesive property. These occur due to a decrease in solvent diffusion 
into the polymer network at very high polymer concentration as highly coiled structures are 
formed (Solomonidou et al., 2001). 
 
  
(d) pH of environment; the pH of the external environment influences the ionization of  the 
functional group(s), affecting the charge distribution on the polymer chains. As discussed 
earlier, mucoadhesion property depends on the presence of these functional groups and 
therefore a change in the pH of the external environment may impact on the mucoadhesive 
property. A typical example is the excellent mucoadhesive property of chitosan (cationic 
polyelectrolyte) in alkaline or neutral environment (Park et al., 1989) 
(e) Method of drying; apart from the above factors, Grabovac et al., (2005) found that the 
method of drying is an important factor influencing the mucoadhesive potential of polymeric 
formulations. Lyophilisation of thiolated chitosan polymers at pH 3 produced greater 
mucoadhesion than other polymers that were dried by casting from organic solvents and air 
dried. On the other hand, polyacrylates showed improved mucoadhesion when precipitated in 
neutral sodium salts.  
 
1.3.3.3 Mucin                                                                                                        
The protein based material, mucin, is the main component of mucus and plays a 
significant role in the mucoadhesive characteristics of chitosan and chitosan derivatives 
(Fefelova et al., 2007; Sogias et al., 2008). The mucosa layer is made up of mucus secreted by 
the goblet cells (glandular columnar epithelial cells) and is a viscoelastic fluid. It lines the 
visceral organs, which are exposed to the external environment, including the alimentary 
canal/ gastrointestinal (oral cavity, stomach and intestines), respiratory and genitourinary 
tracts. The main components constituting the mucosa are water and mucin, which together 
constitute > 99 % of the total composition of the mucus and of this greater than 95 % is water 
(Roy et al., 2009). The other components present in mucus include proteins, lipids and 
mucopolysaccharides. The gel-like structure of the mucus can be attributed to the 
intermolecular entanglements of the mucin glycoproteins along with the non-covalent 
interactions (e.g. hydrogen, electrostatic and hydrophobic bonds) which results in the 
formation of a hydrated gel-like structure and explains the viscoelastic nature of the mucus 
(Andrew et al., 2009). 
Mucins (Figure 1.6) are a family of high molecular weight (anionic polyelectrolytes), 
heavily glycosylated proteins (glycoconjugates) produced by epithelial tissues. Many 
epithelial cells produce mucin, but gel-forming mucins are produced primarily in the goblet or 
mucous cells of the tracheobronchial, gastrointestinal, and genitourinary tracts. In goblet cells, 
mucins are stored intracellularly in mucin granules from which they can be quickly secreted 
upon external stimuli.  
  
Human salivary glands secrete 1000±1500 ml per day of saliva composed of water, 
proteins and low molecular mass substances (mainly electrolytes). Up to 26 % of the salivary 
proteins are mucins. The mucins of human saliva are extremely effective lubricants, which 
provide an effective barrier against desiccation and environmental insult. The functions of 
mucins include controlling permeability of mucosal membrane, limiting the penetration of 
potential irritants and toxins into mucous cells, protecting mucosal cell membranes against 
proteases generated by bacteria in the bacterial plaques around the teeth and regulating 
colonization of the oral cavity by bacteria and viruses. 
 
Figure 1.6: A simplified model of a large secreted mucin. Available at 
<http://www.ncbi.nlm.nih.gov/books/NBK1896/ > [Accessed; 08/08/2011]. 
 
Proline and serine/threonine constitute up to 20±55 % of total amino acids in mucin 
and are concentrated in one or several regions of the polypeptide. These serine/threonine 
residues are heavily glycosylated, and 40±80 % of the mass of such mucins consists of O-
linked oligosaccharides. The cysteines at the N- and C-ends may link mucin monomers by 
disulphide bridges forming linear mucin oligomers. Two types of mucins are present in 
human saliva: oligomeric mucin glycoprotein (MG1) (Levine et al., 1987) with molecular 
mass above 1 MDa, and monomeric mucin glycoprotein (MG2) with molecular mass of 200±
250 kDa. The submandibulary glands containing mucous cells (producing MG1) and serous 
cells (producing MG2) secrete 30 % of the salivary mucins, while sublingual, labial and 
palatal glands (which contain mainly mucous cells) secrete 70 %. Concentration of mucin 
secreted by the sublingual glands is higher than that secreted by the submandibulary glands, 
while the secretion from the parotid glands is devoid of mucins (Zalewska et al., 2000). 
The formation of electrostatic interactions between mucin and chitosan has been used 
to explain the mucoadhesivity with biological membranes (Silva et al., 2012). In addition, the 
formation of in-situ disulphide links between mucin and thiolated polymers such as chitosan, 
carbomers and alginates (Bernkop-Schnürch et al., 2001) has led to improved adhesion 
  
performance (Smart, 2005). The use of mucin for mucoadhesion studies provides a relevant 
platform for predicting the performance of mucoadhesive delivery systems where prolonged 
attachment to the mucosal surface is required for overcoming drug absorption limitations via 
mucosal membranes. 
 
1.4 Mucosal delivery routes  
Bioadhesive systems engage in interfacial molecular attractive forces between the 
surfaces of the biological substrate and the constituent natural or synthetic polymers, thus 
allowing the delivery system to adhere to the biological surface for an extended period of time 
(Khutoryanskiy, 2007; Gu et al., 1998; Duchene et al., 1998). 7KH WHUP³PXFRDGKHVLRQ´ LV
used to describe the adhesion of polymers with the surface of a biological substrate when the 
immediate substrate is a mucosal layer (Robinson 1990). The two terms will be used 
interchangeably in this report. As noted earlier, the mucosal layer lines the GIT, the urogenital 
tract, the buccal, ocular and nasal cavities. These represent potential sites for the attachment 
of any bioadhesive system. Table 1.2 shows various mucosal delivery systems and routes for 
the delivery of insulin. 
 
1.4.1 The oral route 
The absence of specialized regulatory requirements such as sterility, pyrogenicity and 
particulate contamination for oral dosage forms make the gastrointestinal tract (GIT) the route 
of choice for the administration of most drugs, irrespective of molecular structure or weight. 
The successful oral delivery of proteins and peptides however, requires overcoming many 
barriers including enzymatic degradation, achieving epithelial permeability, and preserving 
the bioactivity of the drug during formulation processing.  
 A number of pharmaceutical strategies proposed to maximize protein bioavailability in 
oral delivery systems include the use of absorption enhancers, enzyme inhibitors, 
mucoadhesive polymeric systems, particulate carrier delivery systems and targeted delivery 
systems (Khafagy et al., 2007). Table 1.3 shows current oral protein delivery technologies 
developed for marketing or clinical applications. Notwithstanding the advantages these 
strategies provide, they are limited by transport of undesirable molecules, high toxicity over 
long term use, low incorporation efficiency of hydrophilic drugs, the harsh hydrolytic 
environment of the GIT and the epithelial barriers to absorption.  
  
1.4.2 The nasal route 
Nasal protein delivery offers an alternative to subcutaneous injections due to the large 
surface area for drug absorption, highly vascularized sub-epithelial layer, high total blood 
perfusion, avoidance of first-pass metabolism, rapid onset of pharmacological activity, and a 
porous endothelial basement membrane which is readily accessible, delivering drug directly 
to the brain along the olfactory nerves (Kissel & Werner, 1998). A nasal delivery system of 2 
% HPMC lyophilised insert formulation for INS achieved an extended nasal residence, 
demonstrating an optimum combination of rapid adhesion without over hydration (McInnes et 
al., 2007). Intranasal absorption of high-molecular-weight and hydrophilic peptide drugs is 
however limited by mucociliary clearance, enzymatic activity, and the epithelial-mucus layer 
barriers. The use of absorption enhancers, enzyme inhibitors and mucoadhesive systems has 
been investigated to enhance drug bioavailability via the nasal mucosa (Khafagy et al., 2007). 
  
Table 1.3 Marketed/under development protein oral delivery technology by companies. Adapted from Park et al., 2011. 
Company System Product name Outcomes for absorption Marketed/under development 
products 
Emisphere Carrier molecules Eligen® Increase membrane permeability Calcitonin, Insulin, Growth 
hormone, parathyroid hormone 
Altus Protein 
crystallization 
CLEC® Stable against proteolysis and self-
aggregation 
Calcitonin, other polypeptides, 
lipases, esterases and proteases 
BioSante Calcium 
phosphate 
nanoparticles 
BioOral Protect proteins from acidic 
degradation and improve 
membrane permeability 
Insulin and vaccines 
NOBEX/Biocon Amphiphilic 
oligomers 
HIM2 Resist enzyme digestion and 
increase membrane permeation 
Insulin, enkephalin, calcitonin, 
parathyroid hormone 
Appolo Life Science Nanoparticles Oradel Protect proteins from enzyme 
digestion in the stomach and 
facilitates transport in the intestine 
Insulin and TNF blocker 
Eli-Lilly Oral formulation AI-401 Protect protein from enzyme 
digestion 
Insulin 
Provalis PLC Lipid-based 
microemulsion 
Macrulin Protect proteins from proteolysis 
and enhance protein absorption in 
GIT 
Insulin, salmon calcitonin 
Abbreviation: CLEC, Cross-/LQNHG(Q]\PH&U\VWDO+,0´KH[\O-insulin monoconjugate; TNF, tissue necrosis factor.
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1.4.3 The pulmonary route 
The lungs with a large surface area of approximately 140 m2 and very thin alveolar 
epithelium (approximately 300 million) allows the passage of 5 L of blood per minute 
(Cázares-Delgadillo et al., 2011) leading to rapid drug absorption in addition to avoiding first-
pass metabolism. Furthermore, the metabolic enzymatic activities and pathways in the lungs 
differ from those observed in the GIT, making the pulmonary administration of various 
peptides and proteins very promising (Agu et al., 2001). However, full optimization of 
pulmonary delivery systems requires addressing critical issues relating to particle size 
characteristics, obtaining good encapsulation efficiency, preventing protein degradation and 
predictable drug release. In addition, inhaled peptides may not be suitable for all patients with 
smokers or asthmatics requiring lower (Himmelmann et al., 2003) or higher (Henry et al., 
2003) doses respectively. Furthermore, to achieve a similar glycaemic effect, patients 
receiving pulmonary INS may require a dose approximately 20 times that of subcutaneous 
injection (Gale, 2001) which might lead to breathing difficulties and variability in dosing 
regimen for different categories of patients (Lassmann-Vague & Raccah 2006). 
 
1.4.4 The ocular route 
Drug administration via the ocular route is much easier than injection with comparable 
systemic absorption rates. Drug absorption also by-passes the first-pass gastrointestinal and 
liver effects, resulting in increased bioavailability of peptides and other drugs. The eye tissues 
are much less likely to develop immunological responses compared with other tissues with 
prolonged safety (3 months) of use and no ocular side effects upon daily administration of 
INS eye drops (Chiou, 1994). Chitosan and chitosan derivatives have been developed as drug 
delivery systems for ocular delivery (Fuente et al., 2010, cited in Khutoryanskiy, 2011). The 
major drawback is the need for developing delivery systems that are compatible with the 
conjunctival, corneal and iris tissues with a prolonged residence time. These might raise 
issues with local tissue irritation, however the use of eye-drops which is rapidly eliminated 
seem better than an eye devices which must release the drug in a controlled manner. 
 
1.4.5 Vaginal and rectal routes 
The vaginal and rectal mucosal cavities offer potential alternative routes to attain systemic 
delivery. Although most of the products in the marketplace are designed for local mucosal 
administration, a few target systemic delivery. Valenta et al., (2001) used a thiolated 
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polyacrylic acid conjugate (NaC974P-Cys) composed of L-cysteine and polyacrylic acid 
(Carbopol 974P) to develop a mucoadhesive vaginal delivery system for progesterone. 
Recently, mucoadhesive HPMC and Carbopol tablets have been developed for vaginal 
delivery of benzydamine (Perioli et al., 2011). Patient compliance to these routes tends to be 
low due to socio-cultural acceptance. In addition, and from a delivery perspective, erratic 
local physiological activities such as rectal contents and menstrual-cycle, significantly impact 
drug dissolution and absorption at the site of delivery (Mathias & Hussain, 2009). 
 
1.4.6 Buccal route 
The buccal region is that part of the oral cavity bounded anteriorly and laterally by the 
lips and the cheeks, posteriorly and medially by the teeth and/or gums, and above and below 
by the reflections of the mucosa from the lips and cheeks to the gums (Figure 1.7 (a)). The 
oral mucosa consists of a non-keratinized area (sublingual and buccal mucosa) and the 
keratinized area (the gum or gingiva, the palatal mucosa, and the inner side of the lips). The 
non-keratinized regions are generally more permeable compared to the keratinized areas 
(Veuillez et al., 2001). The oral cavity offers a large surface area for absorption (100± 200 
cm2), is richly vascularized with little proteolytic activity. Blood reaches the buccal mucosa 
via the maxillary artery at a faster (and richer) flow rate (2.4 ml/min/cm2) than that in the 
sublingual, gingival and palatal regions, thus facilitating passive diffusion of drug molecules 
across the mucosa. The estimated turnover time (cell regeneration) for the buccal epithelium 
is between 5 to 6 days (Harris & Robinson, 1992).  
The buccal mucosa is composed of several layers of different cells as shown in Figure 
1.7 (b). The epithelium is about 40±50 cell layers thick and is similar to stratified squamous 
epithelia found in the rest of the body. The epithelium lining of the buccal mucosa is made up 
of non-keratinized stratified squamous epithelium cells with a thickness of 500±ȝPDQG
surface area of 50.2 cm2. The rough textured buccal mucosa is thus suitable for retentive 
delivery systems (Rathbone et al., 1996). Basement membrane and lamina propria followed 
by the submucosa are found below the epithelial layer (Gandhi & Robinson, 1988). The 
lamina propria is rich with blood vessels and capillaries which open to the internal jugular 
vein. Lipids present in the buccal tissues include phospholipid (76.3 %), glucosphingolipid 
(23.0 %) and ceramide NS (0.72 %). The buccal epithelium is primarily designed to offer 
protection of the underlying tissue. In non-keratinized regions, lipid-based permeability 
barriers in the outer epithelial layers protect the underlying tissues against fluid loss and entry 
of potentially harmful environmental agents such as antigens, carcinogens, microbial toxins 
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and enzymes from foods and beverages (Squier & Finkelstein, 1989). This protective system 
also presents a barrier to drug absorption that needs to be overcome as previously mentioned. 
 
Figure 1.7: (a) Cartoon representation of the buccal mucosa (b) cross-section of the buccal 
mucosa structure. Available at < www.cedars sinai.edu/Patients/Programs and-Se..website.> 
[Accessed; 13/08/2010] 
 
1.5 Buccal delivery of proteins 
The buccal mucosa offers a potential portal for the administration of therapeutic 
agents for both systemic and local delivery. The buccal mucosa has fewer proteolytic 
enzymes than the oral (GIT), nasal, vaginal and rectal administration routes (Lee & 
Yamamoto, 1989). The predominant enzymes found in the buccal mucosa are 
aminopeptidases. The proteolytic enzymes such as trypsin, chymotrypsin and pepsin, which 
are present in the gastric and intestinal fluids, are principally absent (Veuillez et al., 2001; 
Stratford & Lee, 1986). This makes it ideal for the delivery of protein and peptide based drugs 
with relatively reduced risk of proteolytic degradation. 
Generex (Toronto, Canada) has recently demonstrated the efficacy of a buccal INS 
delivery system based on an oral spray which delivers INS in the form of a high-velocity, fine 
SDUWLFOH DHURVRO GLUHFWO\ LQWR WKH VXEMHFW¶V EXFFDO FDYLW\ (Figure 1.8). The particles are 
composed of mixed micelles made from absorption enhancers that encapsulate INS (Guevara-
Aguirre, 2004). The penetration of a thin membrane that guards the surface area in direct 
contact with the blood circulation is made possible by the fast moving fine particles. The 
penetrating particles combined with the effect of absorption enhancers, allow a rapid increase 
(a)
 
(b)
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in the uptake of insulin into the systemic circulation (Modi, 2002). The administered INS 
appears in the systemic circulation within 10 minutes of application. A maximum INS 
bioavailability of 7-8 % was reached in about 30 minutes after application compared to 60 
minutes when a subcutaneous INS injection was administered in a proof-of concept study 
involving type 2 diabetic patients (Guevara-Aguirre, 2004). More clinical and toxicological 
data is required to establish the efficacy of this system, however, Generex Oral-O\Q LV
available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes 
and was approved for sale in India in October 2007. It is in various stages of clinical 
development around the world as the global Phase III clinical trial of Generex Oral-O\QKDV
commenced in the USA, Canada, Russia, Ukraine, Romania, Bulgaria and Poland. 
 
 
Figure 1.8: Buccal delivery of insulin from Generex Oral-O\Q. Available at 
<www.pharmapolis.net/news/drugs-and-therapy/32. > [Accessed; 26/05/2011] 
 
1.5.1 Pros and cons of protein delivery via the buccal mucosa  
Among the major mucosal routes, the buccal mucosa has received increased attention 
in recent years for the delivery of peptides as an alternative to currently used parenteral route 
for protein delivery. Its advantages include the avoidance of pain (Antosova et al., 2009), 
avoiding hepatic first-pass effect (Cornelius et al., 2005) and peptidase metabolism in the 
gastrointestinal tract (Sudhakar et al., 2006).  
Protein (peptide) absorption via the buccal mucosa is however, limited by drug 
molecular size, hydrophobicity and low permeability of the mucosal membrane (Merkle & 
Wolany, 1992) due to the relatively thick multi-layered buccal barrier and the high rate of 
mucus turnover. An enzymatic barrier also exists at the mucosa which causes rapid 
degradation of peptides and proteins, limiting their transport across the buccal mucosa. The 
use of absorption enhancers, enzyme inhibitors and mucoadhesive systems which have been 
investigated as strategies to improve absorption of protein drugs across the buccal mucosa 
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(Veuillez et al., 2001; Nagai, 1986; Aungst and Rogers, 1988) have been discussed  in section 
1.3. 
 
1.5.2 Mechanism of protein transport across buccal mucosa. 
Epithelial and endothelial cell layers form selective permeable barriers. Transport of 
molecules and ions from the apical to the basolateral side and vice versa requires passage 
either through the cells (transcellular route) or between the cells and therefore through tight 
junctions (paracellular route) (Figure 1.9). Transport of ions and hydrophilic solutes occur by 
diffusion across the paracellular route along a concentration gradient. The tight junction 
serves as a regulated restricted semi-permeable diffusion barrier that is ion and size-selective 
(Steed et al., 2010). Materials delivered to the buccal mucosa may pass through the 
intracellular or the paracellular route. The aqueous paracellular pathway contains minimal 
peptidases which are located within the cells. It has been suggested that this is the pathway for 
high molecular weight peptides such as INS (Hoogstraate et al., 1996). Absorption and 
transport are affected by charge, conformation and lipophilicity. 
 
 
Figure 1.9: Mechanism of protein transport across epithelial cell layers. (Yu et al., 2009) 
  
1.6 Buccal adhesive polymers 
 The term buccal adhesive polymer encompasses a large and diverse group of 
molecules, including substances from natural polymers that are susceptible to enzymatic 
degradation, or synthetic polymers that possess hydrolyzable moieties, to biocompatible, 
biodegradable grafted copolymers and thiolated polymers. Bioadhesive formulations employ 
such polymers as the adhesive component. These formulations are often water soluble which 
readily attract water from the biological surface and this water transfer leads to a strong 
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interaction (Figure1.10). They also form viscous gels when hydrated with water which 
increases their retention time on mucosal surfaces and may lead to adhesive interactions.  
 
Figure 1.10: Mucoadhesive drug delivery system via the buccal mucosa. Available at 
<http://www.onsolishcp.com/About-Onsolis/About-Onsolis.php >[Accessed; 20/05/2011] 
 
 Certain physicochemical features such as hydrophilicity, hydrogen bond-forming 
groups, flexibility for interpenetration with mucus and epithelial tissue, and visco-elastic 
properties must be possessed by the bioadhesive polymers (Batchelor, 2004). In addition, the 
bioadhesive polymer should have these ideal characteristics: 
x Polymer and its degradation products should be non-toxic, non-irritant and free from 
leachable impurities. 
x Should have good spreadability, wetting, swelling and solubility and biodegradable 
properties. 
x Should adhere quickly to buccal mucosa and should possess sufficient mechanical 
strength. 
x Should possess peel, tensile and shear strengths within the bioadhesive range. 
x Should show bioadhesive properties in both dry and liquid (gel) state. 
x Should demonstrate local enzyme inhibition and penetration enhancement properties. 
x Should have optimum molecular weight. 
x Should be sufficiently cross-linked but not to the degree of suppression of bond 
forming groups and 
x Should not aid in development of secondary infections such as dental caries. 
(Sudhakar et al., 2006). 
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1.6.1 Chitosan 
Chitosan together with chitin is considered the second most abundant polysaccharide 
after cellulose. Chitosan has received a great deal of attention due to its well documented 
degradability by human enzymes, biocompatibility and low toxicity (Oungbho & Muller, 
1997). However, unlike cellulose, the use of chitosan as an excipient in pharmaceutical 
formulations is a relatively new development. Chitosan (poly[-(1,4)-2-amino-2-deoxy-D-
glucopiranose]) (Figure 1.11) differs from chitin in that a majority of the N-acetyl groups in 
chitosan have been hydrolysed. 
 
 
Figure 1.11: Chemical structure of chitosan.  Available at 
<http://dietpilluniverse.com/uncategorized/chitosan/ > [Accessed; 20/05/2011] 
 
 The degree of deacetylation has significant effects on the solubility and rheological 
properties of the polymer. The amine group on the polymer has a pKa in the range of 5.5 to 
6.5, depending on the source of the polymer (Payne et al., 1996). At low pH, the polymer is 
soluble, with the sol-gel transition occurring at approximately pH 7.0. The pH sensitivity, 
coupled with the reactivity of the primary amine groups, make chitosan a unique polymer for 
mucosal drug delivery applications. Furthermore, its gel and matrix-forming ability makes it 
useful for formulating solid dosage forms, such as granules, microparticles and xerogels. 
Microcrystalline chitosan as a gel-forming excipient for matrix-type drug granules has been 
studied by Sakkinen et al., (2003) who observed that crystallinity, molecular weight, and 
degree of deacetylation were major factors that affected the release rates from the chitosan-
based granules. Combination of positively charged chitosan with negatively charged 
biomolecules, such as gelatin, alginic acid, and hyaluronic acid, were tested to yield novel 
matrices with unique characteristics for controlled release of drugs. 
The excipient also has promise for site-specific delivery. Tozaki et al., (2002) utilized 
chitosan capsules into which was encapsulated a 5-amino salicylic acid for colon-specific 
delivery to treat ulcerative colitis. It was observed that chitosan capsules delivered in-vivo to 
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male wistar rats after induction of colitis disintegrated specifically in the large intestines as 
compared to the control formulation (absence of chitosan) which demonstrated absorption of 
the drug in the small intestines.  
Chitosan has mucoadhesive properties and is often exploited to enhance the residence 
time of a drug on the mucosal membrane thereby increasing the drug bioavailability. A 
comparison between chitosan and other commonly used polymeric excipients indicates that 
the cationic polymer has higher bioadhesivity compared to other natural polymers, such as 
cellulose, xanthan gum, and starch (Kotze et al., 1999). 
 
1.6.2 Pharmaceutical and medicinal uses of chitosan 
A number of clinical studies have reported the use of chitosan as cell scaffolds in 
tissue engineering, nerve regeneration tubes, and cartilage regeneration (Khor & Lim, 2003, 
Freier et al., 2005, Mwale et al., 2005). In addition, it has been used extensively as a 
biomaterial, owing to its immunostimulatory activities (Gorbach et al., 1994), anticoagulant 
properties, antimicrobial and antifungal action (Rabea et al., 2003) and for its action as a 
promoter of wound healing in the field of surgery (Khan et al., 2000). Because of its 
biocompatibility and biodegradation properties (Vandevord et al., 2002), chitosan has been 
used in a variety of pharmaceutical formulations, primarily for the purpose of controlled drug 
delivery (Agnihotri et al., 2004), such as mucosal (Illum et al., 2001, Van Der Lubben et al., 
2001, Read et al., 2005), buccal (Giunchedi et al., 2002), and ocular (De Campos et al., 2004) 
delivery of drugs. 
Due to its cationic nature, chitosan is capable of opening tight junctions in a cell 
membrane. This property has led to a number of studies to investigate the use of chitosan as a 
permeation enhancer for hydrophilic drugs such as peptides that may otherwise have poor oral 
bioavailability (Thanou et al., 2000). Because the absorption enhancement is caused by 
interactions between the cell membrane and positive charges on the polymer, the phenomenon 
is pH and concentration dependant. Furthermore, increasing the charge density on the 
polymer would lead to higher permeability. This has been studied by quaternizing the amine 
functionality on chitosan (Hamman et al., 2003). The amine functionality is further explored 
in the proceeding section. 
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1.6.3 Chitosan derivatives 
The excellent properties exhibited by chitosan have further been improved by 
derivatization via the primary amine functional group. A number of approaches, both 
chemical and enzymatic, have been attempted to exploit the reactivity of the amine functional 
group (Payne et al., 1996). A quaternary derivatized chitosan N-trimethylene chloride 
chitosan (TMC) has been shown to demonstrate higher intestinal permeability than 
unmodified chitosan. The TMC derivative was used as a permeation enhancer for large 
molecules, such as octreotide, a cyclic peptide. Hamman et al., (2003) showed that the degree 
of quaternization of TMC influences its drug absorption-enhancing properties. Polymers with 
higher degrees of quaternization (> 22 %) were able to reduce the trans-epithelial electrical 
resistance and thereby increase epithelial transport (in vitro) in a neutral environment (pH 
7.4). This degree of quaternization was also seen to be critical for in-vitro transport of model 
drugs across a Caco-2 monolayer. These and other useful characteristics (e.g. hydrophilicity, 
functional amino groups, and a net cationic charge) have made chitosan a suitable polymer for 
the intelligent delivery of macromolecular compounds, such as peptides, proteins, antigens, 
oligonucleotides, and genes. 
Chitosan esters such as chitosan succinate and chitosan phthalate have been used 
successfully as potential matrices for the colon-specific oral delivery of sodium diclofenac. 
Aiedeh & Taha, (1999) converted the polymer from an amine to a succinate form, changing 
the solubility profile significantly. The modified polymers were insoluble under acidic 
conditions and provided sustained release of the encapsulated agent under basic conditions. 
They also reported the synthesis of an iron cross-linked derivative of hydroxamated chitosan 
succinate as a matrix for oral theophylline beads (Aiedeh & Taha, 1999). One of the most 
commonly used chitosan derivatives is thiolated chitosan which exhibits unique properties 
and is discussed further in the ensuing section. 
 
1.6.3.1 Thiolated chitosans  
A number of natural and synthetic polymers have generally been considered to be 
mucoadhesive. However, polymers with thiol groups exhibit better mucoadhesive properties. 
Figure 1.12 shows the formation of chitosan-thioglycolic acid (TG-chitosan). The formation 
of stronger covalent bonds between the thiolated polymer and the mucus layer forms the basis 
for the enhanced mucoadhesive property as opposed to weaker non-covalent bonds. Simple 
oxidative processes or disulphide exchange reactions are responsible for the interaction 
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between these thiolated ³thiomers´ polymers (see Figure 1.13), with cysteine-rich 
subdomains of mucus glycoproteins (Snyder et al., 1983). 
 
 
Figure 1.12: Synthesis of chitosan thioglycolic acid (TG-chitosan) (Ayensu et al., 2012a) 
 
 
Figure 1.13: Thiolated chitosan moieties (a) chitosan cysteine (b) chitosan thioglycolic acid 
and (c) chitosan-4-thiobutylamidine (Roldo et al., 2004) 
 
1.6.4 Functional properties of thiolated chitosan 
1.6.4.1 Mucoadhesion 
The stronger covalent bond between the thiol groups of the polymer and the cysteine rich 
subunits of glycoproteins in the mucus layer (Figure 1.14) have been used to explain the 
enhanced mucoadhesive properties of the thiolated chitosans (Leitner et al., 2003). These 
arise from the covalent interactions of the thiolated chitosan with anionic sub-structures of the 
mucus layer. The positive correlation between the degree of modification of thiol bearing 
moieties and the adhesive properties of thiolated chitosan tablets in a tensile study supported 
the theory (Kast & Bernkop-Schnürch 2001, Roldo et al., 2004). In another in-vitro 
mucoadhesive test system, the time of adhesion of thiolated chitosan tablets on intestinal 
mucosa was determined. The increase in contact time of the thiolated chitosan derivatives 
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with increasing amounts of immobilized thiol groups confirmed the findings (Kast & 
Bernkop-Schnürch & Walker, 2001, Bernkop-Schnürch et al., 2003a). 
 
 
Figure 1.14: A schematic diagram showing the formation of disulphide linkages between 
thiomer and mucin. Adapted from Kast & Bernkop-Schnürch. 2001. 
 
  
 A 5±10-fold increase in mucoadhesion was achieved with chitosan-thioglycolic acid 
conjugates whiles chitosan-4-thio-butyl-amidine (chitosan-TBA) conjugate, displaying 264 
mM thiol groups per gram of polymer, led to a more than 100-fold improvement in 
mucoadhesion compared to unmodified chitosan. This represents the most significant 
advancement made so far in the development of mucoadhesive polymers. This phenomenon 
can be explained by the fact that chitosan-TBA conjugates, achieved enhanced ionic 
interactions between its additional cationic amidine sub-structure and anionic sub-structures 
(siallic acids) within the mucus layer. Furthermore, tensile studies with chitosan-TBA 
conjugates of low, medium and high molecular weight (150, 400 and 600 kDa) indicated that 
medium molecular weight thiolated chitosans relatively displayed the highest 
mucoadhesiveness (Roldo et al., 2004). 
 
1.6.4.2 Permeation enhancement 
The permeation enhancing capabilities of chitosan was first shown by Illum and co-
workers (Illum et al., 1994). The use of chitosan in various studies carried out on Caco-2 cell 
monolayers demonstrated a significant decrease in the trans-epithelial electrical resistance, 
leading to enhanced membrane permeation (Artursson et al., 1994, Borchard et al., 1996, 
Dodane et al., 1999). Chitosan is able to improve the transport of hydrophilic compounds 
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such as therapeutic peptides and antisense oligonucleotides across the membrane via the 
paracellular route. Structural reorganization of tight junction-associated proteins, which stems 
from the interaction between the positive charges of the polymer and the cell membrane, 
results in the permeation enhancing effect (Schipper et al., 1997). However, in the presence of 
mucus layer, the permeation enhancing effect is comparatively lower, as chitosan cannot 
reach the epithelium due to size exclusion and/or competitive charge interactions with mucins 
(Schipper et al., 1999). On the other hand, the results obtained on Caco-2 cell monolayers 
were confirmed by in-vivo studies, showing an enhanced intestinal absorption of the peptide 
drug, buserelin, in rats owing to the co-administration of chitosan hydrochloride (Luessen et 
al., 1996).  
The permeation enhancing effect of chitosan has been significantly enhanced by the 
immobilization of thiol groups. Bernkop-Schnürch et al., (1999) employed freshly excised 
intestinal mucosa in Ussing-type chambers to demonstrate the permeation effect of thiolated 
chitosans. The use of 0.5 % chitosan-cysteine conjugate instead of unmodified chitosan led to 
a 1.6-fold improvement in the uptake of fluorescence-labelled bacitracin. Langoth et al., 
(2004) showed the permeation enhancing effect of chitosan-TBA in comparison to 
unmodified chitosan while the uptake of the cationic marker compound, rhodamine-123 was 
3-fold higher in the presence of thiolated chitosan. The inhibition of the protein, tyrosine 
phosphatase (which mediates the opening and closing of the tight junctions) is the likely 
mechanism responsible for this improved permeation enhancement. Tyrosine phosphatase 
which is an essential trans-membrane protein of the tight junctions, functions by 
dephosphorylating the tyrosine subunits of the protein, occluden, resulting in the closure of 
the tight junctions. Phosphorylation of these tyrosine subunits, however, opens the tight 
junctions. Compounds such as phenylarsine oxide, pervanadate and reduced glutathione 
inhibit tyrosine phosphatase which leads to phosphorylation and opening of the tight junctions 
(Clausen et al., 2002, Barrett et al., 1999, Staddon et al., 1995).  
The inhibitory activity of glutathione is however, lowered by rapid oxidation on the 
cell surface compared to the stable but toxic tyrosine phosphatase inhibitors, phenylarsine 
oxide and pervanadate (Grafstrom et al., 1980). However, the capability of thiomers to reduce 
oxidized glutathione can restrict the oxidation of the inhibitor on the membrane when reduced 
glutathione is used in combination with thiolated chitosans (Clausen et al., 2002). Data to 
support the use of chitosan and thiolated chitosans as permeation enhancers for buccal 
delivery of proteins is very scanty with respect to polymer interaction with tight junctions. 
The mechanism to explain the phenomenon can therefore be a subject of further research. 
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1.6.6.3 Thiolated chitosans as matrices for controlled drug release 
The excellent mucoadhesive properties exhibited by chitosan make it a useful means 
for non-invasive drug delivery (Takeuchi et al., 2001). The improved bioavailability of 
incorporated drugs from mucoadhesive polymeric formulations is believed to result from the 
prolonged residence time at the site of absorption. However, such enhanced bioavailability is 
provided by formulations that permit controlled release of the active ingredient. Thiolated 
chitosans, in addition to forming disulphide bonds with mucus glycoproteins also forms inter- 
as well as intra-molecular disulphide bonds. Such cross-linking capability of the polymeric 
chains is responsible for the high stability of drug delivery systems based on thiolated 
chitosans (Roldo et al., 2004). Thiolated chitosans also display, excellent cohesive properties 
besides their strong mucoadhesive and permeation enhancing properties. The cohesion and 
stability of a drug delivery system over the intended duration of drug release is an important 
prerequisite for controlled release. Model drugs, such as clotrimazole have been used to 
demonstrate the effectiveness of thiolated chitosans as carrier matrices for controlled drug 
release (Bernkop-Schnürch et al., 2003a; Roldo et al., 2004; Langoth et al., 2004; Kast et al., 
2002). 
 
1.7 Formulation techniques 
1.7.1 Lyophilisation 
1.7.1.1 Lyophilisation principles 
Lyophilisation is a dehydration technique which enables liquid or slurry products, 
which have previously been frozen to be dried under a vacuum. The basic idea of 
lyophilisation is to "lock in" the composition and structure of the material by drying it without 
applying the heat necessary for the evaporation process. Instead, the lyophilisation process 
converts solid water (ice) directly into water vapour (sublimation), skipping the liquid phase 
entirely (Kasper & Freiss, 2011; Wang, 2000). Sublimation occurs when a molecule gains 
enough energy to break free from the molecules around it.  There are two major factors that 
determine what phase (solid, liquid or gas) a substance will adopt: temperature and 
atmospheric pressure. For a substance to assume any particular phase, the temperature and 
pressure must be within a certain range (Bindschaedler 1999, cited in Wang, 2000). Without 
these conditions, that phase of the substance cannot exist. The chart in Figure 1.15 shows the 
necessary pressure and temperature values of different phases of water. 
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Lyophilisation is often used to stabilize protein products with limited shelf lives in 
solution (Fox, 1995). It is therefore, not surprising that over 50% of the therapeutic protein 
products in the market are lyophiles (Constantino, 2004, cited in Kasper & Freiss, 2011). It is 
important to optimise the lyophilisation cycle because of the physical changes that occur for 
proteins in solution during the freezing and drying phases of the process. Due to the 
amorphous nature of proteins and stabilizer (most commonly sugars and polyols), lyophilized 
formulations often exhibit a glass±rubber transition that is an important parameter in the 
development of the optimum freeze±drying cycle (Nail et al., 2002, cited in Kasper & Freiss, 
2011). Therefore it is imperative that the thermal events such as glass transition of a 
lyophilised product be studied and applied to improve processability, quality and stability of 
the final product (Chen & Oakley, 1995). 
 
Figure 1.15: Phase diagram of water. Available at 
<http://langlopress.net/homeeducation/resources/science/content/support/illustrations/ 
Chemistry/ > [Accessed; 25/05/2011] 
 
1.7.1.2 Critical lyophilisation parameters 
Historically, lyophilisation cycle development could involve 15 to 20 pilot runs before 
achieving an acceptable lyophilized product. The final product would then be assessed based 
on physical appearance, reconstitution time, the stability profile of the active constituents and 
residual moisture content. Without neglecting the preferred qualities mentioned above, time 
and cost implications and meeting market demand have however become major determining 
factors in modern lyophilisation cycle development and optimization. A strong foundation for 
novel cycle developed through to data review acquired from pre-formulation, formulation and 
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stability studies among others can assure an optimised cycle and a resultant stable product 
(Wang, 2000). In the selection of excipients and their respective concentrations, their effects 
on stability of bulk drug, existence of polymorphs, crystalline/amorphous/metastable 
characteristics, pH, oxidative and thermal stability profiles must be addressed in order to 
arrive at an optimised cycle (Franks, 1994). An understanding of the thermal characteristics 
and their determination are crucial in the cycle development (Schwegman, 2009).  
Thermodynamic events such as glass transitions, eutectic temperatures and melting 
point which could occur with changing temperature need to be determined and their effects 
minimized on the stability of the final product. Glass transition temperature of polymeric 
amorphous materials has been determined by various methods (Utracki et al., 1989) such as 
dilatometry, differential scanning calorimetry (DSC) or differential thermal analysis (DTA), 
spectroscopy, diffraction, rheological and dielectric methods. Among them, the DSC method 
is one of the most convenient for determining the glass transition temperature of a polymer by 
measuring the difference in heat capacity (Crowe et al., 1998). Section 1.8.5 details the 
application of DSC in lyophilisation process 
 
1.7.1.3 Lyophilisation cycle 
Generally, the lyophilisation cycle consists of three different phases (Wang, 2000; 
Pikal, 2002): namely freezing stage, primary drying and secondary drying which are further 
discussed below. 
 
1.7.1.4 Freezing  
An initial freezing process is selected, with the intent that the product exhibits the 
desired crystalline structure and that the product is frozen below its eutectic temperature 
(lowest possible complete melting point). Upon completion of product freezing, the product 
will have acquired a frozen structure, which cannot be changed during lyophilisation (Pikal, 
1990). Sublimation and the qualities of the finished product are greatly dependent on this 
crystal structure. In fact, it is considered the most crucial stage of the lyophilisation process 
(Willemer, 1992, cited in Wang, 2000). A typical initial shelf temperature of 5 °C is necessary 
for cycles that require pre-chilling before sample loading as this can impact on product 
stability. The samples must be arranged in a way as to help each vial reach temperature 
equilibration before freezing to the final set point. Strambini & Gabelleiri (1996) have 
indicated that stresses associated with freezing can damage some sensitive molecules such as 
proteins. It is therefore crucial that the selection of the rate of shelf cooling be informed by 
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preliminary investigation of the potential for freezing induced damage, super-cooling, product 
characteristics and the attainment of product stability. The final freezing set point must be 
selected below the glass transition (Tg') to avoid having fluid in the interstitial spaces of the 
product. The product must be completely frozen before the start of the primary drying stage. 
 
1.7.1.5 Primary drying 
The primary drying (sublimation) phase is the stage during which the partial pressure 
of the vapour surrounding the product must be lower than the pressure of the vapour from the 
ice at the same temperature (Willemer, 1992, cited in Wang, 2000). The energy supplied in 
the form of heat during primary drying must remain lower than the product's eutectic 
temperature (the highest allowable product temperature during the conditions of sublimation) 
(Wang, 2000). Once the product is properly frozen, it must be sublimated (evaporated) at a 
low temperature under reduced pressure. With the product maintained at a constant 
temperature, it will be necessary to supply the total energy required for sublimation, from a 
combination of the latent heat of fusion (which supplies the transformation of the liquid to the 
ice state) and the sublimation energy (about 700 calories per gram of ice evaporated). The 
temperature difference between the product and the condenser (a minimum of 20 °C below 
the product temperature) is the driving force for water sublimation (Franks, 1990).   
 
1.7.1.6 Secondary drying 
The secondary drying phase is aimed at eliminating the final traces of water which 
remain due to adsorption (Arakawa et al., 1993, cited in Wang, 2000), and where the partial 
pressure of the vapour rising from the product will be at its lowest levels. At the end of the 
sublimation phase (primary drying), all the ice will have disappeared. The product will begin 
to rise in temperature, and will tend to approach the control temperature of the shelf. This 
must be maintained at the most maximum permissible temperature to liberate the small 
amount of residual moisture embedded within the matrix. However, at this stage the product 
is not sufficiently dry for long term storage. For most products, the residual moisture is in the 
region of 5% to 7% (Ward et al., 2008). The lyophilisation cycle then enters the desorption 
phase during which the last traces of water vapour are removed, along with traces of the 
³ERXQG´ ZDWHU ZLWKLQ WKH product matrix (Bindschaedler, 1999, cited in Wang, 2000). The 
aim of this final phase is to reduce the product to the acceptable moisture levels needed for 
long term storage. The reasons for drying the product to these desired levels are to avoid 
product denaturation at higher water content and chemical or enzymatic changes at forced 
lower residual moisture content. The residual moisture content in the product is dependent on 
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the product matrix, the vacuum of the drying chamber, duration of the secondary phase and 
the maximum temperature allowed in the product during secondary drying.  
At the completion of the freeze-drying process, the treated product will have retained 
its form, volume and original structure as well as all its physical, chemical and biological 
properties. It can then be stored for an almost indefinite period of time. As the product is 
porous, it can be re-dissolved by the simple addition of an appropriate solvent (Bunte et al., 
2010). 
 
1.7.2 The Freeze-drier machine 
A typical freeze drier machine [Figure 1.16(b)] consists of a freeze-drying chamber 
with several shelves attached to heating units, a freezing coil connected to a refrigerator 
compressor and a vacuum pump [Figure 1.16(a)]. The freeze dryer is also equipped with a 
condenser designed and constructed with the ability to condense all vapours from the product 
and to provide a route of minimum resistance to avoid hindering vapour flow. The ice 
condenser provides a vacuum effect via the pressure differential created between the surface 
temperature of the product and the condenser. 
 
Figure 1.16: (a) Simplified freeze-dryer (b) Virtis AdVantage XL70 Freeze dryer. Available 
at <http://www.biopharma.co.uk/biopharma-process-systems > [Accessed; 2/04/2011]. 
(a) (b)
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1.7.3 Gel formation 
A gel is a colloidal solution formed from a continuous solid phase within which 
molecules of a discontinuous liquid phase are dispersed. It is characterised by a network of 
polymeric chains connected by either chemical or physical bonds (Benguigui, 1999). Gels are 
mostly liquid; however, they behave like solids, because of the 3-D cross-linked arrangement 
within the liquid, trapping it through surface tension effects. The cross-linkages in gels impart 
hardness (structure) and tack (stickiness) as a result of physical or chemical bonds that are 
maintained within the extending fluid such as water (hydrogel), oil or air (aerogel). The 
fluidity of gels allows for the display of similar densities with those of their component 
liquids.  
Natural or synthetic hydrogels formed from a network of polymer chains are 
hydrophilic, retaining large volumes of water in their swollen structures with a high degree of 
flexibility, resembling natural tissues (Vashist et al., 2011). They are therefore used as 
scaffolds in tissue engineering (El-Tahlawy et al., 2010, cited in Vashist et al., 2011), 
hydrogel coated wells for cell culture, intelligent drug delivery systems (DDS) (Cenci et al., 
2012) and controlled drug release systems (Luo et al., 2008). Synthetic polymers used in 
hydrogel preparation include polyvinyl alcohol, acrylate polymers and sodium polyacrylate. 
Examples of natural hydrogel ingredients studied for tissue engineering and as DDS are 
chitosan and chitosan derivatives, agarose, methyl cellulose and hyaluronan. 
 
1.7.4 Polymeric buccal drug delivery systems  
1.7.4.1 Polymeric films for drug delivery 
Polymeric films for drug delivery purposes are prepared from hydrogels using either 
solvent casting technique (Boateng et al., 2009, 2010) or hot melt extrusion technique 
(Morales & McConville 2011). Solvent cast is the most commonly used method because of 
ease of process and low cost. In the solvent cast method, a gel is prepared by mixing the 
polymer base with other excipients such as plasticizers and active pharmaceutical ingredient 
(API) in a suitable solvent that may be heated to aid dissolution. The rheological properties of 
the solution are of utmost concern during processing (Barnhart, 2008, cited in Morales & 
McConville 2011). The solution is kept under continuous mixing at a controlled temperature 
to ensure uniform drug distribution and viscosity. Entrapped air which affects film uniformity 
is then removed by dearation to obtain films with desired uniformity (Dixit & Puthli, 2009). 
The solution is then cast in moulds to the desired thickness and subjected to drying process in 
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an oven at an appropriate temperature to remove the solvent. The drying process may be 
controlled to achieve films with desired moisture content. 
Due to convenience and patient compliance, polymeric films have gained significance 
as novel DDSs in the pharmaceutical arena. They have been studied for application as 
mucoadhesive buccal films for local (oral candidiasis) (Repka, 2003 cited in Morales & 
McConville, 2011) or systemic effect (INS delivery) (Giovino et al., 2012). Mucoadhesive 
hydrophilic polymers have the ability to swell, allowing interaction with mucin molecules in 
the mucosal membrane for prolonged attachment and subsequent drug release.  
 
1.7.4.2 Lyophilised xerogels (wafers) as drug delivery systems 
A xerogel is a solid formed from the drying of a gel that exhibits high porosity with an 
enhanced surface area. Solvent removal is mostly achieved by lyophilisation or under 
supercritical conditions that results in a solid with low-density and non-shrinking network. 
Lyophilised xerogels (or wafers) are relatively novel formulations prepared by 
lyophilisation of polymeric solutions or gels to yield solid porous cakes that can easily be 
applied to mucosal surfaces (Mathews et al., 2003; Boateng et al., 2010). Xerogels provide a 
potential means of delivering pharmacological agents such as proteins to mucosal surfaces for 
both local and systemic applications. They offer advantages over other delivery systems such 
as semi solid polymer gels and solvent cast films. Unlike semi solid polymer gels which flow 
easily after application, xerogels, can maintain their swollen gel structure for a longer period 
and therefore longer residence time (Mathews et al., 2005) to allow for effective drug 
absorption. Due to their porous nature and larger surface area, xerogels have a higher drug 
loading capacity compared to the thin and continuous solvent cast equivalent (Boateng et al., 
2010). Xerogels have been developed from sodium alginate and sodium 
carboxymethylcellulose for the delivery of hydrophilic drugs via mucosal surfaces (Boateng 
et al., 2010). Lyophilised xerogels produced from xanthan have been studied to provide an 
effective and stable storage medium for insoluble drugs intended for delivery at the site of 
action (Mathews et al., 2008). 
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1.8 Analytical techniques 
1.8.1 Nuclear magnetic resonance (NMR) spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy has been an important analytical 
technique for structural elucidation of organic compounds over the past five decades. It is the 
only spectroscopic technique that offers a complete analysis and interpretation of the entire 
spectrum. NMR is non-destructive requiring less than a milligram of samples to acquire good 
data though the sample size is usually more than that needed for mass spectroscopy 
(www2.chemistry.msu.edu) or circular dichroism. Proton NMR spectroscopy is a well-
established novel application of NMR, where the NMR spectrometer is tuned to a proton 
(specific nucleus). The spectrum may be obtained by continuous wave (CW) (Figure 1.17) or 
the more preferred pulse Fourier transform technique.  
 
 
Figure 1.17: Typical Continuous wave spectrometer. Available at 
<http://www2.chemistry.msu.edu/faculty/reusch/VirtTxtJml/Spectrpy/nmr/nmr1.htm > 
[Assessed; 25/05/12] 
 
Typically, a solution of the sample in a glass tube (5 mm) covered by a receiver coil is 
oriented between the poles of a strong magnet and spun to average out any magnetic field 
variation and tube imperfections. A radio frequency (rf) radiation is then sent from an antenna 
coil with appropriate energy and the absorbed rf energy emitted is monitored and recorded.   
Acquisition of NMR spectra occurs by magnetic field variation or sweeping, while 
monitoring the rf emission from the sample. 
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Several analytical procedures have been employed to characterise chitosan and 
thiolated chitosans. Techniques such as  1H-NMR (Juntapram et al., 2012; Shigemasa et al., 
1996, cited in Fernandez-Megia et al., 2005), solid state 13C-NMR (Rinaudo, 2006), IR 
(Duarte et al., 2002 cited in Fernandez-Megia et al., 2005), and CD (Domard, 1987, cited in 
Fernandez-Megia et al., 2005) have been reported. However, standards requirements for IR 
and CD procedures and time consumption in the case of solid state 13C-NMR makes 1H-NMR 
an excellent technique for the characterisation of chitosan and its derivatives (Fernandez-
Megia et al., 2005). In addition, 1H-NMR is robust and allows the quick identification of 
impurities present in chitosan samples as well as serves as a calibration tool for other 
analytical procedures such as CD and mass spectrometry (Brugnerotto et al., 2001 cited in 
Fernandez-Megia et al., 2005). 
 
1.8.2 Gel permeation chromatography (GPC) 
Gel permeation chromatography (GPC) is an analytical technique that separates 
analytes based on size. The size exclusion chromatographic technique is often used to analyse 
and characterise polymers using polydispersity index (PDI) and the molecular weight. A 
variety of definitions for molecular weight are used when characterising polymers by GPC. 
These include number average molecular weight (Mn), the weight average molecular weight 
(Mw), the size average molecular weight (Mz) and the viscosity molecular weight (Mv). 
Information obtained from PDI and Mv are used with other data to determine the Mn, Mw and 
Mz. The intrinsic viscosity defines the shape function and the molecular volume which is 
actually measured by GPC. The use of comparable standards allows the use of this relative 
data to determine molecular weights within an accuracy of ± 5 %.  
GPC works as a normal chromatographic procedure using carefully controlled gels as 
stationary phase which desirably lacks ionising groups with low affinity for the analyte in a 
given solvent. Gels such as cephalex, bio-gel, agarose gel and styragel are commercially 
available for different separation procedures. GPC gives well defined time separation as well 
as provides narrow bands. There is less likelihood for analyte loss as there is no physical or 
chemical interaction between the column and analyte (Skoog, 2006). GPC is convenient for 
determining the molecular weight of polymers as the method is less time consuming (Cowie 
et al., 2008). 
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1.8.3 Fourier transform infrared (FT-IR) spectroscopy 
Infrared (IR) spectroscopy is a chemical analytical technique, which measures the 
infrared intensity versus wavenumber of light. Based upon the wavenumber, infrared light can 
be categorized as far infrared (4 ~ 400 cm-1), mid infrared (400 ~ 4,000 cm-1) and near 
infrared (4,000 ~ 14,000 cm-1). An FT-IR spectrometer (Figure 1.18) acquires and digitizes 
the interferogram, performs the Fourier transform function, and outputs the spectrum. Infrared 
spectroscopic studies by Dong et al., (1995) concluded that the acute freezing and dehydration 
stresses of lyophilisation can induce protein unfolding. The enhanced FT-IR studied by Roy 
& *XSWD  LQ WKHFDVHRIEDVLF ILEUREODVW JURZWK IDFWRU DQGȖ-interferon showed large 
conformational changes and aggregation during freeze±drying. This could be prevented by 
using sucrose as a lyoprotectant. In the presence of moisture, freeze±dried proteins can 
undergo disulphide interchange and other reactions, which lead to inactivation. Such 
molecular changes during storage have been described for human INS, tetanus toxoid and 
interleukin-2. The underlying assumption is that IR spectral changes in the amides I and II 
regions upon protein dehydration are caused by protein structural changes (Tattini et al., 
2005). This makes IR useful for providing information about protein conformation and 
stability during processing and storage. 
 
Figure 1.18: Schematic illustration (a) and (b) digital image of FT-IR system. Available at 
<http://thermoscientific.com > [Assessed; 20/07/2011] 
 
1.8.3.1 Attenuated total reflection (ATR-FT-IR) spectroscopy 
Attenuated total reflection (ATR) using FT-IR spectroscopy is considered one of the 
most simple, direct, flexible and sensitive in situ infrared technique for the analysis of the 
surface of materials. In ATR-FT-IR spectroscopy, the IR radiation is passed through an IR 
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transmitting crystal with a high refractive index, allowing the radiation to reflect within the 
ATR element several times. 
 
Figure 1.19: Schematic illustration of ATR-IR through a transmitting crystal. Available at 
<http://www.nuance.northwestern.edu/KeckII/Instruments/FT-IR/keck-ii%20pages1.html> 
[Assessed; 25/07/2011] 
 
The sampling surface is pressed into intimate optical contact with the top surface of 
the crystal such as ZnSe or Ge. The IR radiation from the spectrometer enters the crystal, then 
UHIOHFWV WKURXJK WKH FU\VWDO DQG SHQHWUDWLQJ ³LQWR´ WKH VDPSOH D ILQLWH DPRXQW ZLWK HDFK
reflection along the top surface via the so-FDOOHG³HYDQHVFHQW´ZDYH)LJXUH1.19). To obtain 
internal reflectance, the angle of incidence must exceed the so-FDOOHG µFULWLFDO¶ DQJOH 7KLV
angle (equation 1.1) is a function of the real parts of the refractive indices of both the sample 
and the ATR crystal:  
ĬF VLQ-1 (n2/n1) ..........................equation 1.1 
Where n2 is the refractive index of the sample and n1 is the refractive index of the crystal. The 
depth of penetration of the evanescent wave d is defined as the distance from the crystal-
sample interface where the intensity of the evanescent decays to 1/e (37 %) of its original 
value. It can be given by equation 1.2: 
d =  Ȝ ^ʌQ1[sin 2Ĭ-(n2/n1)2]1/2}.....equation 1.2 
Ȝ is the wavelength of the IR radiation. Different crystals have different refractive indices 
depending on the material used and are applied to different transmission ranges (ZnSe for 
20,000~650 cm-1, Ge for 5,500~800 cm-1). 
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1.8.4 X-ray powder diffractometry (XRPD) 
1.8.4.1 X-ray generation and properties 
X-rays are electromagnetic radiation with typical photon energies in the range of 100 
eV - 100 keV. For diffraction applications, only short wavelength X-rays (hard X-rays) in the 
range of a few angstroms to 0.1 angstrom (1 - 120 keV) are used. X-rays are generally 
produced by either X-ray tubes or synchrotron radiation. X-rays are generated when a focused 
electron beam accelerated across a high voltage field bombards a stationary or rotating solid 
target. As electrons collide with atoms in the target and slow down, a continuous spectrum of 
X-rays are emitted, which are termed Bremsstrahlung radiation. Common targets used in X-
ray tubes include Cu and Mo, which emit 8 keV and 14 keV X-rays with corresponding 
wavelengths of 1.54 Å and 0.8 Å, respectively.  
The peaks in an X-ray diffraction pattern are directly related to the atomic distances. 
For a given set of lattice planes with an inter-SODQH GLVWDQFH RI ³G´ )LJXUH 1.20), the 
condition for a diffraction (peak) to occur can be simply written as equation 1.3 which is 
known as the Bragg's law, after W.L. Bragg, who first proposed it.  
GVLQș n Ȝ..................................equation 1.3 
Where ȜLVWKHZDYHOHQJWKRIWKHX-UD\șWKHVFDWWHULQJDQJOHDQGn an integer representing 
the order of the diffraction peak.  
 
Figure 1.20: The relationship between atomic lattice planes and x-ray diffraction pattern 
Available at < http://web.pdx.edu/~pmoeck/phy381/Topic5a-XRD.pdf  > [Assessed 
25/07/2011]. 
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1.8.4.2 Powder diffraction 
Powder XRD (X-ray diffraction) is perhaps the most widely used X-ray diffraction 
technique for characterizing materials. Powder diffraction data can be collected using either 
transmission or reflection geometry, as shown in Figure 1.21. Because the particles in the 
powder sample are randomly oriented, these two methods will yield the same data.  
 
Figure 1.21: Reflection and transmission geometries  
 
Figure 1.22 shows the Bruker D8 Advance X-ray equipment used in this project. It is a very 
easy to use X-ray diffractometer that measures powders and thin films in the two theta ș 
configuration. The system is fitted with a Lynx Eye detector that is five times more sensitive 
than its predecessor. It is fast, high resolution, sensitive, and robust. The D8 can conveniently 
PHDVXUH IURP WRGHJUHHVș'XULQJPHDVXUHPHQWs, the default power level is 40 kV 
and 40 mA. The X-ray source uses a copper target. By default there should be a 0.6 mm slit 
between the source and the sample.  
 
 
 
Figure 1.22: Bruker D8 Advance XRD. Available at < http://www.bruker-
axs.com/d8_advance.html > [Assessed; 27/07/2011]. 
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1.8.5 Differential scanning calorimetry (DSC) 
Materials that are exposed to changing temperatures will undergo physical or chemical 
changes to their structure. When a material goes through these physical or chemical changes 
as a function of temperature, they will either release a small amount of energy to the 
surrounding environment (exothermic), or absorb some heat from the surrounding 
environment (endothermic). This small amount of heat that is either given off or absorbed by 
the system is the basic principle behind DSC (Ford & Mann, 2012). The DSC instrument 
(Figure 1.23) is composed of a sample and reference chamber (furnaces). DSC incorporates a 
separate heating source for both the sample and reference cells. By having separate furnaces 
for the sample and the reference material, the DSC is capable of calculating the heat flow to 
the sample material. When the sample goes through a physical or chemical change in response 
to a change in temperature, it will give off or absorb a small amount of heat from the 
environment. The instrument senses this and applies or removes heat to keep the sample at the 
same temperature as the reference (Spink, 2008). Since the instrument is measuring heat flow 
instead of just the temperature difference between the sample and reference, it is possible to 
calculate some of the thermodynamic values for the transition.   
 
 
Figure 1.23: The DSC instrument (a) a schematic diagram showing the essential parts of a 
DSC (b) picture of thermal analysis DSC adapted from Mettler Toledo. Available at 
<us.mt.com/.../DSC_Module_DSC1.html > [Assessed; 28/5/2011]. 
 
(a) (b)
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1.8.5.1 Interpreting DSC thermogram in lyophilisation 
The DSC technique has been used to provide qualitative and quantitative information about 
the physicochemical status of drug or excipient particles, which may be involved in either an 
endothermic or exothermic process (Mu & Feng, 2001). The DSC thermal analysis 
experiment gives two key pieces of information that were exploited for lyophilisation cycle 
development. The first information gained from these experiments is the physical form of the 
solids formed during freezing. Specifically, it helps in determining if the system is forming an 
amorphous glassy phase, a crystalline eutectic phase, a metastable glassy phase, or is a 
mixture of these different phases. The second information gained from these studies is the 
critical temperature associated with each of these phases. These critical temperatures are 
important, because they represent the maximum temperature that the product can withstand 
during primary drying without suffering from collapse or eutectic melting. The critical 
temperatures of interest determined through DSC thermal analysis are the glass transition 
temperature (Tg), the eutectic melting temperature (Te), and the collapse temperature (Tc) of 
the product. Identification of the type of event that is occurring as the sample is warmed 
(eutectic melt, glass transition) is based upon the characteristic shape of the curve that is 
generated in the thermogram as the sample goes through that particular thermal event (Nail, & 
Gatlin, 1992). Generally, the Tg is read at the initial change in the slope of the heat capacity 
of the DSC thermogram, i.e. the temperature at the onset of a baseline step in the DSC curve 
(Sakurai et al., 1997). It represents the temperature at which a rubbery state is attained by an 
amorphous material from a glassy state (Bley, 2009, cited in Ford & Mann, 2012). Te refers 
to the point where crystallizing out of the least soluble component of an aqueous protein 
formulation and water occurs at the same time as a mixture, following a further reduction in 
temperature after the crystallization of the least soluble component (Wang, 2000). The Tc is 
the temperature at which the interstitial water in the frozen matrix becomes significantly 
mobile (Jenning, 1999, cited in Wang, 2000).  
Occasionally, sensitivity and or resolution enhancement of a thermogram will be 
needed. For example, some glass transitions occur with such low energy, they cannot be 
detected using a typical DSC heating protocol. Furthermore, transitions will sometimes 
overlap because their onset temperatures are so close. In these particular cases, resolution and 
sensitivity of the instrument can be improved by altering the heating rate through the different 
transitions (Nail et al., 2000). Generally, increasing the heating rate (up to 60 °C/minute) 
through the transitions increases the sensitivity, and decreasing the heating rate (down to 0.1 
°C/minute) through the transitions, increases the resolution. A standard protocol for a DSC 
thermal analysis study would involve cooling the sample from ambient to -60 °C at 5 to 10 
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°C/minute. Once the temperature stabilized, the sample would then be warmed back to 
ambient at approximately 20 °C/minute to remove previous thermal history (Boateng, 2005), 
followed by a second cycle of heating. 
 
1.8.6 Circular dichroism (CD) spectroscopy 
 Circular dichroism (CD) refers to the differential absorption of left handed (L) and 
right handed (R) circular plane polarised light by a substance containing one or more chiral 
chromophores.  
&LUFXODUGLFKURLVP ǻ$Ȝ $ȜLCPL - $ȜRCPL.............equation 1.4 
where Ȝ is the wavelength. The resultant radiation is said to possess elliptical polarisation 
which is the CD signal observed due to the chiral chromophoric groups measured as ellipticity 
(ș) in degrees. Figure 1.24 shows a typical CD spectrometer. 
 
 
Figure 1.24&KLUDVFDQ-plus Circular Dichroism Spectrometer. Available at 
<https://www.photophysics.com/chirascan_plus.php. > [Assessed; 28/05/2012] 
 
CD spectroscopy finds its most important application in the study of large biological 
molecules. It is however used extensively in the study of chiral molecules of all types and 
sizes. CD has become a valuable spectroscopic technique for the study of protein structures in 
solution as well as folding thermodynamics (Greenfield, 2006, cited in Khrapunov, 2009). 
Conformational motifs such as Į-KHOL[HVȕ-pleated sheets, poly-ȕ-proline II-like helices and 
turns of proteins exhibit characteristic far-UV CD spectra (absorption below 240 nm), the sum 
of which can be used to assess secondary structure. Disulphide bonds show weak broad 
absorption bands centred around 260 nm. Near-UV CD spectra may also serve as useful 
probes for protein tertiary structure due to chromophores of aromatic amino acid proteins 
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(absorption in the range 260 to 320 nm). Protein-ligand interactions and protein denaturation 
may also be followed quantitatively by CD technique (Greenfield, 1999). In addition, protein 
CD spectroscopy as a low resolution structural technique allows the description of the overall 
structural features unlike X-ray crystallography or NMR which are able to give structural 
information on proteins at atomic level of resolution but requires highly crystalline proteins 
and high protein concentration respectively. The technique is also rapid (less than 30 
minutes), requires small amount of sample (0.1 -1 mg) and is also non-destructive (Kelly et 
al., 2005).  
 
1.8.7   Thermogravimetry (TG) 
Thermogravimetry (TG) measures the amount and rate of change in the weight of a 
material as a function of temperature or time in a controlled atmosphere. Measurements are 
used primarily to determine the composition of materials and to predict their thermal stability 
at temperatures up to 1000 °C. The technique can characterise materials that exhibit weight 
loss or gain due to decomposition, oxidation, or dehydration. The information that may be 
obtained from TG analysis include composition of multicomponent systems, thermal and 
oxidative stability of materials,  estimating the shelf life of a product, decomposition kinetics 
of materials, the effect of reactive or corrosive atmospheres on materials, moisture and 
volatiles content of materials. The technique is also applied for the analysis of product 
deterioration following kinetic oxidation at hiJKWHPSHUDWXUH5RGUÕJXH]-Spong et al., 2004).   
The analyser (Figure 1.25) usually consists of a high-precision balance with a pan 
(generally platinum) loaded together with the sample. The sample is placed in a small 
electrically heated oven with a thermocouple to accurately measure the temperature. The 
atmosphere may be purged with an inert gas such as nitrogen to prevent oxidation or other 
undesired reactions. The instrument is linked with a computer for controls. A dynamic phase 
of heating is carried out by raising the temperature of the sample gradually and plotting 
weight (percentage) against temperature. Curve smoothing and other parameters may be input 
to determine the exact points of inflection after data acquisition. A current method known as 
hi-resolution TG is often employed to obtain greater accuracy in areas where the derivative 
curve peaks. In this method, temperature increase is isothermal as weight loss increases. This 
is to more accurately identify the exact temperature where a peak occurs. Several modern TG 
devices can vent burn-off to an infrared spectrophotometer to analyse composition. 
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Figure 1.25: Thermogravimetric analyser. Available at < http://www.tainstruments.com > 
[Assessed; 25/07/2011] 
 
1.8.8 Scanning electron microscope (SEM) 
        The scanning electron microscope (SEM) is used for observation of specimen 
surfaces. When the specimen is irradiated with a fine electron beam (electron probe), 
secondary electrons are emitted from the specimen surface. Topography of the surface can be 
observed by two dimensional scanning of the eletron probe over the surface and acquisition of 
an image from the detected secondary electrons. 
 The SEM (Figure 1.26) requires an electron optical system, a specimen stage to place 
the sample, a secondary electron detector to collect secondary electrons, an image display 
unit, and an operation system to perform various operations. The electron optical system 
consists of an electron gun, a condenser lens, and an objective lens to produce an electron 
probe, a scanning coil to scan the electron probe, and other components. The electron optical 
system in the microscope column and the space surrounding the specimen are kept at vacuum 
to avoid collisions between electrons of the beam and stray molecule, to avoid damaging the 
filament and to prevent absorption of X-rays produced from the sample by air molecules 
(www4.nau.edu). 
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Figure 1.26: Representation of SEM. Available at < www.purdue.edu/rem/rs/sem.htm> 
[Assessed; 30/05/11] 
 
In a typical SEM, an electron beam is thermionically emitted from an electron gun 
fitted with a tungsten filament cathode. Tungsten is normally used in thermionic electron guns 
because it has the highest melting point and lowest vapour pressure of all metals, thereby 
allowing it to be heated for electron emission, and because of its low cost. Other types of 
electron emitters include lanthanum hexaboride (LaB6) cathodes. The electron beam, which 
typically has an energy ranging from 0.5 keV to 40 keV, is focused by one or two condenser 
lenses to a spot about 0.4 nm to 5 nm in diameter. The beam passes through pairs of scanning 
coils or pairs of deflector plates in the electron column, typically in the final lens, which 
deflect the beam in the x and y axes so that it scans in a raster fashion over a rectangular area 
of the sample surface. When the primary electron beam interacts with the sample, the 
electrons lose energy by repeated random scattering and absorption within a teardrop-shaped 
volume of the specimen known as the interaction volume, which extends from less than 
100 nm to around 5 µm into the surface. The beam current absorbed by the specimen can also 
be detected and used to create images of the distribution of specimen current. Electronic 
amplifiers of various types are used to amplify the signals which are displayed as variations in 
brightness on a cathode ray tube (CRT). The raster scanning of the CRT display is 
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synchronised with that of the beam on the specimen in the microscope, and the resulting 
image is therefore a distribution map of the intensity of the signal being emitted from the 
scanned area of the specimen. The image is digitally captured and displayed on a computer 
monitor. 
 
1.9 Aims and objectives 
The main aim of this project was to develop, formulate, characterise and optimise 
novel lyophilised formulations (xerogels) that will deliver therapeutically relevant protein-
based drugs via the buccal mucosa route. The development will be focused on obtaining 
formulations with optimized drug loading, drug release and permeation, long shelf-life and 
low toxicity.  
 
The main objectives include: 
1. Pre-formulation studies, to identify and characterise biocompatible and biodegradable 
polymeric systems, with potential for targeting particular organs/tissues and ability to deliver 
proteins via the buccal mucosa, will be carried out. Work will range from basic formulation 
(such as polymer gel preparation, film formation, lyophilisation of polymer gels including 
annealing studies to select the optimum freeze-drying parameters that will ensure product 
stability, in vitro and ex vivo evaluation and stability testing (including use of HPLC, DSC, 
ATR-FT-IR, and CD) of the novel formulations. 
2. Lyophilisation cycle and formulation development using various polymeric systems in 
conjunction with the protein based drugs to obtain an optimised lyophilised buccal drug 
delivery system (xerogel). 
3. Physico-chemical and bio-analytical methods (GPC, NMR, SEM, TA, TGA, DSC, ATR-
FTIR, CD, UV, HPLC and XRD) will be used to characterise the physicochemical properties 
of the protein loaded lyophilised xerogels.  
4. Toxicity (cell viability) studies during and after ex vivo drug permeation studies in Epi-
OralTM buccal tissue constructs and sheep buccal tissue. 
5. Accelerated and real time stability evaluation of the novel drug delivery systems using 
International Conference on Harmonisation (ICH) conditions will be determined. 
6. Potential applications of these characterised systems in important areas such as buccal 
mucosal INS delivery will be explored. 
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CHAPTER TWO 
FORMULATION DEVELOPMENT AND OPTIMISATION 
2.1 Introduction 
Parenteral injections have been the major route of systemic delivery of protein and peptide 
drugs for decades. The challenge of high injection frequency, pain, injection site reactions and 
consequent patient non-compliance still remains (Mathias & Hussain, 2010). Alternative non-
invasive routes (e.g. buccal, nasal, ocular and GI tract) for the delivery of proteins and peptide 
drugs have been investigated (Khafagy et al., 2007; Hearnden et al., 2012). These potential 
routes may also be limited by factors such as enzymatic inhibition in the GIT and at mucosal 
sites, hepatic first pass metabolism and size exclusion at epithelial barriers (Morishita & 
Peppas, 2006). The buccal mucosa offers a potential portal for the administration of 
therapeutic proteins/peptides for both systemic and local delivery (Senel et al., 2000). 
 In developing alternative protein/peptide delivery systems with high bioavailability, 
the use of permeation enhancers (PE), enzyme inhibitors (EI) and the exploitation of 
bioadhesive delivery systems have been investigated as strategies to overcome protein 
permeation challenges and for the maintenance of the biological activity of the proteins 
(Bernkop-Schnürch & Dünnhaupt, 2012). Mucosal drug delivery systems promote less 
frequent dosing, site-specific targeting and maintains effective plasma concentration through 
prolonged attachment and subsequent drug release.  
This chapter briefly discusses background to experimental techniques employed to 
develop chitosan and chitosan-thioglycolic acid (TG-chitosan) xerogels as novel drug delivery 
systems for potential protein drug delivery via the buccal mucosa. The chapter describes the 
various optimisation processes such as membrane dialysis, annealing, thiolation, addition of 
permeation enhancer and the use of enzyme inhibitors. The formulation process involved 
developing xerogels from chitosan based matrices which aim to achieve a drug delivery 
system with optimum functional characteristics including higher drug loading, improved 
hydration and subsequent drug dissolution and mucoadhesion compared to related mucosal 
delivery systems such as films (Boateng et al., 2009). The addition of appropriate 
concentrations of glycerol (GLY) and D-mannitol (D-MANN) with the application of 
membrane dialysis and annealed lyophilisation during processing are expected to impart 
critical characteristics to the xerogel such as flexibility, toughness, reduced crystallinity and 
enhanced microscopic architecture.  
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The advantages of lyophilisation as a drying technique for protein containing xerogels 
have been discussed in chapter one. Model protein drug BSA and the antidiabetic hormone, 
INS, will be incorporated in the xerogels that are expected to combine permeation 
enhancement, protease enzyme inhibition and improved mucoadhesion. These would be 
achieved by the addition of a permeation enhancer, an enzyme inhibitor and thiolation of 
chitosan. These strategies are designed to combat drug hydrophilicity, molecular size and 
proteolytic degradation which limit the permeation of proteins across the buccal membrane. In 
addition, the xerogels will be laminated on one surface by an impervious EC backing 
membrane film to ensure release of the protein drug in one direction after application to the 
buccal membrane. 
 
2.1.1 Annealing 
Ice crystallization occurs during the freezing step of lyophilisation with the solute 
phase becoming highly concentrated. Vitrification of the solute phase to a viscous glass 
occurs as the temperature of the maximally freeze concentrated solute is reduced below the 
Tg' (Pikal, 2002). During freezing, primary drying or even storage, however, a number of 
drugs and excipients tend to undergo incomplete or delayed crystallization resulting in 
formation of mixtures of different polymorphic forms or vial breakage as in the case of 
mannitol (Kim et al., 1998; Liao et al., 2007). These may cause characterisation and 
reproducibility problems for the product. The purpose of annealing is to remove stresses, 
soften the material, toughen and reduce brittleness and to obtain a desired structure. It 
involves heating a material to, and holding at a suitable temperature, followed by relatively 
slow cooling. In the design of a lyophilisation cycle for a formulation which incorporates a 
crystallisable compound, this thermal treatment or annealing must be incorporated into the 
initial freezing step before the primary drying phase is initiated (Searles et al., 2001a). The 
process of annealing allows the product to attain a temperature at or above the glass transition 
and is therefore employed to facilitate quantitative crystallization of the solutes. 
Elevation of product temperature above the Tg ' of the crystallizing component results 
in a significant reduction in viscosity with increased solute mobility. Crystalline and single 
polymorphic forms are then formed under these conditions. It should however, be noted that 
the product temperature must be kept below the eutectic point to avoid ice melting. An added 
advantage of the annealing process is the formation of ice and solute crystals, resulting in 
µ2VWZDOGULSHQLQJ¶ZKLFKLVFKDUDFWHULVHGE\UHGXFHGSURGXFWUHVLVWDQFHIDVWHUZDWHUYDSRXU
transport and reduction in primary drying times (Searles et al., 2001b). Searles et al., (2001a) 
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have recommended annealing time of between two and six hours as additional holding hours 
do not offer any further advantage. After holding the product at the annealing temperature for 
the required period of time, it must then be cooled back to the original freezing temperature, 
allowing adequate time to achieve equilibrium. X-ray powder diffraction (XRPD) and Raman 
spectroscopy have been used to evaluate the effectiveness of annealing through the 
characterisation of physical properties of pharmaceutical formulations (Liu, 2006). Luthra et 
al., (2008) demonstrated that annealing decreases the degradation rate of lyophilized 
aspartame/sucrose and aspartame/trehalose formulations. Their results support the hypothesis 
that thermal history affects the molecular mobility required for structural relaxation and such 
an effect is critical for chemical stability. 
 
2.1.2 Effect of cryoprotectants 
A cryoprotectant is a substance that is used to protect biological tissue from freeze 
damage (due to solute concentration). Conventional cryoprotectants include glycols such as 
ethylene glycol, propylene glycol, glycerol (GLY) and mannitol (D-MANN) (Warne, 2011). 
Dimethyl sulfoxide (DMSO) is also regarded as a conventional cryoprotectant. Mixtures of 
cryoprotectants at reduced concentrations have less toxicity and are more effective than 
single-agent cryoprotectants at higher concentration (Ayensu et al., 2011). Cryoprotectant 
mixtures have been used for vitrification (glass formation), i.e. solidification without any 
crystal ice formation. Some cryoprotectants function by lowering a solution's or a material's 
glass transition temperature. In this way, the cryprotectants prevent actual freezing of the 
material, and the solution maintains some flexibility in a glassy phase. Many cryoprotectants 
also function by forming hydrogen bonds with biological molecules as water molecules are 
displaced. Hydrogen bonding in aqueous solutions is important for proper protein and DNA 
function. Cryoprotectants have also been used to preserve foods. These polyhydroxy 
compounds are typically inexpensive and do not pose any toxicity concerns (Wang, 2000).  
Cryoprotectants have been found to reduce or eliminate the perturbation caused by 
freezing. Slow freezing (3 °C/h) results in markedly less turbidity after freezing compared to 
dipping vials in liquid nitrogen (quench freezing), presumably because the relative area of the 
ice-liquid interface is smaller after slow freezing. Jiang & Nail (1998) measured recovery of 
enzymatic activity of lactate dehydrogenase and ȕ-galactosidase as a function of freezing rate 
and found that the rapid freezing of solutions of these proteins using liquid nitrogen 
consistently resulted in decreased recovery of activity relative to slower freezing methods. 
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Lee et al., (2009) observed that freezing rate and concentration affect the effectiveness of 
cryoprotectants used (sucrose, lactose, mannitol, and polyethylene glycol) for a naproxen 
nano-suspension. Fast freezing rate and high cryoprotectant concentration were generall y 
favoured, when they used an apparatus with a freezing gradient to systematically investigate 
the effect of cryoprotectants on the re-dispersibility of nanoparticles as a function of freezing 
rate. In a few cases however, a slower freezing rate resulted in better re-dispersibility under 
certain conditions such as temperature dependence of solubility or crystallization behavior of 
the cryoprotectant. This is probably because slow freezing can produce a more cryo-
concentrated liquid phase, and the concentrated cryoprotectant in the liquid phase can more 
effectively protect the nano-particles. 
There is a significant body of literature supporting the idea that loss of protein 
integrity during freezing and freeze-drying is, at least in part, an interfacial phenomenon 
involving partial denaturation of protein at the ice/freeze-concentrate interface (Strambini & 
Gabellieri, 1996; Kendrick et al., 1995b cited in Wang, 2000). Liu et al., (2005) observed the 
recovery of activity of the model proteins lactate dehydrogenase and glucose 6-phosphate 
dehydrogenase in a sucrose-glycine-based excipient system after freeze drying by adding 0.01 
% polysorbate 80 (a surface active agent) to the formulation. Their data was consistent with 
an interfacial model for lyophilisation-associated loss of protein activity involving 
denaturation at a solid/freeze-concentrate interface. Trehalose, glucose, mannitol, and sucrose 
were chosen as the cryoprotectants in investigating the diameter and the entrapment efficiency 
of ibuprofen-loaded solid lipid microparticles (SLM) during the freeze-drying process. 
Trehalose and glucose at concentrations of 15 % and 5 % (w/w) respectively were adjudged to 
be the most effective in preventing particle aggregation and in inhibiting leakage from drug-
loaded particles during the SLM freeze-drying process (Zhang et al., 2008). Although the 
literature is replete with protein physical stabilization during lyophilisation by the use of 
sucrose, trehalose, D-MANN (Figure 2.3) and polyethylene glycol as cryoprotectants (Lee et 
al., 2009; Wang et al., 2009; Zhang et al., 2008), these studies did not employ the process of 
annealing in addition to a cryoprotectant in preventing premature crystallisation of the 
crystallisable cryoprotectants. 
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Figure 2.1: Chemical structure of cryoprotectant, D-MANN. Available at 
<http://www.bmrb.wisc.edu/metabolomics/mol_summary/?molName=D_mannitol>  
[Accessed; 25/07/2011] 
 
2.1.3 Effect of plasticisers 
Low molecular weight, non-volatile and non-separating substances capable of 
modifying the physical and mechanical properties of polymers are often termed as 
plasticizers. Their addition to polymeric dosage forms impart flexibility, reduce brittleness , 
increase toughness and improve flow. Common examples include water, GLY (Figure 2.2), 
glycol, propylene glycol and ethylene glycol (Boateng et al., 2009). A plasticizer acts by 
interposing itself between the polymer chain, interacting with the functional group which 
results in reduced interaction and therefore the intermolecular cohesive forces between the 
polymer chains. Greater freedom of mobility occurs within the chain segments due to an 
enlarged space created between the polymer chains by the plasticizer. The enhanced mobility 
and flexibility lowers the glass transition, converting the rigid glassy polymer to the rubbery 
state. Molecular aggregates are therefore formed from the intermolecular secondary valence 
forces which hold the plasticizer and polymer together. 
 
Figure 2.2: Chemical structure of plasticiser GLY. Available at 
<http://www.bmrb.wisc.edu/metabolomics/mol_summary/?molName=GLY > [Accessed; 
25/07/2011]. 
  
2.1.4 Permeation enhancers 
A large number of permeation enhancers have been studied to enhance the absorption 
of proteins across the buccal mucosa. These include synthetic surfactants such as sodium 
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lauryl sulphate, alkyl glycosides (Veuillez et al., 2001), non-ionic surfactants such as 
polysorbate 80 and Brij 35 (Rai et al., 2011).  
 
2.1.4.1 Brij L23 (Brij 35)  
Brij® L23 (Brij 35) also called tricosaethylene glycol dodecyl ether is a synthetic non-
ionic polyoxyethylene ether (surfactant) with molecular formula 
CH3(CH2)10CH2(OCH2CH2)nOH (www.sigmaaldrich.com). It is used for selective and rapid 
solubilisation of microbial membrane aldehyde dehydrogenase (Hommel & Kleber, 1990). In 
general, non-ionic compounds are less irritant than ionic compounds (Volkering et al., 1995 
cited in Rai et al., 2011) due to volume of hydrophilic heads that limits greater membrane 
penetration by the former (Vives et al., 1997). With respect to membrane permeation, the 
critical micelle concentration (CMC) and the hydrophilic-lipophilic balance (HLB) 
parameters of surfactant enhancers have been shown to be the key factors that determine their 
ability to disrupt biological membranes and subsequently increase permeation (Egan, 1976, 
cited in Rai et al., 2011).  
Based on these parameters, Brij 35 (MW = 1225; CMC = 0.05-0.1 mM; HLB = 16.9) 
(www.mbio.com) was selected for this study. The choice of Brij 35 as the permeation 
enhancer for this work stemmed from its high HLB coupled with the low CMC, above which 
the surfactant is effective. The permeation enhancing effect of Brij 35 in combination with 
thiolated chitosan and GSH in the delivery of PACAP formulation via the buccal mucosa has 
been demonstrated by Langoth et al., (2006). 
 
2.1.5 Enzyme inhibitors (EI) 
Though the buccal membrane seems deficient in GIT proteinases such as 
chymotrypsin, pepsin and trypsin, a major challenge in buccal protein delivery is the rapid 
degradation by proteolytic enzymes such as aminopeptidases (Stradford & Lee, 1986), 
endopeptidases, carboxypeptidases and deaminases which are found in various buccal 
epithelia (human, porcine, rat rabbit and cultured hamster buccal cells) (Ho et al., 1992, cited 
in Veuillez et al., 2001). The enzymatic activities in the buccal epithelium may cause protein 
drug degradation before they are absorbed. However, the use of enzyme inhibitors has been 
studied to overcome this challenge (Hearnden et al., 2012). This work focuses on the use of 
glutathione and aprotinin as enzyme inhibitors for xerogels containing BSA and INS as the 
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model proteins for buccal delivery. Development studies were conducted to determine the 
optimum concentration of EI for subsequent in vitro permeation studies. 
 
2.1.5.1 Glutathione (GSH, Ȗ-L-Glutamyl-L-cysteinyl-glycine) 
Glutathione (GSH) is a tripeptide which is attached by a peptide linkage between the 
amine group of glycine and the carboxyl group of cysteine. The amine group of cysteine is 
however attached by an unusual peptide linkage with the carboxyl group of the glutamate 
side-chain (Figure 2.3). As an antioxidant, it prevents damage of important cellular 
components by reactive oxidative species such as peroxides and free radicals (Pompella et al., 
2003) 
 
Figure 2.3: Ȗ-L-Glutamyl-L-cysteinyl-glycine (GSH). Available at 
<http://www.sigmaaldrich.com/catalog/product/sial/g4251?lang=en&region=GB >[Assesses 
24/05/2012] 
 
Disulphide bonds formed within cytosolic proteins to cysteines are reduced by 
glutathione via electron donation, converting it to oxidised glutathione (GSSG). Glutathione 
reductase reduces GSSG back to reduced glutathione using NADPH as the electron donor 
(Pastore et al., 2003). Recently, GSH has been used as an inhibitor of melanin in the cosmetic 
industry through competitive interference of L-DOPA (L-3,4-dihydroxyphenylalanine) to 
bind to tyrosinase during the synthesis of melanin (Matsuki et al., 2008).  
It has been suggested by Langoth et al., (2005) that oxidised glutathione located on the 
surface of the buccal mucosa in the presence of free thiol groups such as thiolated chitosan are 
reduced. Protein-tyrosine-phosphatase is therefore inhibited by reduced glutathione with 
subsequent phosphorylation of occludin. The phosphorylation leads to the opening of tight 
junctions and hence the transport of proteins and peptides across the membrane (Barrett et al.,  
1999, cited in Langoth et al., 2005).  
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2.1.5.2 Aprotinin (APR) 
Aprotinin is a naturally occurring monomeric globular polypeptide (Figure 2.4) 
derived from bovine lung tissue. Aprotinin, also termed basic pancreatic trypsin inhibitor 
(BPTI) has a molecular formula of C284H432N84O79S7, an approximate molecular weight of 
65112 and consistVRIGLIIHUHQWDPLQRDFLGVFRQWDLQLQJGLVXOSKLGHVDWZLVWHGȕ-hairpin 
and C-WHUPLQDOĮ-helix (www4.mpbio.com).  
 
 
Figure 2.4: Showing (A) the amino acid sequence of aprotinin and (B) cartoon representation 
of the polypeptide showing sites of disulphide bonds and trypsin binding. Available at 
<http://www.sigmaaldrich.com/life-science/metabolomics/enzyme-explorer/aprotinin-
monograph.html > [Accessed; 24/05/2012]. 
 
Aprotinin has a concentration dependent effect as a serine protease inhibitor (Engles, 
2005) and has many beneficial clinical activities as well as complex effects on functions such 
as coagulation and inflammation. It exhibits a complex interaction with drugs such as 
angiotensin converting enzyme (Waxler & Rabito, 2003). The competitive inhibitor forms 
stable complexes with enzymes and blocks their active sites. The reversible aprotinin-protease 
complexes dissociates at pH < 3.2 or >10. One trypsin inhibitor unit (TIU) decreases the 
activity of 2 trypsin units by 50 %, where 1 trypsin unit will hydrolyse 1.0 µmole of N-Į-
benzoyl-DL-arginine p-nitroaniline (BAPNA) per minute at pH 7.8 and 25°C 
(www.sigmaaldrich.com). It is reactive against trypsin, chymotrypsin, plasmin, kallkrein, 
urokinase, clotting factor XIIa, protein C, proteinases of the complement system and 
leucocytes and tissue proteinases (www4.mpbio.com).  
Aprotinin is relatively stable against denaturation at high temperature, acids, alkalis, 
proteolytic degradation and organic solvents due to its compact tertiary structure. The serine 
protease inhibitor has been used as an enzyme inhibitor to increase the bioavailability in a 
(A) (B)
3 Disulphides 
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microemulsion formulation containing recombinant human INS (Çilek et al., 2005). The 
protective effect of aprotinin and other protease inhibitors against digestive enzymes pepsin, 
WU\SVLQDQGĮ-chymotrypsin has also been studied by Morishita et al., (1997) using Eudragit 
L100 INS microspheres. Their results indicated that protease inhibitors are capable of 
protecting INS from proteolytic degradation. Aprotinin has also been used to minimise the 
degradation of proteins in the rabbit buccal mucosa (Yamamoto et al., 1990, cited in Walker 
et al., 2002). 
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2.2 Materials and methods 
2.2.1 Materials 
Table 2.1: Details of materials used in the formulation development and optimisation  
Material Description Supplier 
Chitosan (medium molecular 
weight) 75-85 % deacetylated 
448877-250 G Sigma-Aldrich, Gillingham, UK. 
Thioglycolic acid T 3758-100 ML Sigma-Aldrich, Gillingham, UK. 
N-(3-Dimethylaminopropyl) -
N- ethyl carbodiimide 
hydrochloride (EDAC) 
E 6383-5 G 
$VVD\ 
Sigma-Aldrich, Gillingham, UK. 
Glycerol (GLY) (anhydrous) $VVD\ Sigma-Aldrich, Gillingham, UK. 
D-mannitol (D-MANN) M9546-250 G Sigma-Aldrich, Gillingham, UK. 
BSA (mol wt. ~66 kDa) A7906-100 G Sigma-Aldrich, Gillingham, UK. 
Acetic Acid A /0360/PB17 Fisher Scientific, (Leicester UK) 
Hydrochloric acid H /1150/PB 17 Fisher Scientific, (Leicester UK) 
Sodium chloride S /3120/60 Fisher Scientific, (Leicester UK) 
Sodium hydroxide  S 240697 Sigma-Aldrich, Gillingham, UK 
Potassium dihydrogen 
phosphate 
P /4760/53 Fisher Scientific,(Leicester UK) 
PBS tablets pH 7.4 Sigma-Aldrich, Gillingham, UK 
Ethylcellulose powder 200646-250G Sigma-Aldrich, Gillingham, UK 
Ethanol (absolute) 02865-2.5L Sigma-Aldrich, Gillingham, UK 
Recombinant human insulin  12643-50MG Sigma-Aldrich, Gillingham, UK 
Brij 35 16005-250G-F Sigma-Aldrich, Gillingham, UK 
L-Glutathione reduced G4251-25G Sigma-Aldrich, Gillingham, UK 
Aprotinin (bovine lung) A1153-25MG Sigma-Aldrich, Gillingham, UK 
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Table 2.2: Details of consumables used in the formulation development and optimisation  
Consumable Supplier 
ȝ/$OXPLQLXPFUXFLEOHV Setaram, UK 
Magnetic stirrer Fisher Scientific,(Leicester UK) 
ȝ/$OXPLQLXPFUXFLEOHV Mettler Toledo, UK 
Aluminium lids Mettler Toledo, UK 
1 mL Eppendorf tubes Fisher Scientific,(Leicester UK) 
Blue, white and yellow micropipette tips Fisher Scientific,(Leicester UK) 
100 Ml, 250 mL, 500 mL, 1 L, 5 L beakers Fisher Scientific,(Leicester UK) 
 
2.2.2 Preliminary investigations: solution preparation and membrane dialysis 
500 mg of chitosan (CS) was dissolved in 50 mL of acetic acid (1 % v/v) and the pH 
adjusted to 6 ± 0.1 with 5M NaOH added dropwise. The resulting polymer gel was dialysed 
against 5 L of 5 mM HCl five (5) times, replacing the dialysate medium every 8 hours using 
Spectra/Por® Float-A-Lyzer® G2 dialysis device (8-10 kDa molecular weight cut-off; 
cellulose ester  membrane, Sigma, Gillingham, UK) (Bernkop-Schnürch et al., 2003b). The 
process was repeated but omitting the exhaustive dialysis phase in order to assess the effect of 
excess acetic acid and the newly formed sodium acetate on formulation characteristics.    
Formulation studies were carried out as summarised in Tables 2.3 and 2.4. Varying 
amounts (0-20 % relative to polymer weight) of GLY and D-MANN as plasticizer and 
cryoprotectant respectively were added to the undialysed or recovered dialysed gel. The 
optimised formulation was then loaded with BSA at two different concentrations as a model 
protein drug (see Table 2.3).  
 
Table 2.3: Matrix chitosan formulations prepared in preliminary stages  
Component  Content of formulations (mg) 
 Non drug loaded Drug loaded 
 Control A B C D E F G1 G2 
Chitosan 100 100 100 100 100 100 100 100 100 
GLY (plasticizer) - - 10 20 20 10 10 10 10 
MANN (cryoprotectant) - 10 10 10 20 - 20 10 10 
BSA (model drug)  - - - - - - - 50 100 
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Table 2.4: Optimised drug loaded chitosan/TG-chitosan formulations with permeation 
enhancer and various amounts of different enzyme inhibitors (cf Table 2.3) 
Component  Formulations (mg) 
G1a  G1b G1c G1d 
Chitosan/ TG-chitosan 100 100 100 100 
MANN 10 10 10 10 
GLY 10 10 10 10 
Brij 35 10 10 10 10 
APR   0 5 0 0 
GSH 0 0 5 10 
BSA 50 50 50 50 
 
 The effects of varying amounts of different enzyme inhibitors (EI) and permeation 
enhancer (PE) on formulation characteristics was studied by incorporating 0-10 % (relative to 
polymer weight) of reduced glutathione (EI), 0-5% aprotinin (EI) and 10% Brij 35 (PE) 
(Langoth et al., 2006) (Table 2.4). The final chitosan gel was stirred continuously for 15 
minutes to obtain a uniform gel at room temperature and kept for 30 minutes to remove all air 
bubbles. 
 
2.2.3 Synthesis of chitosan-4-thioglycolic acid (TG-chitosan) 
TG-chitosan was synthesised as previously described (Saboktakin et al., 2011). 500 
mg of chitosan was dissolved in 50 mL of 0.1 M HCl. An equivalent of 500 mg of 
thioglycolic acid (TGA) was added, followed by 50 mM EDAC in order to activate the 
carboxylic moieties of TGA and the pH adjusted to 5 with 1M NaOH. After an incubation 
period of 4 hours at room temperature under continuous stirring at 150 rpm in the dark, the 
resulting thiolated polymer was dialysed to eliminate unconjugated TGA against different 
aqueous media: (i) 8 hours against 5 L of 5 mmol/L HCl, (ii) 8 hours against 5 mmol/L HCl 
containing 1% NaCl (twice) to curtail ionic interactions between the cationic CS and the 
anionic sulfhydryl ligand and finally (iii) 8 hours against 5 L of 5 mmol/L HCl (twice) in the 
dark using the dialysis device previously described. The dialysed products were either used 
directly for formulation or first lyophilised (section 2.2.5) and stored at 4 °C pending further 
analysis. The process is summarised in Figure 2.5.  
Gel formulations were prepared as previously described in section 2.2.2 (formulation 
G1, Table 2.3 with TG-chitosan replacing chitosan) and the final gel containing 1 % w/v TG-
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chitosan was stirred continuously for 15 minutes to obtain a uniform gel at room temperature 
and kept for 30 minutes to remove all air bubbles. Unmodified chitosan served as the control. 
  
2.2.4 Preparation and permeability studies of ethyl cellulose (EC) backing membrane 
 To ensure unidirectional release of BSA in the buccal mucosa, an impervious backing 
film (laminate) made of 1 g ethyl cellulose dissolved in 20 mL of ethanol and plasticized with 
2 g of GLY (Cui et al., 2008) was prepared. 250 mg of the resultant gel was poured into 24 
well polystyrene moulds (diameter 12 mm) (Thermo Fisher Scientific, Leicester, UK) and 
dried over silica beads in a desiccator for 24 hours and subsequently at room temperature for 
24 hours. The dried films were covered with parafilm and kept in the refrigerator till required.  
To assess the permeability of the EC laminates, the final weights of the films after 
immersion in phosphate buffered saline (PBS) pH 6.8 was statistically compared with their 
initial weights. In addition, the EC laminate was used as a membrane between the donor and 
receiver compartments of a Franz-type diffusion cell and sealed with parafilm. 1.50 mL 10 % 
w/v solution of BSA in 0.1 M PBS (pH 6.8) was placed in the donor compartment and the 
receiver compartment filled with 8.00 mL 0.1 M PBS with magnetic stirring. The 
permeability of the EC laminate was determined by evaluating the amount of BSA in both 
FRPSDUWPHQWVDIWHUKRXUXVLQJ%UDGIRUG¶VDVVD\ 
 
 
Figure 2.5: A schematic diagram for the synthesis of thiolated chitosan. 
 
 
Chitosan (500mg) + 
0.1M HCl
Thiolated chitosan. Stirred 
at room temp. For 3-4hrs
pH 5 1M NaOH
Dialysis in aqueous media
Lyophilisation
Formulation
EDAC 50mM Thioglycolic acid 500mg
Thiolated
polymer 
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2.2.5 Annealing studies  
A DSC-1 Thermal Analyser (Mettler Toledo Ltd, Leicester, UK), calibrated with 
indium was used to analyse the thermal events in the formulated gels to determine a suitable 
lyophilisation cycle.  The chitosan gels (undialysed, unmodified dialysed and thiolated) were 
initially cooled in 40 µL aluminium pans with pierced lids on the DSC from 25 to - 55 °C at a 
rate of 10 °C/min. They were then heated to 25 °C at a rate of 20 °C /min to improve 
sensitivity and the cycle repeated twice. Based on thermal events observed during the heating 
cycles, an annealing temperature of -25 °C was deemed optimum. The samples were then 
warmed to -25 °C after initial cooling to - 55 °C and held at this temperature for 10 minutes. 
They were cooled back to the original freezing temperature and then warmed through to 25 
°C at 20 °C /min (Ayensu et al., 2011). 
 
2.2.6 Lyophilisation 
1 g each of the homogeneous (formulated chitosan and TG-chitosan) gels were added 
unto the dried hydrophobic EC films in the moulds and lyophilised using the automated novel 
lyophilisation cycle shown in Table 2.5 on a Virtis AdVantage XL 70 freeze dryer 
(Biopharma Process Systems, Winchester, UK). The freeze-drying cycle was developed based 
on the preliminary thermal characterization (annealing) by DSC as described in section 2.2.5 
above. The end of the primary drying (ice sublimation) stage was determined by probes 
signalling equal product and shelf temperatures. The effect of annealing on the drug loaded 
formulations was determined by carrying out the lyophilisation cycle with and without the 
process of annealing. The resulting lyophilised xerogels were stored over silica gel in 
desiccators to maintain low water content ideal for maintaining protein stability, till ready for 
characterisation. In addition, xerogels obtained directly from lyophilised dialysed TG-chitosan 
gel were assessed against those formulated from freeze-dried TG-chitosan powder. The 
characteristics of the optimised formulation were further explored by loading with 
recombinant human INS powder (Table 2.6) which had previously been dissolved in a 
minimal amount of 0.01 M HCl (200 µL HCl/mg insulin) (Portero et al., 2007). The effects of 
the EI on INS containing xerogel properties were studied.  
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Table 2.5: Lyophilisation cycles with and without an annealing process 
Step Thermal treatment  Primary drying process 
 Temperature                
(°C) 
Time 
(min) 
Ramp/Hold 
R/H 
Temperature 
(°C) 
Time 
(min) 
Vacuum 
(mTorr) 
 Annealed Non-annealed 
1 +05 +05 30 H -30 420 50 
2 -05 -05 30 H -30 420 20 
3 -55 -55 120 H   Secondary drying process 
4 -25 -55 180 H +20 360 10 
5 -55 -55 180 H    
 
Table 2.6: Optimised chitosan/TG-chitosan formulations loaded with INS. 
Component Formulations (mg) 
INS1 INS2 INS3 
TG-chitosan 100 100 100 
MANN 10 10 10 
GLY 10 10 10 
Brij 35 10 10 10 
APR   0 5 0 
GSH 0 0 10 
INS 20 20 20 
INS1, TG-chitosan-INS; INS2, TG-chitosan-APR-INS; INS3, TG-chitosan-GSH-INS.  
 
2.3 Results and discussion 
2.3.1 Preliminary investigations: 
2.3.1.1 Gel preparation 
In the present study, medium molecular weight chitosan of concentration 1% w/v was 
used as the base matrix in order to guarantee high mucoadhesive properties (Roldo et al., 
2004). Various formulations containing different combinations of a plasticiser and a 
cryoprotectant were screened for acceptable lyophilisation behaviour and visual elegance of 
the resulting product. Physical examination of the unplasticised formulation (A), revealed 
strong but brittle xerogels that were easily broken along fractured surfaces. There was 
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increased flexibility with increasing GLY content as it lowered the stresses generated during 
lyophilisation, allowing the xerogels to accommodate the stress. The plasticizer acts by 
interposing itself between the polymer chains and interacting with the functional groups 
which resulted in reduced interaction and therefore the intermolecular cohesive forces 
between the polymer chains. In the case of hLJKO\SODVWLFL]HGIRUPXODWLRQVµ'¶DQGµ&¶ (Table 
2.3), the xerogels were sticky, making removal from the mould and handling difficult. 10 % 
(per polymer weight) of GLY in fRUPXODWLRQVµ%¶ (Figure 2.6 image a) DQGµE¶7DEOH 
however, produced adequately flexible, tough and non-brittle xerogels.  
During the formulation optimization studies, 10 % (per polymer weight) of D-MANN 
was found effective, as xerogels with no cryoprotection could not be expected to maintain 
stability of the protein in the lyophilised product. Although loading up to 20 %  (per polymer 
weight) of D-MANN formed tough, flexible, porous and structurally stable xerogels, 
combinations with varying concentrations of GLY produced xerogels with rough and cracked 
surfaces with the sides caving inwards as was observed in formulations µD¶ (Figure 2.6 image 
bDQG µ)¶ (Table 2.4). Such formulations were difficult to remove from the mould without 
damaging the xerogels. D-MANN as a cryoprotectant for the model protein drug (BSA) is 
important in preventing actual freezing of the drug and causing the solution to maintain some 
flexibility in a glassy state. During the freezing stages, hydrogen bonds form between the 
cryoprotectant and the protein molecules as water molecules are displaced. As the 
cryoprotectant replaces the water molecules, the protein material retains its native 
physiological structure (and function), although they are no longer immersed in an aqueous 
environment.   
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Figure 2.6: Photographs of non-GUXJORDGHGFKLWRVDQ[HURJHOVSUHSDUHGIURPIRUPXODWLRQµ%¶
(image a) showing a flexible, tough and non-EULWWOH [HURJHO DQG IRUPXODWLRQ µ'¶ image b) 
showing a rough and cracked surface. Images labelled (c) and (d) are annealed and non-
annealed BSA loaded chitosan xerogels respectively. 
 
Functionally, both GLY and D-MANN could act as plasticizers as well as 
cryoprotectants (Dashnau et al., 2006, Karbowiak et al., 2006, Tommaso et al., 2010). When 
used on their own however, the formulations obtained were not deemed ideal whilst a 
combination of the two in a single formulation creates a synergistic effect. Additionally, using 
a combination of the two compounds, each at a lower concentration, produced better 
formulations as undesirable effects of a single agent at a higher concentration were 
minimized.  
On the basis of structural integrity of xerogels and prevention from structural collapse 
after lyophilisation, the formulation µB¶ containing equal proportions of both GLY and D-
MANN (10% each respectively) was the formulation of choice for drug loading (Table 2.3). 
These xerogels were white, flexible and tough, porous, of uniform mass, texture and 
thickness. Furthermore, they were elegant in appearance with no visible cracks, easily 
regained their original configuration upon gentle compression and did not break when bent. 
Such optimised characteristics make formulation µB¶ suitable for easy application and 
potentially ensuring patient compliance.  
Optimised BSA amount of 50 % per polymer weight in the optimised formulation was 
adequate to prevent problems encountered with high-dose products during the lyophilisation 
d
ba
c
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process. These include the inability to form xerogels of the same thickness as the original gel 
but instead resulted in a powdery product similar to freeze-dried powder injections for 
reconstitution. This made it difficult to test for hydration, mucoadhesion and drug dissolution 
characteristics. Formulations with high drug loading do not leave much room for 
lyophilisation agents. A CS: BSA ratio of 2:1 gave a better lyophilised xerogel compared to 
the powdery product that was obtained when a 1:1 ratio of CS: BSA was used. 
 
2.3.1.2 Membrane dialysis 
The process of dialysis was employed to remove excess acetic acid and sodium acetate 
(NaAc) that crystallizes during lyophilisation and interfere with the physico-mechanical 
properties and characterisation of the lyophilised chitosan cakes. Physical examination of 
dialysed xerogels (17.1 ± 2 mg), with theoretical composition by weight of chitosan (10.0 
mg), BSA (5.0 mg), GLY (1.0 mg) and D-MANN (1.0 mg) per xerogel, revealed tough and 
flexible (non-brittle) xerogels. Although the undialysed xerogel (33.9 ± 3 mg) which had a 
similar theoretical composition by weight of chitosan, BSA, GLY and D-MANN as in the 
dialysed xerogel above, seemed elegant in appearance, a closer physical examination showed 
much brittleness and hardness even with the presence of plasticiser. It showed approximately 
double, the average weight per xerogel and the difference in weight (16.8 mg) is attributable 
to the formation of NaAc during the gel preparation stage (Ayensu et al., 2012b) 
 
2.3.2 Synthesis of chitosan-4-thioglycolic acid (TG-chitosan) 
In the thiolation study, TGA was bound to chitosan via amidation between the 
carboxylic group of TGA and primary amino groups of the polymer. The reactivity of the 
primary amino group at the 2-position (Figure 1.11, chapter 1) of the glucosamine subunit of 
chitosan was exploited for the immobilization of thiol groups. The primary amino group was 
covalently attached to the sulfhydryl bearing agents via an amide linkage. For ligands such as 
cysteine and thioglycolic acid, the amide bond formation between the carboxylic acid group 
and the primary amino group is mediated by a water soluble coupling agent, N-(3-
Dimethylaminopropyl)-N-ethyl carbodiimide hydrochloride (EDAC), (Kast & Bernkop-
Schnürch, 2001)7KHSURFHVVZDVSHUIRUPHGDWDS+WRSUHYHQWWKHDFFLGHQWDOIRUPDWLRQ
of disulphide bonds by air oxidation during synthesis. The reactive thiolate anion 
concentration for the oxidation of thiol groups is low at this pH, excluding the formation of 
disulphide bonds. Inert conditions may alternatively be employed for the coupling reaction. A 
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simple one step coupling reaction involving the use of 2-iminothiolane as a coupling reagent 
offers an advantage in the case of amidine bond formation (Bernkop-Schnürch et al., 2003a). 
The chemical structure of the reagent protects the thiol group of the reagent against oxidation. 
This reaction is however, limited by cost and time.  
 
2.3.3 Preparation of ethylcellulose (EC) backing membrane 
The thin opaque films of thickness range 230 ± 15 nm obtained were flexible and 
tough. The controlled drying in the desiccator followed by drying at room temperature 
prevented rapid evaporation of alcohol that results in the formation of patched brittle films. 
The use of GLY as plasticizer helped to increase flexibility in addition to improving the 
adhesion process for the attachment of chitosan/TG-chitosan gel to the hydrophobic EC 
laminate (Cui et al., 2008). The films were deemed impervious as no statistically significant 
differences were observed between the initial and final weights after submersion in PBS for 4 
hours. The impermeability of the EC laminate was further confirmed with the complete 
absence of BSA in the receiver compartment of the Franz-type diffusion cell. In addition, 
there was no change in the concentration of BSA in the donor compartment of the Franz-type 
diffusion cell.  
Figure 2.7 summarises the processes involved in the gel formulation and drying of the 
EC backing membrane, on which the chitosan/TG-chitosan polymeric gel formulations were 
added and subsequently lyophilised to obtain the EC laminated chitosan/TG-chitosan xerogels 
which were stored over silica gel in desiccators until ready for characterisation.  
 
 
Figure 2.7: A schematic diagram for the preparation of EC laminated chitosan/TG-chitosan 
xerogels. 
 
EC gel
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Lyophilisation
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2.3.4 Annealing studies   
Representative DSC thermograms of chitosan-BSA gel (undialysed and dialysed) are 
shown in Figure 2.8. Glass-transition (Tg') temperature of -44.5 °C (Figure 2.8 [b]) was 
observed for the undialysed non-annealed Chitosan-BSA gel. The eutectic and ice melts were 
observed between an onset of -5 °C and midpoint of 13.0 °C. To avoid the formation of a  
 
Figure 2.8: DSC thermograms of different CS-BSA gels which were (a) dialysed annealed 
(b) undialysed non-annealed and (c) undialysed annealed.  
 
metastable glass which will eventually crystallize and affect the stability of the protein, 
samples were heated to -25 °C above the measured glass transition temperature (but below the 
eutectic and/or ice melting temperature) of the mixture, allowing the glass to relax and 
crystallize during the freezing stage. Figure 2.8 (c) shows the thermogram of the heating stage 
of the undialysed annealed Chitosan-BSA gel, where no glass transition but rather the 
eutectic/ice melt, was observed between onset -4 °C and midpoint 14.5 °C. The effectiveness 
of the annealing process was evidenced by the disappearance of the glass transition in the 
heating cycle. Based on the thermal events observed during the heating cycle, an annealing 
temperature of -25°C was chosen and incorporated into the thermal treatment step for the 
freezing stage of the lyophilisation cycle. For the dialysed Chitosan-BSA gel in Figure 2.8 (a), 
no glass-transition was detected by the DSC in the frozen concentrate implying no phase 
separation during the freezing stage of the lyophilisation process.  
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2.3.5 Lyophilisation   
The primary drying phase of the lyophilisation cycle was deemed complete when the 
product temperature measured by means of probes equalled the shelf temperature of -30 °C 
after 14 hours (Figure 2.9). The incorporation of an annealing process helped to achieve faster 
water vapour transport, shorter primary drying time and elegant porous xerogels.  
 
Figure 2.9: Schematic diagram of the annealed and non-annealed lyophilisation cycles 
 
 Annealing as a process step maintained the samples at a specified temperature below 
the equilibrium freezing point but above the glass transition temperature (-25 °C) for 3 hours. 
This allowed for the formation of larger ice crystals resulting in increased sublimation rate 
during the primary drying stage, creating larger pores in the process (chapter 3, Figures 3.30 
A and C). In addition, the process of annealing facilitated quantitative crystallisation of the 
active ingredients and led to improved pore size distribution of ice crystals as in Ostwalt 
ripening, a process that allows smaller ice crystals to fuse together, forming large crystals that 
leaves in its wake, large pores following ice sublimation [Searles et al., 2001(b)].  
Flexible, tough, non-brittle and porous lyophilised TG-chitosan xerogels were also 
produced. The presence of GLY in the TG-chitosan xerogel led to enhanced flexibility as 
freeze induced stress generated during lyophilisation is lowered, allowing the xerogels to 
accommodate the stress as was observed with the chitosan xerogels.  A combination of two 
different cryoprotectants (or plasticizers), each at reduced concentration, has a better outcome 
since undesirable effects such as brittleness (D-MANN) or stickiness (GLY) produced by 
higher concentrations of a single agent was reduced. Furthermore, elegant porous TG-chitosan 
xerogels were achieved by incorporating an annealing process during the freezing stage. 
Annealing also promotes ice crystal growth and complete crystallisation of MANN (maximise 
the degree of crystallinity in materials), thus preventing premature crystallisation of mannitol 
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(Searles et al., 2001a). The reason for annealing MANN is to allow crystal formation from the 
amorphous phase so that metastable MANN does not re-crystallize on storage, which will 
affect product stability.  
Xerogels obtained directly from dialysed TG-chitosan gel were evaluated against 
those formulated from lyophilised TG-chitosan powder. The dialysed gel produced elegant 
xerogels and prevented double lyophilisation, saving time and cost. Since no significant 
differences were observed between the characteristics of the xerogels from the two processes, 
industrial applicability of direct formulation would be of more benefit than manufacture via 
lyophilised TG-chitosan powder 
Different xerogels were obtained from the optimised formulations containing different 
EI (GSH and APR) at varying concentration and a PE (Brij 35). The presence of EIs and PEs 
in formulations intended for protein delivery via the buccal mucosa is critical to allow 
improved absorption of the protein drug through the buccal membrane which exhibits limited 
absorption for protein drugs due to peptidase activities and low epithelial permeability. The 
effect of the EIs on xerogel characteristics such as drug dissolution, mucoadhesion and 
permeation are reported elsewhere in this report. The characteristics of optimised xerogels 
containing INS were also determined and have been described elsewhere. 
 
2.4 Conclusions 
 Mucoadhesive systems for potential protein delivery via the buccal mucosa using 
lyophilised chitosan based xerogels have been developed. The removal of NaAc by membrane 
dialysis was essential for obtaining optimised xerogels with excellent characteristics for 
application to the buccal mucosa surface. On the basis of characteristic performance and 
structural integrity after lyophilisation, the non drug-loaded xerogel formulation µ%¶
containing 10 % (per polymer weight) each of plasticizer and cryoprotectant was the 
formulation of choice for drug loading and further development. Stable TG-chitosan based 
system has also been developed. Annealing, plasticisation and cryoprotection procedures were 
critical in obtaining porous and flexible dialysed xerogels. The annealing step in the 
lyophilisation cycle helped to remove stresses, softened the components, toughened and 
reduced brittleness to obtain the desired porous structure for the final optimised formulations. 
The final lyophilised products backed with an impervious EC laminate film were elegant, 
mechanically strong cakes and are expected to exhibit long-term storage stability. In addition 
EI and PE have been incorporated in the xerogels to offer improved permeability of the buccal 
mucosa.  
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 The foremost implication of these findings is the potential application of the novel 
lyophilised system for the delivery of proteins via the buccal mucosa. These will be 
characterised by a number of analytical techniques and further be investigated using in vitro 
and ex vivo mucosal environments, drug dissolution, permeation and long-term stability 
evaluation. 
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CHAPTER THREE 
ANALYTICAL, PHYSICO-CHEMICAL CHARACTERISATION OF XEROGELS 
AND STABILITY EVALUATION OF MODEL PROTEIN DRUGS (BSA, INSULIN) 
IN OPTIMISED TG-CHITOSAN XEROGELS 
3.1 Introduction 
The development and characterisation of chitosan based xerogels for the delivery of 
proteins via the buccal mucosa has been the major goal for this report. It is however essential 
to have an optimised system that ensures that the model protein drug incorporated in the 
xerogels be found conformationally stable during and after lyophilisation and over a long 
storage period. Further, proteins by nature have a narrow stability window when exposed to 
conditions that lead to aggregation, hydrolysis and denaturation caused by heat, moisture and 
other organic solvent (Estey et al., 2006). It is therefore critical that appropriate conditions of 
storage be established for the novel protein delivery systems developed. %UDGIRUG¶VDVVD\DQG
HPLC procedures were employed to estimate the protein content of the xerogels. The 
Bradford assay for protein quantification is a rapid and accurate method with less interference 
by non-protein components (Kruger, 2008).   
Although drug content is a crucial stability indicating parameter, the method of 
determination must also be able to identify and quantify possible degradation products in 
order to assure safety and efficacy. Accordingly, the International Committee for 
Harmonisation (ICH) (2003) recommends that stability studies must include testing of those 
attributes of the drug substance that are liable to change during storage and are likely to affect 
quality, safety and/or efficacy. These may include physical, chemical, biological and 
microbiological attributes, using validated stability indicating analytical procedures.  
The current chapter discusses the analytical characterisation of chitosan and TG-
chitosan xerogels as polymeric matrices for the delivery of protein via the buccal mucosa 
using various analytical techniques. The principles underlying the techniques used and their 
application in the bioanalytical characterisation of pharmaceutical and biopharmaceutical 
materials have been reviewed (chapter 1, section1.8). The characterisation of the model 
hydrophilic protein drugs; BSA and INS, both in the pure form and incorporated in the 
chitosan based xerogels using the various analytical techniques is reported. The chapter also 
details accelerated stability studies of BSA and INS incorporated in the optimised TG-
chitosan xerogels using ICH (2003) conditions. Results covering the first six months of 12 
months study are presented. 
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3.2 Materials and methods 
3.2.1 Materials  
Table 3.1: Materials 
Material Description/Batch Supplier 
L-cysteine hydrochloride C1276-10G Sigma, (Gillingham, UK) 
ƍ-Dithiobis (2-nitrobenzoic 
DFLG(OOPDQ¶VUHDJHQW 
D8130-5G Sigma-Aldrich, (Gillingham, UK) 
Pullulan 200,000 standard 01615-25MG Sigma-Aldrich, (Gillingham, UK) 
Sodium acetate W302406-1KG-K Sigma-Aldrich, (Gillingham, UK) 
%UDGIRUG¶VUHDJHQW B6916-500ML Sigma-Aldrich, (Gillingham, UK) 
BSA powder A7906-100 G Sigma-Aldrich, (Gillingham, UK) 
Acetic acid A /0360/PB17 Fisher Scientific (Leicester, UK) 
PBS tablets pH 7.4 Sigma-Aldrich, (Gillingham, UK) 
Human INS 12643-50MG Sigma-Aldrich, (Gillingham, UK) 
Acetonitrile 34967-2.5L 
(Fluka) 
Sigma-Aldrich, (Gillingham, UK) 
Copper(II) chloride 451665-5G Sigma-Aldrich, (Gillingham, UK) 
Trifluoroacetic acid (TFA) 302031-100ML Sigma-Aldrich, (Gillingham, UK) 
Potassium dihydrogen 
phosphate 
P /4760/53 Fisher Scientific(Leicester UK) 
   
   
3.2.2 Structural elucidation of chitosan and TG-chitosan-1H-NMR 
Proton nuclear magnetic resonance (1H-NMR) spectra were acquired using a Jeol 
ECA, 500 MHz FT NMR spectrometer, incorporating a NM-50TH5AT/FG2 probe (Tokyo, 
Japan). Chitosan powder and TG-chitosan were dissolved in 2 % deuterium chloride (DCl) 
solution in D2O and placed in a 5 mm borosilicate glass NMR tube and spun at 15 Hz. 1H 
spectra were acquired using a single pulse experiment and the 1H ±NMR parameters are 
summarised in Table 3.2. The degree of acetylation (DA) was determined from equation 3.1 
DA = (ICH3/3)/(IH2-H6/6) x 100 % equation 3.1 
Where ICH3 is the integral intensity of N-acetyl protons and IH2-H6 is the sum of the integral 
intensities of H-2. -3, -4, -5 and H-6 of the acetylated rings (Sogia et al., 2008). 
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Table 3.2: 1H parameters for Jeol ECA, 500 MHz FT NMR 
Parameter 1H-NMR 
Frequency 500 [MHz] 
Scans  64 
Pulse angle  45° 
Points 32768 
Offset  6.0 [ppm] 
Sweep 8.75 [kHz] 
Relaxation delay 6 [s] 
Pulse width >ȝV@ 
Acquisition delay 3.74[s] 
Temperature  27 °C 
 
3.2.3 Quantification of immobilised thiol group 
The amount of thiol group immobilised was determined by Ellman¶V UHDFWLRQ
(Bernkop-Schnürch et al., 2004). 2 mg/mL solution of thiolated polymer was prepared in 
GHLRQLVHGZDWHUȝ/DOLTXRWVZHUHDGGHGWRȝ/RI M phosphate buffer pH 8.0 and 
WRȝ/RIEllman¶V UHDJHQW PJP/RI'71%LQ M phosphate buffer pH 8.0) to 
obtain a final thiolated polymer concentration of 0.5 mg/mL. The reaction was allowed to 
proceed for 2 hours at room temperature and the absorbance was measured at a wavelength of 
405 nm with a Multiskan EX microplate photometer equipped with Ascent software (Thermo 
Scientific, Hampshire UK). The amount of thiol moieties immobilised was estimated from the 
corresponding standard curve of L-cysteine HCl (0.25-1.50 µmol/mL, r2 > 0 .99) (Figure 
3.12). Unmodified chitosan was used as control. 
 
3.2.4 Molecular weight monitoring of chitosan and TG-chitosan by gel permeation 
chromatography (GPC)  
The weight average molecular weights (Mw) of chitosan and TG-chitosan were 
monitored with Agilent 1100 series gel permeation chromatography (GPC) analysis system 
equipped with an isocratic pump and a refractive index detector. Samples were dissolved in 
buffer 0.2M CH3COOH/0.1M CH3COONa (Yu et al., 2010) and eluted through a Tosoh 
TSK-GEL PW column (7.8 x 300mm, 10 µm) at a flow rate of 1mL/min at 30 °C using the 
same buffer as mobile phase and pullulan 200,000 as reference standard. Collected GPC data 
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were analysed with Agilent Chemstation software. The Mw of chitosan and TG-chitosan were 
estimated from equation 3.2: ܮ݋݃ܯݓሺܵሻ ൌ ܮ݋݃ܯݓሺܴሻ ൈ ௏௢ ௏௘ሺௌሻ ?௏௢ ௏௘ሺோሻ ?    .........................equation 3.2 
 
where Mw (S) is the molecular weight of the sample polymer, Mw (R) is the molecular weight 
of the reference polymer, Vo/Ve (S) is the ratio of the free volume elution time to analyte 
volume elution time of the sample and Vo/Ve (R) is the ratio of the free volume elution time to 
analyte volume elution time of the reference polymer. 
 
3.2.5 ATR-FT-IR analysis 
ATR-FT-IR spectra of the xerogel samples as well as other materials listed in Table 
3.3 were acquired on an Excalibur series FTS 3500 ARX Fourier transform infrared 
spectrophotometer (FT-IR), equipped with Specac Golden gate (Varian, Oxford UK). A WIN-
IR PRO software of wavenumber range 600 ± 4000 cmí was used for the analysis. The 
spectra were collected at a resolution of 1.5 cmí with 16 scans per spectrum. A background 
spectrum of CO2 was acquired and assigned for use on subsequent spectral acquisitions. 
Table 3.3: Xerogels and materials characterised by ATR-FT-IR 
Xerogels Other materials 
Chitosan-BSA (dialysed) Chitosan powder 
Chitosan-BSA (undialysed) TG-Chitosan powder 
TG-Chitosan-BSA BSA powder 
TG-chitosan-INS INS powder 
 Sodium acetate powder (anhydrous) 
 
3.2.6  X-ray powder diffraction (XRPD)  
The physical form (crystalline or amorphous) of the formulations was determined on a 
D8 ADVANTAGE X-ray diffractometer  (Bruker AXS GmbH, Karlsure, Germany) equipped 
with a Goebel mirror with exit slits of 0.6 mm and a Lynx eye detector. The 5 mm width 
lyophilised xerogels were compressed to a width size of 0.5 mm using a clean pair of 
compression glasses and inserted in the sample holder. The transmission diffractograms were 
acquired using DIFFRAC plus XRD Commander over a start to end diffraction DQJOHRIș 
5°± 45°, step size of 0.02 and a scan speed of 0.4 s. The operating conditions during the 
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H[SHULPHQW ZHUH  N9 DQG  P$ ZLWK &X .Į UDGLDWLRQ 'DWD ZDV SURFHVVHG ZLWK (9$
software for native BSA powder, chitosan powder, Chitosan-BSA (dialysed and undialysed) 
and TG-chitosan-BSA xerogels. INS loaded TG-chitosan xerogels were also analysed. 
 
3.2.7 Differential Scanning Calorimetry (DSC) 
The lyophilised protein loaded xerogels were studied for possible phase separation by 
observing the thermal events that occurred in the samples after lyophilisation on a DSC-1 
Thermal Analyser (Mettler Toledo Ltd, Leicester, UK), calibrated with indium (based on 
heating range). This involved the initial cooling on the DSC at 10 °C/min from 25 to - 50 °C. 
It was then heated at 20 °C /min to 200 °C and the cycle repeated. An empty aluminium pan 
was used as reference. Mettler STARe software was used to analyse and evaluate the DSC 
thermograms.  
 
3.2.8 Physical stability of model drugs by far-UV CD spectroscopy 
The conformational structure of BSA was examined by far-UV CD. Spectra of a 1 
mg/mL solution of native BSA in 0.01M PBS (pH 6.8) as the negative control or BSA 
UHOHDVHGIURPWKH[HURJHOVZHUHUHFRUGHGDW&IURPZDYHOHQJWKUDQJHȜZLWK
bandwidth 1 nm, time-per-point 0.5 s, and  cell path-length of 0.1 mm using CD spectroscopy 
(Chirascan, Applied Photophysis). The same conditions were applied to native and released 
INS in 0.01M HCl (pH = 2.3) and 0.01 M PBS (pH = 6.8) using cell path-length of 0.05mm. 
The PHDQUHVLGXHHOOLSWLFLW\>ș@mrw, k was determined using equation 3.3 below:  
 
 
ZKHUH05:LVWKHPHDQUHVLGXHZHLJKWșk is the observed ellipticity (degrees) at wavelength 
k, d is the pathlength (cm), and c is the concentration (g/mL) (Kelly et al., 2005).  
 
3.2.9 Thermogravimetric analysis for moisture content  
The percentage residual moisture of the lyophilised xerogels was estimated using a 
Thermal Advantage TGA 2950 (TA Instruments, Crawley UK) (Wang, 2000). A dynamic 
phase of heating at 15 °C/min from ambient temperature to a maximum of 150 °C was applied 
with a constant stream of dry nitrogen to the xerogels weighing between 3 ± 6 mg in a 
 
MRW x TN/ 10 x d x c[T] mrw, k = ............... equation 3.3 
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previously tarred 70 µl aluminium crucible. The TA Universal Analysis 2000 programme was 
used to determine the percentage weight loss from a second derivative plot.  
 
3.2.10 Calibration curves for BSA and INS  
6WDQGDUGFRQFHQWUDWLRQV RI%6$ ȝJP/ - 400 µg/mL) were prepared in 1 % v/v 
acetic acid and 0.01M PBS (pH 6.8ȝ/RIHDFKVWDQGDUGZDVSODFHGLQDP/HSSHQGRUI
WXEHDQGPORI%UDGIRUG¶V UHDJHQWZDV DGGHGJHQHUDWLQJDFKDUDFWHULVWLFEOXHFRORXU7KH
absorbances of the standard solutions were measured at 595 nm. The measurements were 
repeated at 450 nm and the ratio of the absorbances 595/450 nm was plotted against the 
concentration to obtain linearised calibration curves as shown in Figures 3.27 and 3.28 for 
BSA in 1% acetic acid and 0.01 M PBS respectively. Similarly, standard INS concentrations 
ȝJP/- 400 µg/mL) ZHUHSUHSDUHGLQ0+&ODQGWUHDWHGZLWK%UDGIRUG¶VUHDJHQWDV
above and absorbances measured at 450 and 595 nm. The linearised calibration curve for INS 
from the plot of absorbance ratio 595/450 against INS concentration is shown in Figure 3.19.  
 
3.2.11 Drug loading capacity 
The drug loading capacity was determined from the ratio of actual and theoretical 
BSA loading x 100 %. 35 mg of drug loaded xerogel was dissolved in 25 ml of 1 % v/v acetic 
acid. The solution was magnetically stirred at 50 rpm to avoid bubble formation for 10 
minutes at room temperature. 50 µL of the solution was withdrawn and treated with 1ml 
%UDGIRUG¶V UHDJHQWDQG WKHDEVRUEDQFHPHDVXUHGDWQPDQGQPIRU OLQHDULVDWLRQRI
absorbance (Zor & Selinger, 1996; Ernst & Zor, 2010) using a Multiskan EX microplate 
photometer equipped with Ascent software (Thermo Scientific, Hampshire UK). The amount  
of BSA was determined by interpolation from the linearized calibration curve (r 2 >  0.99) 
(Figure 3.18). To estimate the recovery of this method, the same procedure was carried out 
using a known amount of non-drug loaded xerogel (25 mg) seeded with BSA powder (10 
PJ7KHDPRXQWRI%6$ZDVHYDOXDWHGXVLQJWKH%UDGIRUG¶VPHWKRGDVGHVFULEHGLQVHFWLRQ
3.2.10.  
 
3.2.12 Scanning electron microscopy (SEM) 
The lyophilised xerogels were prepared for morphological studies on SEM by placing 
double-sided adhesive carbon tape on labelled stainless steel stubs. The samples were placed 
on the exposed side of the carbon adhesive being careful not to dent the surface topography of 
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the xerogels. These were sputter coated with gold for 120 seconds at 1 kV and 30 mA 
(Edwards Sputter Coater S150B) and placed in the chamber of a Cambridge Stereoscan S-360 
SEM (Class one equipment, London UK). Images were acquired at an accelerating voltage of 
20 kV, a working distance of 15 mm and processed with i-scan2000 software. 
The laminated xerogels were carefully cut from the upper surface all through the 
laminate. The cut xerogels were placed on double sided adhesive carbon tape previously stuck 
onto labelled stainless steel stubs with the cross-sectional surface on the exposed side of the 
adhesive, sputter coated for 2 minutes at 25 mA and 1 kV with chromium (EmiTECH K575X 
Sputter Coater) and placed in the chamber of a Hitachi SU8030 Scanning electron microscope 
(Hitachi, Krefeld Germany). Images acquired at an accelerating voltage of 20 kV and working 
distance of 15 mm were processed with i-scan2000 software. Similarly, images of undialysed 
chitosan xerogels and the impervious EC backing film were acquired for characterisation.  
 
3.2.13 Stability evaluation  
3.2.13.1 Preparation and storage of BSA/INS xerogels for stability studies 
BSA loaded xerogels (prepared in chapter 2 section 2.2.2 and section 2.2.6) were 
either stored in a refrigerator (long-term study) or kept under ICH conditions (for drug 
products intended for storage in a refrigerator) in a humidity chamber with 60 % relative 
humidity (RH) ± 5 % RH maintained with CuCl2 (solubility 0.76 g/mL) (www.mitegen.com) 
at 25 °C (ICH, 2003) for accelerated stability studies (Table 3.4). Similarly, INS containing 
xerogels for stability studies prepared using method described in chapter 2, (Table 2.6  section 
2.2.6) were stored according to ICH conditions (ICH, 2003) in Table 3.4 until ready for 
analysis at selected time points. 
 
Table 3.4:  ICH conditions for drug products intended for storage in a refrigerator 
Study  Storage condition Minimum time period 
covered by data at 
submission 
Long-term 5 °C ± 3 °C 12 months 
Accelerated 25 °C ± 2 °C/ 60 % RH ± 5% RH  6 months 
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$VVD\RI%6$DQG,16FRQWHQWE\%UDGIRUG¶VDVVD\ 
The BSA and INS contents in xerogels at the various time points (0, 3 and 6 months) were 
GHWHUPLQHGXVLQJWKH%UDGIRUG¶VDVVD\ (chapter 3, section 3.2.11). The xerogels were analysed 
for protein content immediately after freeze-drying to represent the zero time point 
determination.  
 
 3.2.13.3 HPLC assay of BSA and INS content. 
The amount of BSA at the zero time point was determined with an Agilent 1100 series 
size-exclusive high performance liquid chromatography (SE-HPLC) analysis system equipped 
with an isocratic pump and a UV detector. Samples were dissolved in 0.01 M PBS pH 7 
(Estey et al., 2006) filtered (0.45 µm membrane, Minisart biotech.) and eluted through a 
Tosoh TSK-GEL PW column (7.8 x 300mm, 10 µm) with a flow rate of 1 mL/min at ambient 
temperature and detected at a wavelength of 215 nm using the same PBS as mobile phase and 
pure BSA powder as reference standard. Collected SE-HPLC data were analysed with Agilent 
Chemstation software and content of BSA was estimated from a calibration curve with 
linearity verified over concentration range of 0.1±1.00 mg/mL (r2 >  0.99). The procedure was 
repeated for the time points of three (3) and six (6) months for the various storage conditions 
(Table 3.4) as specified in the ICH protocol. 
The amount of  INS loaded in the xerogels was determined by reversed-phase High-
Performance Liquid Chromatography (RP-HPLC) (Agilent Technologies, Santa Clara, CA, 
USA) with a Jupiter 5-ȝm C18 column (250 mm ×  PP $Û  3KHQRPHQH[ 86$ 
with the following conditions: mobile phase²water: acetonitrile (67: 33, v/v) containing 
0.1% (v/v) of TFA; flow rate²1 mL/min; detection wavelength²220 nm and injection 
volume - 20 ȝL (Giovino et al., 2012). All samples were analysed in duplicate and the protein 
concentration was determined based on interpolation from a calibration curve with linearity 
verified over concentration range of 50±250 ȝg/mL (r2 >  0.99). The procedure was carried 
out for the time points of zero (0), three (3) and six (6) months for the various storage 
conditions (Table 3.4). 
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3.3 Results and Discussion 
3.3.1 Structural elucidation of chitosan and TG-chitosan-1H-NMR 
The 1H-NMR spectra of chitosan and TG-chitosan determined in 2 % DCl are shown in 
Figure 3.1. The proton signal assignments for the various residues summarised in Table 3.5 
were based on previous works by Fernandez-Megia et al., (2005) and Rinaudo, (2006). The 
calculated degree of acetylation of chitosan and TG-chitosan were consistent with the degree 
of deacetylation of 75 - 85 % provided by the supplier. The 1H-NMR also confirmed the 
purity of the chitosan as well as the derivatised TG-chitosan.  
The aqueous acidic media, 2 % DCl is usually considered the optimum solvent for 
1HNMR of chitosan (Fernandez-Megia et al., 2005), which naturally causes hydrolysis of 
some of the N-acetyl groups and production of free acetic acid (AcOH) with a proton peak at 
1.82 ppm in both chitosan and TG-chitosan. The multiplet peak at 3.52- 3.68 was assigned to 
the proton peaks of glucosamine unit, H-3, H-4, H-5 and H-6 (Li et al., 2010).  
No new peaks corresponding to protons of thiol group from the covalent attachment 
between thioglycolic acid and chitosan to form TG-chitosan were identified. Nuclear 
magnetic resonance (NMR) was therefore not suitable for evaluating the level of free thiol 
groups and disulphide bonds since two equivalent carbons and two equivalent protons of 
thioglycolic acid appeared overlapped with those of chitosan in the NMR spectrum as 
reported by Juntapram et al., (2012) and Lee et al., (2007). 
 
Table 3.5: 1H-NMR signal assignments for chitosan and TG-chitosan 
Proton residue Chemical shifts (ppm) 
Chitosan                                   TG-chitosan 
NAc 1.81 1.81 
AcOH 1.82 1.82 
H-2 (GluNH2) 2.95 2.95 
H-2 (GluNAc) /H-3-H-6 3.52-3.68 3.52-3.68 
H-1 (GluNAc) 4.38 4.38 
H-1 (GluNH2) 4.74 4.74 
Abbreviations: NAc; (N-acetyl group), AcOH; (Acetic acid) D-glucosamine; (GluNH2), N-
acetyl-D-glucosamine; (GluNAc). 
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Figure 3.1: 1H-NMR spectra of (A) chitosan and (B) TG-chitosan in 2 % DCl. 
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3.3.2 Quantification of immobilised thiol group 
The calibration curve for standard cysteine HCl is shown in Figure 3.2. 
Spectrophotometric assay using Ellman¶V reagent was employed in the determination of the 
amount of reduced and oxidized thiol groups immobilized (Hornof et al., 2003) without 
previous quantitative reduction of disulphide bonds using borohydride. 
 
Figure 3.2: Calibration curve of L-cysteine HCl 
 
 The TG-chitosan conjugate had 236 ± 26 µmol thiol groups per gram of polymer. 
Unmodified chitosan showed no thiol groups after addition of thioglycolic acid in the absence 
of water soluble coupling agent N-(3-Dimethylaminopropyl)-N-ethyl carbodiimide 
hydrochloride (EDAC). According to Sreenivas & Pai (2009), a degree of modification of 25±
250 µmol thiol groups per gram of chitosan results in the highest improvement in the 
mucoadhesive and permeation enhancing properties of these TG-chitosans. This range fits in 
with the results obtained for the current study which is interesting and is expected to impact 
on the mucoadhesive (chapter 4) and permeation (chapter 6) characteristics of the TG-
chitosan xerogels. 
 
3.3.3 Molecular weight monitoring of chitosan and TG-chitosan - GPC 
Figure 3.3 shows a representative GPC chromatogram of chitosan. GPC analysis for 
monitoring the polymer Mw before and after derivatization showed no statistically significant 
difference (p = 0.2709, n = 4) between the calculated mean molecular weights.  
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Figure 3.3: Representative chromatogram of chitosan from GPC analysis. Vo is the free 
volume elution time and Ve is the analyte volume elution time. 
 
 However the slight difference in the calculated Mw of chitosan (196.7 ± 5.1 kDa) and 
TG-chitosan (200.7 ± 2.1 kDa) after the conjugation reaction could be attributed to the 
addition of thioglycolic acid molecules unto the chitosan chains. This suggests that polymeric 
chains may not have been degraded during the synthesis process. 
 
3.3.4 ATR-FT-IR analysis 
Structural information was obtained for the protein loaded lyophilised xerogels 
through the analysis of the conformationally sensitive amide I band, which is located between 
1600 and 1700 cmí1 (Figure 3.4). This band is due to the in-plane C=O stretching vibration, 
weakly coupled with C-N stretching and in-plane N-H bending. Each type of secondary 
VWUXFWXUH LH Į-KHOL[ ȕ-turn and disordered) gives rise to a different C=O stretching 
frequency and hence, has a characteristic band position. The secondary structural types 
present in a protein are determined by band positions.  
The ATR-FT-IR spectra (Figure 3.4) show the respective absorption peaks of chitosan 
and TG-chitosan at 1666.35 and 1618.27 cmí1 which corresponds to the characteristic amide 
I band (Qin et al., 2006). The peaks at 1556.55 cm-1 and 1522.67 cm-1  were assigned to amide 
II band (CN stretching and NH bend) present in both chitosan and TG-chitosan respectively. 
The absorption bands at 3271.26 cm-1 and 3255.48 cm-1 are for NH stretch and the weak peak 
at 2525.68 cm-1 corresponds to SH (Saboktakin et al., 2011), confirming the conjugation 
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between thioglycolic acid and primary amine of chitosan in TG-chitosan. The absorption 
bands at 3342.63 cm-1 and 3332.98 cm-1  were for chitosan-OH and TG-chitosan-OH 
respectively, the band at  997.19 -1060.85 cm-1 was due to CO and the 2850-2900 cm-1 band 
resulted from aliphatic CH stretch. 
 
Figure 3.4: ATR-FT-IR spectra of [a] chitosan and [b] TG-chitosan 
 
 The AT-FT-IR spectra in Figure 3.5 show the absorption peaks of [d] dialysed and [e] 
undialysed xerogel DWDQGFPíwhich corresponds to the characteristic amide I 
and II bands (CN stretching and NH bend), respectively, present in both chitosan and BSA. 
Analysis of the amide I band showed that the conditions employed in the formulation process 
prevented perturbation of the protein secondary structure, maintaining the conformation of the 
model drug. Spectral assignments for the undialysed xerogel, consistent with the results of 
Kakihana et al., (1982) for solid NaAc were however, obtained with similar peaks at 623, 
  DQG  FPí FRUUHVSRQGLQJ WR RXW-of-plane O±C±O rock, O±C±O bend, C±C 
stretch and asymmetric C±O stretch. These peaks were conspicuously missing in the spectral 
assignments for the dialysed chitosan-BSA xerogel (Figure 3.5 [d]). This confirmed the 
importance of the dialysis step which helped remove the formed NaAc. 
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Figure 3.5: AT-FT-IR spectra of [a] NaAc powder, [b] BSA powder, [c] chitosan powder, [d] 
dialysed xerogel and [e] undialysed xerogel.   
  
To investigate the secondary structure of INS loaded TG-chitosan xerogels containing 
different EIs, the vibrations were monitored via ATR-FT-IR spectroscopy (Figures 3.6 and 
3.7). A typical INS FT-IR pattern is characterized by a very marked band in the range 1648-
1660 cm-1, that represents the predominant content of D-helix, and other two bands at a range 
of 1690-1625 cm-1 and 1681-1678 cm-1 attributed to the E-sheet and E-turn, respectively 
(Nielsen et al., 2000). Usually, the intensity of these two latter bands is lower than that 
observed at 1648-1660 cm-1, indicating that the D-helix is the main contributor to the 
secondary structure of INS. As illustrated in Figure 3.16 ATR-FT-IR spectra of pure INS is 
dominated by bands around 1254, 1646, 3190 and 3300 cm-1  assigned to the amide III, I, B 
and A, respectively. Specifically,  the main strong bands were detected at 1646 cm -1 which 
reflects the stretching C=O of the amide I, while the band around 1550 cm-1,  usually 
attributed to the amide II reflects CN stretching and NH bend. Figures 3.6 and 3.7 also show 
the ATR-FT-IR spectra of TG-chitosan-INS, TG-chitosan-APR-INS and TG-chitosan-GSH-
INS. In comparison with the pure INS spectra, it could be observed that the characteristic 
absorption peak of the amide I occurs around 1650 cm-1 for all formulated xerogels. However, 
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though the position of this band is not significantly different from that of pure INS, it is 
evident that the shapes and intensities decreased. 
 
Figure 3.6: ATR-FT-IR spectra of TG-chitosan-INS, INS powder and TG-chitosan-APR-
INS. 
 
 
Figure 3.7: ATR-FT-IR spectra of INS powder and TG-chitosan-GSH-INS 
 
This effect could be linked to the presence of absorption peak around 1550 cm-1 attributed to 
the secondary amide (C-N stretching and N-H bend) present in both INS and chitosan. In all 
the ATR-FT-IR spectra, the main peaks corresponding to Į-helical chain remained 
unchanged, suggesting that the protein structure was not unfolded, degraded or hydrolysed 
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during the xerogel preparation process. Similar results were reported  by Zhang et al., (2008), 
demonstrating that the protein secondary structure was not significantly altered in terms of Į-
helix and ȕ-sheet during the production of chitosan based xerogels.  
 
3.3.5 X-ray powder diffraction (XRPD)  
XRPD analysis was used to study the physical form (crystalline or amorphous) of 
chitosan and chitosan derivatives since these properties are known to affect water uptake and 
biodegradability characteristics of polymers (Prabaharan & Gong, 2008). Figure 3.8 shows 
representative XRPD transmission diffractograms of pure chitosan powder, TG-chitosan, 
chitosan-BSA xerogel, TG-chitosan-BSA xerogel and native BSA. Crystalline chitosan 
showed its characteristic intense peak at ș  (Nagahama et al., 2009). The synthesised 
TG-chitosan and the formulated xerogels however, had the intensity of this peak minimized, 
leaving the peak at ș EHWZHHQ  WR  which was a shoulder to the right of the main 
chitosan peak.  
 
Figure 3.8: XRD-transmission diffractogram of chitosan powder, TG-chitosan, chitosan-BSA 
xerogel, TG-chitosan-BSA xerogel and native BSA powder.  
 
These results revealed the existence of amorphous structures in the xerogels that 
resulted from chemical modification of chitosan following formulation with amorphous BSA, 
and other excipients (GLY and D-MANN), leading to the alteration of the original crystalline 
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structure. The interposing of plasticizer and cryoprotectant between the polymer chains and 
their interaction with functional groups of chitosan resulted in reduced intermolecular 
cohesive forces of attraction between the polymer chains. They also show that the freeze-
drying procedure did not alter the amorphous structures formed during gel formulation prior 
to the freezing step when ice crystal formation occurs. The final amorphous xerogel could 
help in maintaining the stability of the model protein drug which was originally added as an 
amorphous powder and also enhance the mucoadhesive properties of the formulated polymer 
(Prabaharan & Gong, 2008) as a result of improved hydration and reduced rigidity (Kasper & 
Freiss, 2011). 
Figure 3.9 shows the XRPD patterns of undialysed xerogel, dialysed xerogel and 
chitosan powder. The undialysed xerogel demonstrated a crystallinity of 96% whereas that of 
the dialysed xerogel was 32%. The three-fold increase in crystallinity showed by the 
undialysed xerogel was a result of the presence of NaAc produced as a process impurity.  
 
Figure 3.9: X-ray-transmission diffractogram of (a) Undialysed xerogel (depicting NaAc 
peaks), (b) dialysed xerogel and (c) chitosan powder.  
 
The brittleness observed in the undialysed xerogel could be attributed to the newly 
formed crystalline NaAc from the use of NaOH to neutralise acetic acid, which was used to 
protonate the chitosan in order to improve its solubility for gel formation. The data highlights 
the importance of the dialysis step during processing. 
The effect of EIs (10 % GSH and 5 % APR) on the physical form of TG-chitosan 
xerogel containing either BSA or INS were also evaluated. Figure 3.10 and 3.11 show 
representative X-ray diffractograms of TG-chitosan-BSA and TG-chitosan-INS xerogels with 
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and without APR respectively. The reduced peak of chitosan at ș around 22° to 24° was 
observed in all the formulations irrespective of whether there was EI present or not. Moreover 
loading the polymer matrix with a different protein (INS) did not affect the amorphous nature 
of the lyophilised xerogels. 
 
Figure 3.10: XRD-transmission diffractogram of TG-chitosan-BSA xerogels with and 
without the EI, aprotinin. 
 
 
  
 
Figure 3.11: XRD-transmission diffractogram of TG-chitosan-INS xerogels with and without 
the EI, aprotinin.  
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3.3.6 Differential scanning calorimetry (DSC) 
For phase separation studies after lyophilisation, multiple glass-transition (Tg) 
temperatures were detected at 40.3 °C and 130.1 °C in the undialysed xerogels (Figure 3.12 c) 
due to possible formation of metastable glass and subsequent crystallisation of the formed 
NaAC which might result in product instability during storage. However, for the dialysed 
chitosan-BSA and TG-chitosan-BSA xerogels in Figures 3.12 (a) and (b) respectively, no 
glass-transition temperatures were detected after lyophilisation, an indication of potential 
product stability during storage (Seales et al., 2001b) 
 
Figure 3.12: DSC thermograms of (a) chitosan-BSA (b) TG-chitosan-BSA and (c) undialysed 
chitosan-BSA xerogels. 
 
 
 The endothermic events observed from the representative thermograms in Figure 3.12 
during the first heating cycles are the result of changes in heat capacity due to water loss from 
the xerogels. The application of the annealing process prevented the formation of metastable 
glass which would have eventually crystallized and affect the stability of the protein in the 
xerogels. It is however, important to note that it is difficult to detect the Tg´ of a freeze-
concentrated chitosan (an aminopolysaccharide) as it is extremely weak (Ford & Mann, 2012) 
and this challenge could be exacerbated by a period of annealing the freeze-concentrate. The 
effectiveness of the annealing process led to no glass-transition detection by the DSC in the 
frozen concentrate as well as the lyophilised xerogel, implying no phase separation of the 
amorphous protein drug. Furthermore, the process of dialysis was critical in averting 
interferences from the effect of the excess acetic acid and the sodium acetate formed during 
the preliminary gel formation stages. 
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3.3.7 Physical stability of BSA and INS by far-UV CD spectroscopy 
CD spectroscopy was applied to determine the conformational stability of the protein 
loaded lyophilised xerogels. An absolute requirement for a successful biotherapeutic is a 
correctly folded protein whose desired conformational stability is maintained by a suitable 
formulation. The knowledge of the secondary structure before and after gel formulation and 
lyophilisation was an essential step in determining possible conformational changes in the 
model protein drugs in the chitosan based xerogels.  
Figure 3.13 shows the far-UV CD spectra of BSA released from dialysed and 
undialysed xerogels and native BSA in PBS. The two minima bands observed at 209 and 222 
nm were respectively assigned to the Į DQG ȕ-helical structures of BSA as reported by 
Quiming et al., (2005). BSA released from the chitosan xerogels and native BSA 
GHPRQVWUDWHGVLPLODUPHDQUHVLGXHHOOLSWLFLW\UDWLRVDWDQGQP>ș@209>ș@222) of 1.10.   
 
Figure 3.13: CD spectra of native BSA, dialysed and undialysed xerogels loaded with BSA  
 
 The similarity of the far-UV CD spectra and the mean residue ellipticity ratios 
obtained confirmed the conformational stability of BSA in the lyophilised xerogels. The 
presence of salts such as NaAc in the undialysed xerogel has been reported to induce protein 
unfolding (McNay et al., 2001). However, in all the CD spectra, the main bands 
corresponding to Į-helical structure remained unchanged, suggesting that the protein structure 
maintained its folded conformation, and was neither degraded nor hydrolysed during the 
production of lyophilised chitosan xerogels irrespective of whether there was a dialysis step 
involved or not.  
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Figure 3.14 shows the CD profiles of native BSA and BSA released from the chitosan-
BSA, TG-chitosan ±BSA and TG-chitosan ±GSH-BSA xerogels in PBS at pH 6.8 in far-UV 
range. The ratios between the mean residue ellipticity at 209 and 222 nm (>ș@209>ș@222) were 
1.10, 1.10, 1.10 and 1.14 for native BSA, BSA released from the chitosan-BSA, TG-chitosan-
BSA and TG-chitosan-GSH-BSA respectively. The similarity of the far-UV CD spectra and 
the mean residue ellipticity obtained confirmed the conformational stability of BSA in the 
lyophilised xerogels except for the GSH containing xerogel where possible adsorption of BSA 
by GSH at pH 6.8 caused a slight increase in the Į-helical structure of BSA released. 
 
Figure 3.14: CD spectra of native BSA, chitosan-BSA, TG-chitosan±BSA and TG-chitosan ± 
GSH-BSA xerogels. 
  
The conformational stability of native INS, in vitro released INS from TG-chitosan-
INS and TG-chitosan-INS-APR were also assessed by CD. The CD profiles in 0.01 M HCl at 
pH 2.3 and 0.01 M PBS at pH 6.8 in the far UV range are shown in Figures 3.15 and 3.16 
respectively. As is evident from these figures, the native INS had two minima around 209 and 
222 nm. The first band was assigned to the Į-helical structure, while the second band was 
DVVLJQHG WR WKH ȕ-structure. These results are consistent with the crystal structure of the 
hexamer determined by Wood & Blundell (1975) and the structure of native INS by Cui et al., 
(2008). These were similar to INS released from the TG-chitosan xerogels with or without the 
EI, 5 % APR in 0.01 M HCl. 
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Figure 3.15: CD spectra of insulin released from TG-chitosan xerogels in 0.01M HCl         
(pH 2.3) 
 
 
Figure 3.16: CD spectra of insulin released from TG-chitosan xerogels in 0.01 M PBS (pH 
6.8)  
 
The CD spectrum of INS released from the xerogels in PBS however, showed marked 
negative peaks at 209 nm with weak peaks at 222 nm. The ratios between the mean residue 
ellipticity at 209 and 222 nm >ș@ 211>ș@222) were also calculated and have been presented in 
Table 3.6. It is well known that the addition of chitosan to a system intended for protein 
delivery affects the circular dichroism band (Zhang et al., 2003). It was observed that the 
release of INS in PBS resulted in a higher mean residue ellipticity ratio due mainly to the 
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Table 3.6: Mean residue ellipticity ratios at 209 and 222 nm for INS loaded Xerogels 
Formulation 0.01 M HCl (pH 2.3) 
>ș@211>ș@222) 
0.01 M PBS (pH 6.8)  
>ș@211>ș@222) 
Pure INS 1.09 1.09 
TG-chitosan-INS 1.20 1.26 
TG-chitosan-INS-
APR  
1.09 1.34 
intermolecular interaction between the positively charged chitosan derivative and INS 
(isoelectric point 5.4) which would carry a negative charge at the environmental pH of 6.8. 
The enhanced value for the xerogel with APR may be due to further interaction between this 
EI and the released INS. The formulation process however preserves the protein 
conformational structure and physical stability. In addition, because the presence of INS in the 
monomeric form is higher than the native form, it is expected that it will result in better in 
vivo adsorption when applied to the buccal mucosal area (Blundell et al., 1972).   
 
3.3.8 Thermogravimetric analysis - Moisture content  
The residual moisture contents of the lyophilised xerogels are shown in Table 3.7. The 
range of residual moisture content from 1.8 ± 0.7 % to 2.7 ± 0.3 % falls within the 
UHFRPPHQGHGUHVLGXDOPRLVWXUHFRQWHQWUDQJHRI- IRUSURWHLQO\RSKLOHV:DUGet 
al., 2008). The loss in weight observed for all the samples during the dynamic heating stage 
occurred between 60 °C and 120 °C, is an indication of the fact that weight loss was due to 
bound water. 
Table 3.7: Percentage drug loading capacity and moisture content of xerogels 
Sample 
 
% Drug loading 
(n=4,mean +SD) 
% Moisture content 
(n=4,mean + SD) 
Undialysed  Chitosan-BSA 54.0 ± 5.4 2.7 ± 0.3 
Annealed Chitosan-BSA 91.6 ± 4.0 1.8 ± 0.7 
Non-annealed Chitosan-BSA 90.5 ± 4.0 2.2 ± 0.2 
Annealed    TG-chitosan-BSA 94 ± 1.6 1.8 ± 0.1 
Non-annealed TG-chitosan-BSA  88.8 ± 4.0 1.8 ± 0.4 
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Since no product melt-back was observed after the freeze drying process, the 
robustness of the freeze drying cycle is depicted, with the primary drying stage removing all 
the loose water. The formation of a dry state by lyophilisation is essential to prevent 
premature release of the active protein drug. Attaining adequate residual moisture content for 
the xerogels was also vital as lower water content reduces molecular mobility and increases 
shelf-life by avoiding premature hydration of the active protein drug. The annealed xerogels 
had a slightly lower residual moisture content compared to the non-annealed products, as ice 
crystals were large enough for easy sublimation, allowing the drying phase to reach the 
bottom of the mould. The presence of GLY in the formulations could account for the levels of 
residual moisture observed. This was expected as GLY could slow down the drying process 
due to its humectant property. Again the combination of water, GLY and MANN results in 
synergistic plasticizing effect that can affect the thermal properties of the formulations.  
 
3.3.9 Calibration curves for BSA and INS in 1% acetic acid, 0.01 PBS and 0.01 M HCl. 
The calibration curves for BSA in 1% acetic acid and 0.01M PBS are shown in 
Figures 3.17 and 3.18 respectively with Figure 3.19 showing that of INS in 0.01 M HCl. The 
Bradford method relies on the binding of Coomasie blue G250 dye (Bradford reagent) to 
proteins. Although different ionic forms of the dye exist, the more anionic blue form of the 
dye binds to protein with a characteristic absorption maximum at 590 nm.  
In this project, the assay was based on the improved Bradford protein assay protocol 
by Ernst & Zor (2010) that measures the ratio of the absorbance at 590 nm and 450 nm and 
provides significant advantages over the original Bradford protocol involving single 
measurement of absorbance at 590 nm. They further recommended the measurement of 
absorbance at 590-600 nm, to achieve maximal sensitivity to protein concentration change, 
and at 450-485 nm, to ensure linearization. This simple procedure increases the accuracy and 
improves the sensitivity of the assay about 10-fold, permitting quantification down to 50 ng of 
BSA. With the original Bradford protocol, diminished response to protein would result due to 
the interference by detergents. The improvement of sensitivity by one order of magnitude 
enables dilution of the samples up to a point where the interference by detergents is 
eliminated.  
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Figure 3.17: Calibration curve of BSA in 1% acetic acid. 
 
 
Figure 3.18: Calibration curve of BSA in 0.01 M PBS 
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Figure 3.19: Calibration curve of INS in 0.01 M HCl 
 
3.3.10 Drug loading capacity 
A high drug loading capacity above 90 % (Table 3.7) explains the high total 
percentage cumulative release profiles observed for the annealed Chitosan-BSA and TG-
chitosan-BSA xerogels (see chapter 5). The porous and fibrous networks of the lyophilised 
cakes allowed for higher drug loading capacity compared to related formulations such as 
solvent cast films. This is due to the fact that lyophilised xerogels maintain their original 
volume during the freezing stage while solvent cast films collapse during drying to yield a 
dense product with precipitation of excess drug on the surface (Boateng et al., 2010). There 
was no impedance from  formulation excipients during analysis by the direct dissolution 
method. The drug loading capacities above 90 % also gave an indication of the efficiency of 
the drug incorporation into the gels and the recovery efficiency through formulation and 
freeze-drying (lyophilisation) steps to obtain the xerogels. The annealing and thiolation 
processes did not seem to have had much effect on the loading capacity as non-annealed 
Chitosan-BSA and TG-chitosan-BSA had similar values. The undialysed xerogels however, 
showed a low drug loading capacity of 54.0 ± 5.4 % due to interferences from sodium acetate 
and excess acetic acid present within the xerogel. 
 
3.3.11 Scanning electron microscopy (SEM) 
Representative scanning electron micrographs of the lyophilised xerogels are shown in Figure 
3.20 [A-F]. The porous structure shows the effect of dialysis on the pore thickness and 
configuration. Dialysed chitosan-BSA xerogel (Figure 3.20 A) formed a porous polymeric 
network which had thinner walls as well as many smaller sub-pores. The undialysed xerogel 
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(Figure 3.20 B) on the other hand had similar pore sizes (150±200µm) and distribution but 
with thicker walls and fewer sub-pores within the network structure. Gel dehydration induced 
by the lyophilisation process resulted in the formation of NaAc crystals in the undialysed 
xerogel (Figure 3.21). Crystallisation and subsequent deposition of NaAc on the outer and 
inner walls of the interconnecting pores of the xerogels explains the rather thick walls 
observed in the undialysed xerogel (Ayensu et al., 2012b).  
 The micrographs also show the effect of annealing on the pore size. The optimally 
plasticized annealed chitosan-BSA xerogels formed a porous interconnecting polymeric 
network of sponge-like circular pores, with closer pore distribution and larger pore sizes with 
an average pore diameter of 200 µm (Figure 3.20 A and C). Non-annealed xerogels (Figure 
3.20 D) also formed an interconnecting network, but with relatively smaller sized pores with 
an average pore diameter of 133µm. The sublimation of larger ice crystals formed from the 
merging of smaller ice crystals due to annealing, resulted in xerogels with large pores. The 
variation in the performance of the different formulations with respect to hydration capacity, 
in vitro mucoadhesion properties and release characteristics, could be attributed to differences 
in pore size of the annealed and non-annealed xerogels. The micrographs also show the effect 
of thiolation on xerogel pore size (Figure 3.20 E-F).  
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Figure 3.20: Representative SEM micrographs of lyophilised xerogels (magnification x 200).  
 
 Whereas unmodified chitosan-BSA xerogels were more regularly distributed, the TG-
chitosan-BSA xerogels formed a fibrous, sponge-like, porous interconnecting polymer 
network but with smaller pore sizes and a more irregular pore distribution. The presence of 
low molecular weight compounds such as GLY, D-MANN and thiol ligand with high affinity 
for water is likely to have an effect on ice crystal ripening during the slow freezing process, 
which affects ice crystal size and subsequently pore size, hence the differences observed in 
the morphologies of the chitosan-BSA and TG-chitosan-BSA xerogels. Such differences in 
morphology (such as in pore size) can affect functional properties including rate of hydration, 
Dialysed chitosan-BSA Undialysed chitosan-BSA100 µm 100 µm
A B
Annealed chitosan-BSA Non-annealed chitosan-BSA100 µm 100 µm
C D
Non annealed TG-chitosan-
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swelling, mucoadhesion and subsequent drug release rates. This arises primarily from the 
differences in rate of water ingress, swelling and subsequent diffusion of drug from the 
swollen matrix (Boateng et al., 2010). Wu et al., (2009) have observed that pore size 
qualitatively correlated with the degree of swelling of hydrogels. In addition, the possible 
formation of disulphide bonds in the thiolated xerogels could affect pore size as distances 
between polymer chains are decreased by the degree of cross-linkages (Wu et al., 2009). 
 
Figure 3.21: High magnifications of undialysed chitosan-BSA xerogel showing crystals of 
NaAc (Magnification: (I) x2000), (II) x10000). 
 
The optimised thiolated chitosan xerogel was loaded with INS and the representative 
SEM micrograph as shown in Figure 3.32 also displayed smaller circular pores with thin 
sheet-like walls.  
 
Figure 3.22: SEM micrographs of xerogel loaded with insulin (magnification x200). 
 
Insulin xerogel
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High magnification SEM micrograph of the EC laminate used as a backing membrane 
to ensure uni-direction release of protein loaded in the chitosan based xerogels is shown in 
Figure 3.33. The non-porous EC laminate formed a dense continuous sheet with no fractures. 
 
Figure 3.23: High magnification SEM micrographs of impervious EC laminate to be used as 
a backing membrane for xerogels (magnification x200 ± x10000). 
 
Figure 3.2µ$¶ shows a representative cross-sectional micrograph of a porous chitosan based 
xerogel overlaid on dried EC laminate prepared by solvent casting. The presence of GLY in 
the EC laminate as a plasticizer aids in the attachment of the xerogel to the laminate film as 
seen from the SEM micrograph.  An enhanced stereo-paired image of the laminated xerogel 
(Figure 3.24 B) is shown to the right which is better viewed using a red/green filter. 
 
 
Figure 3.24: SEM micrographs of µ$¶porous xerogel with an impervious EC laminate as a 
EDFNLQJPHPEUDQHDQGµ%¶ Stereo-paired image of laminated xerogel viewed with red/green 
filters (magnification x200). 
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3.3.12 Stability evaluation  
The BSA and INS contents of the optimised TG-chitosan xerogels were initially 
HVWLPDWHG E\ %UDGIRUG¶V DVVD\ DQG +3/& PHthods. Xerogels were kept in 24 well plates 
sealed with parafilm and lids to limit moisture absorption, stored in the refrigerator (RF) at 5 
°C ± 3 °C and analysed for BSA and INS content at a frequency of 3 months intervals. The 
accelerated stability studies of BSA and INS incorporated in the chitosan based xerogels was 
E\ WKH ,QWHUQDWLRQDO &RPPLWWHH IRU +DUPRQLVDWLRQ ,&+¶V FRQGLWLRQV for drug products 
intended for storage in a refrigerator. The exposure of the xerogels to varying conditions of  
temperature and moisture (relative humidity) had a profound effect on the chemical stability 
of the model protein drugs. Generally, INS xerogels stored in the refrigerator showed no signs 
of protein degradation/fragmentation throughout the entire period of evaluation with the 
assayed protein content within the range of 95 ± 105 % as specified by the British 
Pharmacopoeia (BP 2012) for INS. This was however, not the case with xerogels stored at 
ambient temperature at a relative humidity of 60 % in a humidity chamber.  
 
%6$DQG,16FRQWHQWE\%UDGIRUG¶VDVVD\ 
Figure 3.25 shows the stability curves for TG-chitosan xerogels containing BSA and 
INS determined using %UDGIRUG¶VDVVD\No significant differences were observed between the 
mean protein content of all xerogels irrespective of storage conditions (p < 0.05). In addition, 
all time points of analysis showed that the protein content of all xerogels were intact 
indicating product stability after storage under ICH conditions. However, since the Bradford 
method of protein estimation depends on binding with proteins, the possibility of binding all 
degraded/fragmented protein products may exist, thus giving a determination of total protein 
present. This constitutes a limitation of the method if all fragmented products contain arginyl 
and lysyl residues of proteins which bind readily with the Coomasie blue dye (Congdon et al., 
1993 cited in Kruger, 2008). Such a method cannot be used to detect the presence of degraded 
proteins and thus will not be suitable to differentiate between the protein products in the 
xerogels after storage under the ICH conditions.  
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Figure 3.25: Stability curves REWDLQHGE\%UDGIRUG¶VDVVD\$DQG%VKRZWKHFRntent for 
BSA while (C) and (D) show the content of INS in TG-chitosan xerogels after six months 
storage in the refrigerator (RF) and under ICH conditions.  
 
3.3.12.2 HPLC determination of BSA and INS content. 
 Figure 3.26 shows the calibration curves for %6$µ$¶DQG ,16 µ%¶XVLQJ6(-HPLC 
and RP-HPLC respectively. The respective SE-HPLC and RP-HPLC estimation of BSA and 
INS contents provided evidence for the existence of fragmented proteins from xerogels stored 
under ICH conditions. Storage of xerogels in the refrigerator resulted in the maintenance of 
their initial content after six months storage. No significant loss in protein was detected when 
stored in the refrigerator (Figure 3.27 µ$¶ DQG µ&¶ +RZHYHU, storage at 25°C and relative 
humidity of 60 % showed significant reduction in protein content down to 40 % and 20 % for 
BSA and INS respectively (Figure 3.27 µ%¶DQGµ'¶) after six months of storage. 
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Figure 3.26: %6$µ$¶DQGINS µ%¶calibration curves using SE-HPLC and RP-HPLC 
respectively. 
 
 
 
Figure 3.27: Stability curves obtained by SE-HPLC and RP-HPLC for BSA and INS 
respectively. (A) and (B) show the content for BSA while (C) and (D) show the content of 
INS in TG-chitosan xerogels after six months storage in the refrigerator (RF) and under ICH 
conditions.  
 
 The representative HPLC chromatograms in Figure 3.28 also show the peaks of 
chemically degraded BSA and INS along with the remaining BSA and INS originally present 
in the xerogels (Figure 3.28 µ&¶ DQGµ)¶). The exposure of the xerogels to extreme moisture 
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conditions leads to protein hydrolysis. The fragmented protein species from the BSA 
containing TG-chitosan xerogels stored under ICH conditions are most likely the result of 
hydrolysis of peptide bonds (Manning et al., 1989, cited in Estey et al., 2006). They appeared 
as unresolved species eluting before the minimised BSA peak as a result of progressive BSA 
loss. The reduced content of BSA detected at the end of the incubation suggests that the 
hydrolysis process was continuous throughout the incubation period and was incomplete at 
the last time point of six months. 
The stability of INS in the xerogels stored in a refrigerator could stem from 
formulation TG-chitosan, which as a hydrophilic polymer would deposit on the substrate 
surface, preventing moisture from reaching the proteins and thus limiting continuous INS 
degradation (Maroni et al., 2009). However the poor stability of most therapeutic proteins 
under room conditions is well documented (Strickley & Bradley, 1997 cited in Maroni et al., 
2009). Non- enzymatic degradation reactions occur with both solid and aqueous state INS 
leading to the formation of degradation products. Several INS degradation products including 
A21-desamido insulin, Other Insulin Related Compounds (OIRCs) and High Molecular 
Weight Proteins (HMWPs) have been described in the literature (Brange, 1992, cited in 
Maroni et al., 2009). The degradation of INS from the TG-chitosan xerogel at 25 °C/60 % RH 
could stem from hydration and hydrolysis of the polymer matrix allowing moisture to reach 
the exposed large surface area of INS.  
The primary packaging of parafilm sealing on the 24 well plates does not seem to have 
limited moisture absorption as originally suggested. In addition the instability of the model 
protein drugs could be due to poor air and moisture tightness of the sealing material
  
 
Figure 3.28: SE-HPLC chromatograms  µ$¶ shows BSA powder SHDNUHWHQWLRQWLPHDURXQGPLQXWHVµ%¶BSA released from TG-chitosan 
xerogels stored at 5  &DQGµ&¶ BSA and degraded BSA products released from TG-chitosan xerogel stored under ICH accelerated stability 
conditions for six months. The RP-+3/&FKURPDWRJUDPµ'¶VKRZVWKHSHDNRISXUH,16SRZGHUUHWHQWLRQWLPHDURXQGPLQXWHVµ(¶WKHSHDN
of INS from TG-chitosan stored in a refULJHUDWRUDQGµ)¶,16DQGGHJUDGHG,16SURGXFWVIURP[HURJHOVVWRUHGXQGHU,&+FRQGLWLRQV
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3.4 Conclusions 
Analytical characterisation of the chitosan based xerogels has been carried out using 
various analytical techniques. Structural information obtained from the 1HNMR and ATR-FT-
IR spectra have been used to confirm the chemical functional groups present in chitosan and 
TG-chitosan. 1HNMR was however not suitable for the determination of free thiol groups or 
disulphide bonds. Therefore UV spectroscopy using (OOPDQ¶V UHDFWLRQ was employed to 
quantify the amount of thiol groups immobilised covalently on the primary amine groups of 
chitosan to obtain TG-chitosan. The difference in polymer molecular weight between chitosan 
and TG-chitosan monitored by GPC confirmed the covalent attachment.   
ATR-FT-IR analysis of the conformational sensitive amide I and amide II bands 
indicated the conformational stability of the secondary structures of the loaded model protein 
drugs BSA and INS which were confirmed by CD spectroscopy. With respect to protein 
physical stability, no multiple glass-transition temperatures were detected by DSC after 
lyophilisation for all formulations except for the undialysed chitosan xerogel. The XRPD 
analysis of crystalline chitosan powder displayed its characteristic peak which was minimised 
in the formulated xerogels resulting in amorphous structures. However the presence of NaAc 
crystals identified by ATR-FT-IR spectra and XRPD diffractogram and confirmed with SEM 
microscopy resulted in thick walled xerogels for the undialysed chitosan samples. 
Furthermore, the SEM micrographs showed highly porous xerogels due to annealing which 
allowed for high drug loading capacities of the dialysed and annealed xerogels which also 
exhibited optimal moisture content for maintaining protein stability. The EC laminate 
however formed a continuous non porous sheet which effectively attached to the chitosan 
based xerogel, to serve as a backing membrane to assure uni-directional release of protein 
drug. 
The chemical stabilities of BSA and INS incorporated in chitosan based xerogels have 
been critically examined in this study. The results showed that storage of xerogels using 
accelerated stability conditions at 25 °C/ 60 % RH for six months resulted in substantial loss 
of native protein. Such reduction in protein content observed may have resulted from 
increased peptide bond hydrolysis due to enhanced moisture ingress during storage. Storage 
of xerogels at 5 °C in a refrigerator maintained protein nature up to six month however, 
further studies to establish the full extent of stability after storage in the refrigerator for up to 
12 months is required. The use of SE-HPLC and RP-HPLC methods respectively for BSA 
and INS estimation yielded chromatograms that suggested the presence of degraded protein 
SURGXFWVIRU[HURJHOVXQGHUDFFHOHUDWHGVWDELOLW\VWXGLHV7KHHPSOR\PHQWRI%UDGIRUG¶VDVVD\
  
for protein quantification, however, could not be used to determine the presence of protein 
degraded products from all xerogels.  
It is essential that the development of chitosan based delivery systems for controlled 
release of therapeutic proteins takes into consideration the stability of the protein drug. In 
addition, to improve stability of proteins within chitosan based systems, formulations must be 
protected from potentially extreme hydrolysing conditions to ensure maintenance of the native 
structure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER FOUR 
HYDRATION CAPACITY AND IN VITRO MUCOADHESION STUDIES 
4.1 Introduction 
Mucoadhesive polymeric drug carriers can have intimate contact with mucosal 
surfaces without absorption to induce systemic toxic side effects. In addition, they provide 
prolonged residence time of drugs on the mucosal surface, creating higher drug concentration 
and consequent controlled release of drugs (Grabovac et al., 2008). Other advantages of 
buccal mucoadhesive polymeric delivery systems include overcoming environmental factors 
such as salivary flow and shearing forces generated from tongue movements, chewing and 
swallowing, which can displace an adhered system (Eouani et al., 2001). For this reason, 
mucoadhesive polymeric systems have been used as an established alternative strategy for the 
delivery of proteins and peptides to combat low membrane permeability. Furthermore, 
thiolated polymers have also been studied and applied to impart improved mucoadhesion as 
well as permeation enhancing properties (Bernkop-Schnürch, 2005). 
Several approaches including the use of mucoadhesive polymeric gels (Patel et al., 
2011), films and wafers (Boateng et al., 2009) have been explored as putative mucoadhesive 
dosage forms for controlled drug delivery. Physical entanglement and secondary bonding 
such as hydrogen bonding and Van der Waals forces have been proposed as the major 
interaction between the mucoadhesive polymers and mucin (Eouani et al., 2001). Recently, 
thiomers with sulphydryl ligands have also been suggested to form disulphide covalent bonds 
with cysteine-rich mucin glycoproteins (Albrecht et al., 2006). These forces of interaction 
which contribute to this type of adhesion are related to the surface functional groups of the 
mucoadhesive polymers such as amines, amides, carboxyls, hydroxyls and sulphydryl groups. 
The mucoadhesivity and consequent duration of retention of the polymeric matrices are 
significantly impacted by physical properties such as rate of hydration and rheological 
properties (Smart, 1999, cited in Eouani et al., 2001). Hydration study of mucoadhesive 
polymeric systems is essential as it gives information on polymer chain structural behaviour 
and allows complete analysis of the rigidity as well as deformability of the polymeric system 
(Eouani et al., 2001). In addition, the determination of the hydration capacity informs 
functional characteristics such as swelling and rate of drug diffusion from the polymer matrix. 
In this chapter, the hydration capacities of various chitosan based xerogels containing 
BSA or INS as model protein drugs are evaluated and the effect of formulation processes such 
as membrane dialysis, annealing and thiolation determined. In addition, the driving 
mechanism for hydration in the thiolated xerogels was examined by carrying out the 
procedure with or without the presence of a reducing agent dithiotreitol (DTT). The 
  
mucoadhesive performance of the xerogels was assessed in an in vitro environment using a 
texture analyser to measure the peak adhesive force (PAF), total work of adhesion (TWA) and 
cohesiveness. The effect of mucin concentration, membrane dialysis, annealing, thiolation and 
enzyme inhibitors (EI) on mucoadhesion properties were determined. 
 
4.2 Materials and methods 
4.2.1 Materials  
Table 4.1: Details of materials used in hydration and mucoadhesion studies. 
Material Description Supplier 
Sodium hydroxide  S 240697 Sigma-Aldrich, Gillingham, UK 
Potassium dihydrogen phosphate P /4760/53 Fisher Scientific (Leicester UK) 
Mucin from bovine submaxillary 
gland, Type I-S 
M 3895-1 G Sigma-Aldrich, Gillingham, UK 
Gelatine (pulverised) G /0150/53 Fischer Scientific (Leicester UK) 
DL Dithiotreitol (DTT) D0632-1G Sigma-Aldrich, Gillingham, UK 
PBS tablets (pH 7.4) 4P4417-50TAB  Sigma-Aldrich, Gillingham, UK 
 
4.2.2 Hydration capacity  
The hydration capacities of the formulated lyophilised xerogels containing BSA (see 
Tables 4.3) were determined by incubating the samples in 25 mL of 0.01M PBS solution (pH 
6.8 ± 0.1 simulating salivary pH) at 37 ± 0.1°C. The solution was prepared by dissolving a 
tablet of PBS (pH 7.4) in 200 mL of deionised water and adjusting the pH to 6.8 using 
potassium dihydrogen phosphate and sodium hydroxide.  The xerogels were initially weighed 
and the hydration and swelling behaviour observed at predetermined time intervals (Wu et al., 
2009). The samples were removed and blotted off carefully between tissue papers to remove 
the surface-adhered liquid droplets and reweighed on an electronic balance to constant weight. 
These studies were performed in quadruplicate (n = 4) for each set of formulated samples and 
average values were calculated for data analyses. The percentage water uptake (hydration 
capacity) was calculated using equation 4.1: 
Water uptake (%) = 100 x (Ws ±W) /W............. equation 4.1 
where Ws is the weight of the hydrated xerogel, and  W is the initial weight of xerogel. 
  
4.2.2.1 Effect of formulation processes on xerogel hydration capacity 
 Xerogel hydration characteristics with respect to annealing, dialysis, thiolation and in 
the presence of EI were investigated. In addition, the effect of a reducing agent on hydration 
capacity of thiolated xerogels (Table 4.3) was studied with or without the addition of 10 mM 
Dithiotreitol (DTT) (Verheul et al., 2011)  to the PBS solution. The neutrality or otherwise of 
the xerogels was also established by immersing the samples in de-ionised water (pH 7.0) for 4 
hours and determining the subsequent pH.  
 
4.2.3 In-vitro mucoadhesion studies 
The in vitro mucoadhesion (peak adhesive force-PAF; total work of adhesion-TWA 
and cohesiveness) properties of the lyophilised xerogels were studied utilizing a texture 
analyser. The samples (n = 4) were attached to a 75 mm diameter adhesive rig probe with a 
double sided adhesive tape on a TA.HD.plus Texture Analyser (Stable Micro Systems, 
Surrey, UK) fitted with a 5 kg load cell in tension mode [Fig 4.1 (a)]. A 6.67 % gelatine 
solution allowed to set as a gel in a Petri-dish (diameter 88 mm), was equilibrated with 1 mL 
of 1-5 % mucin solution (pH of 6.8 ± 0.1) for 60 seconds to represent the buccal mucosal 
surface was placed on the instrument platform. The optimum mucin concentration was 
selected to equilibrate the mucosal substrate in subsequent determinations (see section 
4.2.3.1). The probe, lined with xerogel was set to approach the model buccal mucosal surface 
with the set parameters for adhesivity as shown in Table 4.2 (Thirawong et al., 2007), 
allowing 60s for complete contact and hydration before being detached.  
Texture Exponent 32 software was employed to record and process the data. The 
maximum force required to detach the xerogel from the mucosal surface, (PAF) was 
determined. The area under the curve (AUC) representing total work of adhesion (TWA) was 
estimated from the force-distance plot whiles the cohesiveness of the samples was determined 
by the distance of travel [Fig.4.1 (b)].  
 
 
 
 
 
 
 
 
  
Table 4.2: Texture analyser settings for determining the peak adhesive force (PAF), total 
work of adhesion (TWA) and cohesiveness of formulations. 
Parameters TA settings 
Pre-test speed 0.5 mm/sec 
Test speed 0.5 mm/sec 
Post-test speed 1.0 mm/sec 
Applied force 100.0 g 
Return distance 10.0 mm 
Contact time 60.0 sec 
Trigger type Auto 
Trigger force 5.0 g 
 
 
Figure 4.1: (a) Schematic diagram of texture analyser with xerogel attached to the probe and 
the mucosal substrate on the platform (b) Typical texture analysis force-distance plot. 
 
4.2.3.1 Investigation of factors affecting mucoadhesion properties of xerogels. 
The influence of various parameters on adhesive properties of the lyophilised xerogels 
was investigated as follow: 
(a) Mucin concentration; varying concentrations of mucin solution (1-5 %) 
prepared with 0.01 M PBS (pH 6.8) were used in equilibrating the gelatine 
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substrate in order to select the optimum concentration for further 
mucoadhesion characterisation of the xerogels.  
(b) Effect of membrane dialysis; the mucoadhesive properties of chitosan 
xerogels obtained from gels formulated by incorporating membrane dialysis 
were evaluated against xerogels obtained from gels formulated without the 
membrane dialysis stage. 
(c) Annealing; mucoadhesive properties of annealed and non-annealed xerogels 
were evaluated. 
(d) Thiolation; the effect of thiolation on mucoadhesive properties was studied 
using unmodified and thiolated chitosan xerogels. 
(e) Enzyme inhibitors (EI); using thiolated xerogels loaded with BSA/INS with or 
without an EI, the effect of varying concentrations of reduced GSH (0 ± 10 %) 
and APR (5 %) on mucoadhesive characteristics were measured. Optimised 
GSH concentration was selected for further development and characterisation. 
 
4.2.4 Statistical data analysis. 
Statistical data evaluation was performed using two tailed student t-test with 95 % 
confidence interval (p-value < 0.05) as the minimal level of significance. The pairs of data 
evaluated included the following; µGialysed vs undialysed [HURJHOV¶, µDnnealed vs non-
annealed [HURJHOV¶ µthiolated vs unmodified chitosan [HURJHOV¶DQGµ(,[HURJHOV vs non-EI 
[HURJHOV¶ 
 
4.3 Results and Discussion 
4.3.1 Hydration capacity 
Adequate hydration capacity of a buccal adhesive system is an essential property for 
uniform and prolonged release of the protein drug and effective mucoadhesion (Peppas & 
Bury, 1985). During the preliminary hydration studies, the hydration capacity was observed to 
increase with increasing concentration of GLY and D-MANN. However, physical 
examination of these xerogels with higher GLY and D-MANN FRQWHQWUHYHDOHGWKHµLQZDUG-
FDYLQJ¶ RI WKH [HURJHOV DIWHU O\RSKLOLVDWLRQ $Q HQODUJHG VSDFH PD\ KDYH EHHQ FUHDWHG
  
between the polymer chains by the plasticizer resulting in a loose and unstable micro-porous 
structure, which allowed a higher rate of water ingress and hence the enhanced water 
absorption capacity.  
The difference in the hydration capacity of the optimised annealed xerogel (1110.3 ± 
23.3 %) and the non-annealed xerogel (800.0 ± 21.4 %) was statistically significant (p < 
0.05). The water uptake of the samples reached the maximum value within 30 minutes of 
incubation, due to increased hydrophilicity of the chitosan xerogels with the presence of GLY 
and D-MANN. In addition, the annealing process enhanced ice crystal pore size during the 
freezing stage to increase xerogel porosity as shown in the previous chapter. Furthermore, the 
difference in the hydration capacities of annealed and the non-annealed TG-chitosan-BSA 
xerogels (Table 4.3) was statistically significant (p < 0.05). It is interesting to note that all the 
annealed xerogels maintained structural integrity after 4 hours of incubation due possibly to 
the mechanically stronger formulations obtained by annealing. The non-annealed xerogels 
however, formed a loose jelly-like and unstable swollen structure that consequently 
disintegrated after two (2) hours of incubation in PBS at 37 °C.  
The difference in the mean hydration capacities between dialysed and undialysed 
(both annealed) xerogels was not statistically significant (p > 0.05). The large pore sizes of 
both dialysed and undialysed xerogels were responsible for the high rate of water access with 
hydration capacities of 1110.3 ± 23.3 and 1090.0 ± 10.8, respectively. The presence of 
hygroscopic GLY in the xerogels could have enhanced the swelling capacities by increasing 
the intermolecular spaces between the polymer chains. In spite of the high capacities 
recorded, the dialysed xerogel was structurally stable under the excessive hydrated weight,  
resisting collapse for up to 4 h. The undialysed xerogels however, formed slippery gelatinous 
masses after 2 h of incubation, making handling difficult and was therefore discontinued. In 
addition, there was a reduction in the pH of the PBS solution containing the undialysed 
xerogels from 6.8 to 6.6 during the hydration studies due to the possible presence of excess 
acetic acid. 
However, upon the addition of xerogels to 10 mL of deionised water (pH 7), the pH of 
water was observed to have decreased to 6.0 for the dialysed xerogels and 6.5 for the 
undialysed xerogels. ,W LV HVVHQWLDO WKDW [HURJHO¶V S+ GRHV QRW VLJQLILFDQWO\ DOWHU WKH
environmental pH of the buccal mucosa to induce irritation when applied. This explains the 
rational for neutralising the excess acetic acid used in dissolving chitosan with NaOH during 
the gel formulation stage. The dissociation of NaAC (present as a by-product during gel 
formation) in the undialysed xerogels, to form NaOH and acetic acid in solution could explain 
the difference in pH observed when the xerogels were added to the deionised water.  
  
Table 4.3 Hydration capacity of xerogels 
Sample Treatment Hydration capacity (%) 
(n=4, mean ± SD) 
Chitosan-BSA Non-annealed 800.0 ± 21.4 
Chitosan- BSA Annealed/dialysed 1110.3 ± 23.3 
Chitosan- BSA Annealed/undialysed 1090.0 ± 10.8 
TG-chitosan-BSA Non-annealed 433.6 ± 3.1 
TG-chitosan-BSA Annealed 480.0 ±18.2 
 
The evaluation of the hydration capacities of dialysed chitosan-BSA and TG-chitosan-
BSA xerogels (annealed) revealed the effect of thiolation on xerogel hydration characteristics. 
The difference in the hydration capacities of the chitosan-BSA xerogel (1110.3 ± 23.3 %) and 
TG-chitosan-BSA xerogel (480.0 ± 18.2%) (Table 4.3) was statistically significant (p < 0.05) 
in the absence of a disulphide reducing agent (DTT). The swelling capacity of the chitosan-
BSA xerogel reached the maximum value within 30 minutes of incubation, which was due to 
the increased hydrophilicity of chitosan in the presence of GLY and D-MANN as discussed 
above. In addition, the enhanced pore size allowed for a higher rate of water ingress with a 
swelling capacity greater than 2-fold that of the TG-chitosan. It was observed that the rate of 
water ingress and swelling was slower for the TG-chitosan-BSA xerogel which prevented the 
formation of an excessively hydrated structure. This could be attributed to the oxidation of 
free thiol groups to form inter- and intra-molecular disulphide bonds in PBS at a higher pH of 
6.8 which subsequently limited the hydration process during the incubation period. It has been 
shown by Plunkett et al., (2003 cited in Wu et al., 2009) that osmotic pressure changes may 
occur with the formation of disulphide bonds and that the extent of hydration is decreased 
with increased cross-linking density (Shu et al., 2002, cited in Wu et al., 2009). However, in 
the presence of a disulphide reducing agent (DTT), a dramatic increase in hydration capacity 
was observed for the TG-chitosan xerogel (Table 4.4) due to the breaking of the disulphide 
bonds with subsequent decrease in cross-linking density. This gives evidence that the swelling 
characteristic was driven by the formation of internal disulphide cross-linkages in the TG-
chitosan xerogels (Ayensu et al., 2012b). Mucoadhesive xerogels are expected to be hydrated 
on the underlying mucosal tissue by water absorption, swelling and capillary action resulting 
in stronger adhesion (Eouani et al., 2001). 
  
Table 4.4 Effect of reducing agent 10 mM DTT on hydration capacity of thiolated chitosan 
xerogels 
Sample Treatment % Hydration capacity 
(n=4, mean + SD) 
TG-chitosan-BSA Annealed without DTT 480.0 ±18.2 
TG-chitosan-BSA Annealed with DTT 1086.8 ± 5.1 
TG-chitosan-GSH-BSA Annealed without DTT 912.5 ± 25.1 
TG-chitosan-GHS-BSA Annealed with DTT 910.2 ± 24.7 
 
The hydration capacities of annealed thiolated xerogels with 10 % GSH as EI were 
evaluated with or without the presence of the reducing agent DTT. No statistical significant 
difference (p > 0.05) was found between the mean hydration capacities of the xerogels with or 
without DTT (Table 4.4). The presence of GSH in the xerogel could have prevented 
disulphide bond formation in the thiolated chitosan xerogels at the pH of 6.8 resulting in the 
improved hydration capacity observed. Thiolated chitosans have shown the capacity to reduce 
oxidised glutathione by restricting oxidation of GSH on membranes when the two are used in 
combination as permeation enhancers (Clausen et al., 2002). Therefore, the interaction 
between the thiomer and GSH in the xerogels does not result in the formation of disulphide 
cross-linkages that have the ability to reduce hydration capacity. It was however, observed 
that the GSH containing xerogels formed loose gels after 2 hours of incubation, affecting their 
structural integrity over a prolonged period.  
  
4.3.2 Mucoadhesion 
 Gelatine as a representative mucosal substrate was chosen over non-protein based gel 
sources as the presence of methionine (a sulphur-containing proteinogenic amino acid), and 
the equilibration of the surface with cysteine-rich mucin glycoprotein augmented the adhesion 
process. The hydration of xerogels contributes to their mucoadhesion properties. Sufficient 
hydration of the xerogels facilitates the establishment of hydrogen bonding, allowing the 
polymeric chains to spread easily while diffusing along the xerogel/mucosal substrate 
interface. Initial hydration of the xerogels results in a hydrated gel layer which exposes the 
adhesive sites via relaxed molecules and allows easy interpenetration of the substrate 
molecules which subsequently creates the adhesive bonds (Tamburic et al., 1997).  
 
  
4.3.2.1 Factors affecting mucoadhesive properties of xerogels 
(a) Effect of mucin concentration; mucoadhesive characteristics were exhibited by 
the chitosan xerogels as a result of hydrogen bonding, electrostatic forces and hydrophobic 
interactions between the functional groups of chitosan and the sialic acid residues found in 
mucin (Sogia et al., 2008) [Figure 4.2 (a)]. Enhanced mucoadhesion properties were however 
observed for the thiolated chitosan xerogels as a result of stronger covalent bonding between 
the thiol ligands and the cysteine rich residues on the glycoproteins of mucin [Figure 4.2 (b)]. 
The differences  
 
Figure 4.2: In-vitro mucoadhesion measurements of (a) chitosan and (b) TG-chitosan 
xerogels showing the effect of mucin concentration on PAF, TWA and cohesiveness (n=4 
mean ± SD). 
 
observed between the varying concentrations of mucin were the result of reduced 
intermolecular ionic bond and enhanced hydration in the dilute 1 % mucin solution and the 
increased intra-molecular attraction of the concentrated 5 % mucin solution. The increased 
likelihood of the formation of internal disulphide cross-linkages within the 5 % mucin 
solution prepared with PBS of pH 6.8 could lead to an entangled structure that might limit 
solvent diffusion into the polymeric matrix. However, at the optimum mucin concentration (2 
%), the interpenetration between polymer and mucin was not restrained due to adequate rate 
of ingress of mucin solution with subsequent improvement in mucoadhesion properties. 2 % 
mucin solution exhibited mucoadhesive characteristics that were similar to that of 1 % mucin 
solution for chitosan xerogel and with more than 2-fold increase in the adhesion properties for 
the TG-chitosan xerogels when compared with 5 % mucin solution. Since excessive hydration 
in the case of 1 % mucin solution could affect structural integrity during mucoadhesion 
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measurements, as well as limited hydration, coupled with reduced interpenetration in the case 
of 5 % mucin solution, both of which adversely affect mucoadhesion characteristics, 2 % 
mucin solution was selected for further mucoadhesion measurements.   
 
 (b) Effect of membrane dialysis; statistically significant differences were observed 
between the PAF, TWA and the cohesiveness of the dialysed and undialysed xerogels (Figure 
4.3).  
 
Figure 4.3: In-vitro mucoadhesion measurements of chitosan-BSA xerogels showing the 
effect of membrane dialysis on PAF, TWA and cohesiveness (n=4 mean ± SD). 
 
The dialysed xerogel showed a higher PAF of 5.3 ± 0.7 N compared to 2.9 ± 0.4 N of the 
undialysed xerogel (p < 0.05). TWA values of 9.2 ± 1.0 and 2.4 ± 0.7 mJ were recorded for 
the dialysed and undialysed xerogels respectively (p < 0.05). In addition, the dialysed xerogel 
showed a cohesiveness of 4.4 ± 0.2 mm against 2.1 ± 0.7 mm of undialysed xerogels (p < 
0.05). The enhanced mucoadhesive properties exhibited by the dialysed xerogels may be 
attributed to the ease of wetting by the mucosal substrate, formation of strong intermolecular 
hydrogen bonding with the mucosal substrate and improved penetration of the mucosal 
substrate crevices (Sudhakar et al., 2006). In the case of the undialysed xerogels, the presence 
of NaAc may have interfered with the physical properties of the delivery matrix and reduced 
the extent of adhesion to the mucosal substrate (Sudhakar et al., 2006). In addition, the 
resultant change in the pH of PBS during the hydration of the undialysed xerogel may have 
influenced the mucoadhesive properties.  
Chitosan exhibits excellent mucoadhesive properties in alkaline or neutral 
environment (Park et al., 1989), however, this slight reduction in the pH of the environment 
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impacted on the mucoadhesive properties of undialysed xerogel by increasing the dissolution 
of the polymer matrix to form the slippery gel previously described. Consequently, the 
contact and consolidation stage of the adhesion process were affected by the reduced physico-
chemical interaction between the slippery chitosan gel and the mucosal substrate (Smart, 
2005; Andrew et al., 2009).  
 
(c) Effect of annealing; The PAF was used as a measure of the in-vitro mucoadhesive 
performance (Figure 4.4). The annealed xerogels with larger pore size distribution [see Figure 
3.22(A), chapter 3] and better hydration capacity, had higher PAF (5.3 ± 0.7 N) compared to 
the non-annealed xerogels (4.1 ± 0.1 N) which was statistically significant (p < 0.05). Again 
the absorbent properties of GLY in combination with D-MANN could have aided in the 
stronger initial attachment of the formulations to the model mucoadhesive surface. 
The TWA represented by the AUC gave dissimilar profiles for the formulations, with 
the annealed and non-annealed xerogels showing values of 9.2 ± 1.0 and 6.4 ± 1.2 Nmm 
respectively. The difference observed in the TWA of the xerogels which was statistically 
significant (p < 0.05) could be attributed to differences in pore size distribution and stability 
of the mechanically strong structure. Furthermore, the cohesiveness of the xerogels showed a 
statistically significant (p < 0.05) difference between the annealed (4.4 ± 0.6 mm) and non-
annealed xerogels (3.1 ± 0.2 mm). The reduced cohesiveness of the non-annealed xerogels 
may have given rise to the collapse of the mechanically weak structure of the xerogels two (2) 
hours into the hydration test.  
 
Figure 4.4: In-vitro mucoadhesion measurements of chitosan-BSA xerogels showing the 
effect of annealing on PAF, TWA and cohesiveness (n=4 mean ± SD). 
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The process of annealing also led to significant differences in the mucoadhesive 
properties of the TG-chitosan xerogels. The annealed TG-chitosan-BSA xerogels showed a 
significant improvement in mucoadhesive properties (Figure 4.5) compared to the non-
annealed TG-chitosan-BSA xerogels. The annealed TG-chitosan-BSA xerogels with enhanced 
swelling capacity had higher PAF and cohesiveness compared to the non-annealed TG-
chitosan-BSA xerogels. The total work of adhesion (TWA) further showed a statistically 
significant difference (p < 0.05) between the annealed and non-annealed TG-chitosan-BSA 
xerogels, with an approximate 3-fold increase in mucoadhesive strength. The major 
differences observed in the PAF, TWA and cohesiveness of the xerogels were largely due to 
the increased mucoadhesive strength influenced by the mechanically strong and fibrous 
porous structure of the annealed xerogels. 
Mucoadhesive performance is important as it determines the residence time of 
formulations at the absorption site to allow for sustained drug release and ultimately 
bioavailability. 
 
Figure 4.5: In-vitro mucoadhesion measurements of TG-chitosan-BSA xerogels showing the 
effect of annealing on PAF, TWA and cohesiveness (n=4 mean ± SD). 
 
(d) Effect of thiolation; the effect of thiolation on in vitro mucoadhesive performance 
was measured by evaluating the PAF, the TWA and the cohesiveness of the annealed chitosan 
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and TG-chitosan xerogels.  The chitosan-BSA xerogels had lower PAF compared to the TG-
chitosan-BSA xerogels (Figure 4.6) with mean difference that was statistically significant (P 
< 0.05). This difference was expected to be much higher, however, the combined effect of the 
absorbent properties of GLY and D-MANN and the enhanced inter molecular hydrogen 
bonding with the gelatine substrate employed could have aided in the strong initial attachment 
of both chitosan-BSA and  TG-chitosan -BSA xerogels to the model mucoadhesive substrate.  
 
Figure 4.6: In-vitro mucoadhesion measurements of xerogels showing the effect of thiolation 
on PAF, TWA and cohesiveness (n=4, mean ± SD). 
 
 The total work of adhesion (TWA) represented by the area under the curve also 
showed a statistically significant difference (p < 0.05) between the chitosan-BSA and  TG-
chitosan -BSA  xerogels, with about two-fold increase in mucoadhesive strength of the latter. 
Furthermore, the cohesiveness of the xerogels also displayed a two-fold increase in the TG-
chitosan based xerogels which was statistically significant (p < 0.05).  
The major differences observed in the PAF, TWA and cohesiveness of the xerogels 
were attributed largely to the increased mucoadhesive strength arising from the thiolation 
process via the formation of stronger covalent interactions between the cysteine-rich mucin 
glycoproteins and the sulphydryl ligands of TG-chitosan. In addition, the formation of inter 
and intra molecular disulphide linkages within the TG-chitosan xerogels and the stability of 
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the fibrous structure may have augmented the mucoadhesive strength (Ayensu & Boateng, 
2012). The relatively low mucoadhesive strength of the unmodified chitosan xerogels may 
have arisen from the excessive hydration of the porous structure leading to the formation of a 
slippery gel that lost its mucoadhesive strength. The excessive hydration of the chitosan 
xerogels leading to the significant reduction in adhesive strength was due to disentanglement 
at the xerogel/mucosal substrate interface resulting in separation of the xerogel and mucosal 
substrate due to slippage of the macromolecular chains of the formulation (Eouani et al., 
2001). 
Mucoadhesive strength is a key property for the determination of the functional 
characteristic of residence time of xerogels at the absorption site to allow for sustained drug 
release and eventually bioavailability. Though significant differences were observed in the 
mucoadhesive performance between the chitosan and TG-chitosan xerogels, the differences 
were much lower compared to those reported by Roldo et al., (2004) where different 
formulation systems and bioadhesion membranes were used. It must however be emphasised 
that the process of thiolation greatly influenced the mucoadhesive performance.  
(e) Effect of EIs; the effect of GSH concentration (EI) on the mucoadhesive properties 
of thiolated xerogels containing BSA was evaluated. The formulation containing 5 % GSH 
showed significant reduction in mucoadhesion characteristics compared to thiolated xerogel 
without an EI (Figure 4.7). Statistically significant differences were observed between the 
mean PAF (p < 0.05) and TWA (p < 0.05) of the xerogels with no GSH and with 5 % GSH. 
The difference between the cohesiveness values was not statistically significant (p > 0.05).  
  
 
Figure 4.7: In-vitro mucoadhesion measurements of xerogels showing the effect of varying 
GSH concentration on PAF, TWA and cohesiveness (n=4, mean ± SD). 
 
 However, the formulation containing 10 % GSH demonstrated enhanced 
mucoadhesion properties though there was no statistically significant difference between its 
mean TWA and that of the control formulation with 0 % GSH (p = 0.241). Similar trends 
were observed for the PAF and the cohesiveness. The hydration studies in the presence of a 
reducing agent DTT (see Table 4.4), has shown that the presence of GSH limits the formation 
of disulphide bonds from free thiol groups in the thiolated xerogels. However, the reduced 
mucoadhesion observed with the presence of 5% GSH indicates that the ability of GSH to 
inhibit disulphide formation is concentration dependent. Furthermore, the adsorption of BSA 
by GSH (Vallee et al., 2008) at the physiological pH (6.8) must have depleted the 5 % GSH 
such that not much was available to prevent disulphide bond formation in the thiolated 
xerogel. A concentration of 10 % GSH was optimum to allow for the availability of free thiol 
groups and for interaction with BSA, with the resultant enhanced mucoadhesion observed. 
The free thiol groups present in xerogels with 10 % GSH may have formed stronger covalent 
bonds with cysteine-rich residues in mucin glycoproteins on the surface of the mucosa 
substrate as discussed earlier. Thiolated xerogel with 10 % GSH was deemed optimum for 
further development and characterisation. 
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The thiolated chitosan formulation was loaded with INS and the mucoadhesive 
properties measured from xerogels with or without EIs. Xerogels containing 10 % GSH or 5 
% APR were evaluated against xerogels containing 0 % of EI. A statistically significant 
difference (p < 0.05) was observed between the PAF of formulations B and C (Figure 4.8). 
There was however, no statistically significant differences (p > 0.05), between the TWA and 
the cohesiveness of all the formulations. Formulation B showed improved mucoadhesion 
properties compared to formulations A and C which had similar characteristics. The results 
confirm the ability of GSH to limit disulphide bond formation in the thiolated xerogel which 
allowed more free thiol groups to interact covalently with cysteine-rich mucin glycoproteins 
to enhance mucoadhesion characteristics. It also demonstrates the importance of EI 
specificity. 
Figure 4.8: In-vitro mucoadhesion measurements (PAF, TWA and cohesiveness) of TG-
chitosan-INS xerogels containing (A) 5% aprotinin, (B) 10% GSH and (C) no EI. (n=4, mean 
± SD). 
 
4.4 Conclusions 
Significantly higher hydration capacity was recorded for annealed chitosan xerogel 
compared to non-annealed xerogel. The formulation process of annealing in addition to 
plasticization (GLY) and cryoprotection (D-MANN) may have created enlarged pore spaces 
within the polymer chains which allowed for easy water ingress and enhanced the hydration 
capacity. Membrane dialysis did not have any significant effect on the hydration capacity, 
however, the presence of process impurity NaAc resulted in xerogels with poor structural 
stability as was observed for non-annealed chitosan xerogels which gelled and subsequently 
collapsed within two hours of hydration. 
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Annealed TG-chitosan xerogel similarly showed higher hydration capacity compared 
to non-annealed TG-chitosan xerogel which was mechanically weak, forming a loose gel. 
However, disulphide bond formation in the thiolated xerogel limited the hydration capacity 
hence the significant difference observed between hydration capacities of the thiolated and 
unmodified chitosan xerogels. The hydration capacity of the thiolated xerogel increased 
significantly in the presence of a reducing agent DTT which confirms that the hydration 
characteristics is driven by the cross-linked disulphide bond formation. The introduction of 
GSH as an EI to the thiolated xerogel may have prevented the formation of disulphide bonds 
leading to a higher hydration capacity with or without DTT. 
The hydration capacity of the xerogels directly impacted their mucoadhesion 
properties determined in the presence of 2 % optimal mucin concentration. The annealed 
chitosan xerogels showed better mucoadhesion properties compared to non-annealed chitosan 
xerogels. However, undialysed chitosan xerogel demonstrated reduced mucoadhesion 
characteristics due to the presence of NaAc. Improved mucoadhesion properties were 
obtained for the annealed thiolated xerogels compared to non-annealed thiolated and 
unmodified chitosan xerogels. Covalent interactions between the free thiol moieties on the 
thiolated xerogels and cysteine-rich mucin glycoproteins have been used to explain the 
improved mucoadhesion.  
The effect of EI on mucoadhesion was concentration dependent as 10 % GSH led to 
increased mucoadhesion compared to 5 % GSH. The effect was also inhibitor specific as 
significant differences were observed between the mucoadhesion properties of the thiolated 
xerogel loaded with INS and containing either 10 % GSH or 5 % APR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER FIVE 
IN VITRO DRUG DISSOLUTION CHARACTERISTICS AND RELEASE 
MECHANISMS OF CHITOSAN AND TG-CHITOSAN XEROGELS LOADED WITH 
BSA AND INS.  
5.1 Introduction 
 The increased understanding of the human body anatomy and physiology, the 
elucidation of disease pathophysiology and the continuous advancement experienced in the 
pharmaceutical world have provided the impetus for research into novel delivery systems with 
µVPDUW¶FKaracteristics over the last decade (Sood & Panchagnula, 2003; Friend, 2005). The 
overall objective for the development of novel drug delivery systems is to enhance the 
efficacy of the active pharmaceutical ingredient, reduce side effects and to improve patient 
compliance. Polymeric hydrogel matrices and controlled drug delivery systems offer a great 
potential for achieving better control of administered drugs (Jain et al., 2009). The flexibility 
offered by hydrogels in obtaining desirable drug release profiles, biocompatibility, 
biodegradability and cost effectiveness have rendered them useful in a wide range of 
controlled drug delivery systems (Morales & McConville, 2011). A complex interaction 
between diffusion, dissolution and erosion mechanisms has been used to explain drug release 
from hydrophilic matrices. A number of polymeric hydrogels including hydroxypropyl 
methylcellulose (HPMC), chitosan and its derivatives have been employed in formulations 
due to their advantage of offering robust mechanisms and reproducibility of drug release 
profiles, cost effectiveness and choice of viscosity grades (Shoaib et al., 2006). The hydration 
capacity of the polymeric matrix which results in a gel barrier through which the drug diffuses 
controls water ingress, polymer swelling, drug dissolution, drug diffusion and matrix erosion 
(Sung et al., 1996 cited in Shoaib et al., 2006).  
A number of mathematical kinetic models have been proposed to elucidate water and 
drug transport through polymeric matrices and to predict the consequent drug release kinetics 
(Korsmeyer et al., 1986; Ju et al., 1995; Gao et al., 1995; Siepmann et al., 1999, cited in 
Shoaib et al., 2006). In using these mathematical models to describe the entire drug release 
process, a number of physical characteristics such as rate of water diffusion into polymer 
matrix, polymer swelling, drug diffusion out of the delivery system, axial and radial 
movement in a 3-dimensional system, porosity and composition must be taken into 
consideration. The above parameters make the description a complex process which requires 
  
that each model makes assumptions that are applicable to certain drug-polymer systems 
(Siepmann et al. 2000, cited in Shoaib et al., 2006). 
Different kinetic models have been employed to describe the release kinetics of drugs 
from polymeric matrices based on drug dissolution or release data. A zero order rate equation 
[5.1] is used to describe a system where the drug release rate is concentration independent 
(Hadjiioannou et al., 1993, cited in Shoaib et al., 2006) whereas a first order rate equation 
[5.2] describes a concentration dependent drug release rate (Bourne 2002, cited in Shoaib et 
al., 2006). The Fickian diffusion equation [5.3] proposed by Higuchi (1963, cited in Shoaib et 
al., 2006) describes the release of drugs from insoluble matrices as being dependent on the 
square root of time. The Hixson-Crowell cube root law equation [5.4] on the other hand 
describes drug release systems which involve a change in surface area and diameter of 
particles or tablets (Hixson and Crowell, 1931 cited in Shoaib et al., 2006)  
M = k0t                                            equation [5.1] 
where, k0 is rate constant for the zero-order drug release and t is the time.  
Log M = Log M0 í kt / 2.303                 equation [5.2] 
where, M0 is the drug initial concentration and K is first order rate constant. 
M = Kt1/ 2                                            equation [5.3] 
where, M is the drug concentration and K is the constant that relates to the design variables of 
the system. 
M01/3 ± Mt1/3 = KHC t                            equation [5.4] 
where, Mt is the amount of drug released in time t, M0 is the initial amount of drug in 
tablet/formulation and KHC is the rate constant for Hixson-Crowell rate equation.  
For a polymeric system, Korsmeyer et al., (1983, cited in Shoaib et al., 2006) proposed a 
relationship that may be used to determine the drug release mechanism by fitting the first 60% 
drug release data in the Korsmeyer-Peppas model; equation [5.5]. 
Mt /M = Kt n                                        equation [5.5] 
where Mt / M is the fraction of drug released at time t, k is the rate constant and n is the 
release exponent. The value of n is used to describe different release mechanisms shown in 
Table 5.1 for polymeric matrices of cylindrical shape. 
 
 
 
 
  
Table 5.1: Diffusion exponent and drug diffusion mechanism for cylindrical shaped matrices 
Diffusion exponent (n) Drug diffusion mechanism 
0.45  Fickian diffusion 
0.45 < n < 0.8 Anomalous (non-Fickian) diffusion 
0.89 Case-II transport 
n > 0.89  Super case-II transport 
 
 The Moore and Flanner (1996) equations [5.6 - 5.7] which are model independent, are 
employed to estimate the difference (f1) and the similarity (f2) factors which compare the 
dissolution profiles of different formulations under evaluation. The f1 value determines the 
percent error between two curves over all time points and the f2 value is a logarithmic 
transformation of the sum-squared error of differences between the test (T j) and reference 
(Rj) formulations over all time points. N is the number of samples. 
 
f1 ൌ  ? ሃୖ୨ି୘୨ሃ೙ೕసభ ? ୖ୨೙ೕసభ ൈ  ? ? ?                                              equation [5.6] 
 
 f2 =  ? ?ൈ  ሼሾଵே  ? Ň െ Ň௡௝ୀଵ ଶሿି଴Ǥହ ൈ  ? ? ?ሽ     equation [5.7] 
 
Test and reference formulations may be considered similar if f1 value is less than 15 % 
(0.15). F2 value higher than 50 (50-100) which shows similarity of the dissolution profiles 
is used when f1 is more than its limit of 15 % (Dash et al., 2010). The Food and Drug 
Administration (FDA) advice that two dissolution profiles be declared similar for f2 values 
between 50 and 100 (www.fda.gov).  
The present chapter aims to determine the release profiles of BSA and INS from 
lyophilised chitosan and TG-chitosan xerogels. These xerogels have been formulated by 
incorporating appropriate concentrations of GLY and D-MANN as plasticizer and 
cryoprotectant respectively (see chapter two). In addition, formulation processes such as 
membrane dialysis, annealing during lyophilisation and thiolation have been applied and their 
effects on drug release characteristics investigated. Furthermore, the effects of the EI 
(presence or absence) on protein drug release were investigated. The mechanisms of drug 
release were evaluated by fitting the drug release data to different kinetic models including, 
zero order, first order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas equations. Model 
  
independent difference and similarity factors were used to evaluate the release profiles of the 
xerogels. 
 
5.2 Materials and methods 
5.2.1 Materials 
Table 5.2: Materials for drug release studies 
Material Description Supplier 
BSA (mol wt. ~67 kDa) A7906-100 G Sigma-Aldrich Gillingham, UK. 
Acetic Acid A /0360/PB17 Fisher Scientific (Leicester UK) 
Hydrochloric acid H /1150/PB 17 Fisher Scientific (Leicester UK) 
Potassium dihydrogen phosphate P /4760/53 Fisher Scientific (Leicester UK) 
Sodium hydroxide  S 240697 Sigma-Aldrich, Gillingham, UK 
PBS tablets (pH 7.4) 4P4417-50TAB Sigma-Aldrich, Gillingham, UK 
Recombinant human INS 12643-50MG Sigma-Aldrich, Gillingham, UK 
BradIRUG¶VUHDJHQW B6916-500ML Sigma-Aldrich, Gillingham, UK 
 
5.2.2 In vitro BSA release profiles using beakers 
The BSA loaded lyophilised xerogels from the preliminary formulation investigations 
were immersed in beakers containing 50 ml of 0.01M PBS (pH 6.8 ± 0.1) solution as 
dissolution medium at 37 ± 0.1 °C and covered (Nochos et al., 2008). The dissolution 
medium was pepared by dissolving a tablet of PBS (pH 7.4) in 200mL of deionised water and 
adjusting the pH to 6.8 with potassium dihydrogen phosphate and sodium hydroxide. The 
dissolution medium was stirred at 150 rpm with a magnetic stirrer. For each sample, 5ȝ/RI
the dissolution medium was sampled at predetermined time intervals and replaced with the 
same amount of the PBS solution to maintain a constant volume for 7 hours. The sampled 
GLVVROXWLRQPHGLXPZDVWUHDWHGZLWKP/%UDGIRUG¶VUHDJHQWDQGWKHDEVRrbance measured 
as previously described in chapter 3 section 3.2.10. The concentration of BSA released from 
the xerogels was determined by interpolation from the linearized calibration curve (r 2 > 0.99) 
(Chapter 3, Figure 3.18). Corresponding cumulative percentage drug release profiles of BSA 
were then plotted for the different formulations: (i) dialysed and undialysed chitosan xerogels; 
(ii) annealed and non-annealed chitosan xerogels and (iii) annealed and non-annealed TG-
chitosan xerogels. The BSA release profiles from the chitosan and TG-chitosan xerogels were 
  
evaluated in order to obtain optimised formulations for further development and 
characterisation. 
 
5.2.3 In vitro release of BSA and INS using Franz-type diffusion cell 
20 mg of drug loaded optimised laminated xerogels were placed in the donor 
compartment (chamber) on stainless steel wire mesh ( 0.5 mm x 0.5 mm) which separated the 
donor and receiver compartments, with the mucoadhesive surface in contact with the wire 
mesh and facing the receiver compartment of the modified Franz diffusion cell (Cui et al., 
2009). The receiver chamber was filled with 8 mL of 0.01M PBS pH 6.8 at 37 °C with 
magnetic stirring at a speed of 150 rev/min. The chambers were held together by a cell clamp 
and sealed with parafilm to limit evaporation (Figure 5.1).  
 
Figure 5.1: Photograph of modified Franz-type diffusion cell as set up for drug release 
experiment.  
 
 ȝ/ RI WKH GLVVROXWLRQ PHGLXP ZDV VDPSOHG DW SUHGHWHUPLQHG WLPH LQWHUYDOV DQG
replaced with the same amount of fresh medium to maintain a constant volume for 4 or 7 
KRXUV 7KH VDPSOHG GLVVROXWLRQ PHGLXP ZDV WUHDWHG ZLWK PO %UDGIRUG¶V UHDJHQW DQG WKH
absorbance measured at 595 nm and 450 nm for linearisation of absorbance using a Multiskan 
EX microplate photometer equipped with Ascent software (Thermo Scientific, Hampshire 
UK). The concentration of the BSA and INS released from the xerogels was determined by 
interpolation from the linearized calibration curve (r 2 > 0.99) and cumulative percentage drug 
  
release profiles plotted. Blank control was determined with non-drug loaded laminated 
xerogel. The release profiles of BSA from xerogels containing different EIs at varying 
concentrations (TG-chitosan-BSA, TG-chitosan-GSH-BSA 5 % and TG-chitosan-GSH-BSA 
10%) were determined. INS released from xerogels with or without EI (TG-chitosan-INS, 
TG-chitosan-APR-BSA and TG-chitosan-GSH-INS) using 0.01 M PBS as dissolution 
medium were also analysed. 
 
5.2.4 Evaluation of drug release mechanisms 
Model dependent release mechanisms:  
 Based on the drug dissolution results, the following plots with their corresponding 
kinetic/mechanism models in Table 5.3 were constructed by fitting the drug release data to 
equations [5.1 ± 5.5] (section 5.1 above). 
 
Table 5.3 Various plots with corresponding kinetic /mechanism model 
Plot Kinetic/mechanism model 
Cumulative % drug release against time  Zero order kinetic model 
Log cumulative of % drug remaining against time First order kinetic model 
Cumulative % drug release against square root of time Higuchi model 
Log cumulative % drug release against log time Korsmeyer model 
Cube root of % drug remaining in matrix against time Hixson-Crowell cube root law 
 
 
Model independent release mechanism:  
 The difference (f1) and similarity (f2) factors were estimated using equations 5.6 ± 5.7 
(section 5.1.1.2). The values were used to compare the release profiles of the different 
formulations.  
  
5.3 Results and Discussion 
5.3.1 In vitro BSA release profiles 
The drug release profile determined for the dialysed chitosan-BSA xerogel showed a 
three-fold increase in total cumulative BSA release, compared to the undialysed chitosan-
BSA xerogel (Figure 5.2). The ideal characteristics of a mucoadhesive polymer matrix 
  
include minimum interference to the release of the active agent (Sudhakar et al., 2006). This 
was exhibited by the dialysed xerogels where typical controlled release of active ingredient 
was obtained, reaching a total cumulative per cent release of 91.8 ± 4.0 after 7 hours of 
incubation. The release of the model protein from the undialysed xerogel was however, 
inhibited to a greater extent by the presence of the crystalline NaAc as only 30.1 ± 2.6 % BSA 
was released within 7 hours.  
Although the undialysed xerogel showed a porous structure due to annealing (Chapter 
3, Figure 3.22 [B]), the release profile was not characteristic of chitosan. The presence of 
crystals in the undialysed xerogel affected the initial hydration, thus slowing down the rate of 
water ingress into the polymeric network. In addition, the differences observed in the 
thickness of the xerogel walls consequently affected the release of drug by differences in the 
thickness of swollen gel formed during the release studies. 
 
 
Figure 5.2: Cumulative percent BSA release from dialysed and undialysed chitosan-BSA 
xerogels. (n=4 mean ± SD). 
  
Interferences with the release of BSA could also have resulted from the altered 
environmental pH originating from a solution of NaAc (conjugate base of a weak acid) and 
acetic acid acting as a new buffer maintaining a relatively constant pH of 6.6, different from 
the original PBS pH of 6.8. Furthermore, the presence of the crystalline NaAc may have 
caused a decrease in surface area of the dispersed drug in the porous cake, decreasing 
dissolution rate considerably with consequent suppression of drug release (Bunte et al., 2010).  
 A stronger charge to charge interaction between BSA and chitosan could lead to 
decreased cumulative per cent BSA release from both xerogels (Ma et al., 2002) observed in 
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the second phase of the release process after 1 hour. However, Boeris et al., (2010) have 
shown that the non-covalent chitosan-BSA complex gradually dissolves in the presence of 
NaCl, supporting the higher % release of BSA from the dialysed xerogel. A common ion 
effect however, results from the sodium ions in PBS and NaAc, limiting the solubility of the 
crystalline NaAc which subsequently affects the rate of release of BSA from the BSA-
chitosan complex in the undialysed xerogel. 
Figure 5.3 shows the dissolution profiles of BSA from annealed and non-annealed 
chitosan xerogels. The total cumulative percent BSA release in 7 hours from the annealed and 
non-annealed chitosan xerogels were 91.5 ± 3.7 % and 80.1 ± 4.9 % respectively which was 
statistically significant (p < 0.05), though both formulations exhibited a sustained (controlled) 
release typical of chitosan based formulations. In addition, the rate of release (indicated by the 
slope of the initial linear portion of the curve) was faster from the non-annealed than the 
annealed xerogels within the first hour of release due to its lower cohesiveness and 
mechanically weak structure which formed a gel that easily disintegrated in the dissolution 
medium during the initial stages of the drug dissolution study. Bunte et al., (2010) observed 
that drug release is facilitated by the porous network of lyophilised xerogels. An increased 
surface of the dispersed drug in the porous cake occurs, accelerating dissolution significantly. 
Annealed xerogels showed a loose but stable structure, with many micropores (Chapter 3, 
Figure 3.22 [A]), which allowed for easy hydration and therefore faster drug release rate. The 
amine and hydroxyl groups of chitosan can both couple with proteins under mild conditions 
(Yang et al., 2001). Hydrophobic interactions between chitosan and BSA within the network 
might also be favoured. Strong charge to charge interactions have also been demonstrated 
between proteins and chitosan with a reduced cumulative release in the amount of protein 
even after dissolution of the chitosan matrix (Ma et al., 2002). 
 
 
 
  
 
Figure 5.3: Cumulative percent BSA release from annealed and non-annealed lyophilised 
chitosan-BSA xerogels. (n=4 mean ± SD). 
 
 BSA release rate from the xerogels could have been influenced concurrently by these 
factors to different extents. The dissolution profiles of BSA from the lyophilised annealed and 
non-annealed TG-chitosan xerogels in 0.01M PBS is shown in Figure 5.4. The total 
cumulative percent BSA release from the annealed and non-annealed TG-chitosan -BSA were 
95.2 ± 7.3 % and 84.0 ± 4.7 % respectively. This difference was statistically significant (p < 
0.05) with both formulations exhibiting sustained release profiles, typical of chitosan based 
formulations. The drug release may have been facilitated by the porous polymeric network of 
the freeze-dried xerogels as a result of increased surface of the dispersed drug in the porous 
cake which accelerates dissolution significantly (Bunte et al., 2010). 
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Figure 5.4: Cumulative percent BSA release from annealed and non-annealed TG-chitosan-
BSA xerogels (n=4 mean ± SD). 
 
 The total cumulative percent release was higher from the annealed TG-chitosan than 
the non-annealed TG-chitosan xerogels due to its higher rate of hydration and enhanced 
cohesiveness. The cohesion and stability of a drug delivery system over the intended duration 
of drug release is often a requirement for controlled release (Peppas & Bury, 1985).  
The dissolution profile of BSA from annealed chitosan-BSA and TG-chitosan-BSA 
xerogels in 0.01M PBS is shown in Figure 5.5. The total cumulative percent BSA release 
from the chitosan-BSA and TG-chitosan-BSA were 91.5 ± 3.7 % and 94.4 ± 7.3 % 
respectively. This difference was not statistically significant (p > 0.05) with both formulations 
exhibiting classical sustained release profiles characteristic of chitosan based formulations. 
The similar release profiles from the xerogels exhibited a burst release of about 57% and 45% 
for chitosan and TG-chitosan respectively in the first 1 hour, followed by a constant 
controlled release. This could be attributed to two different release mechanisms; (a) diffusion 
of protein molecules based on concentration and (b) degradation of polymer matrix. The 
initial BSA burst release was due to drug molecules adsorbed to the xerogel surface or loosely 
associated with the surface which easily diffused out in the initial incubation period of 1 hour 
(Xu & Du, 2003). 
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Figure 5.5: Cumulative percent BSA release from annealed chitosan and  TG-chitosan  
xerogels from 0.01M PBS at 37 ± 0.1 °C (n=4 mean ± SD). 
 
 The movement of water molecules containing dissolved hydrophilic proteins is not 
restricted between the release medium and the polymer matrix (Kang & Song, 2008). The 
high loading concentration of BSA enhanced its release from the xerogels as the large 
concentration gradient between the release medium and the polymer surface resulted in a high 
diffusion rate. In addition, proteins dispersed within the polymer matrix may have escaped 
through cracked pores formed during processing, therefore increasing the initial release.  
 A prolonged release period however, ensued after the initial burst release due to BSA-
chitosan complexation. At pH 6.8, BSA (isoelectric point around 5) carries a net negative 
charge and complexes with positively charged chitosan. As a result, a slower diffusion of 
entrapped protein from hydrated chitosan and TG-chitosan xerogels occurred (Wang et al., 
2009). Disulphide formation in TG-chitosan could have limited TG-chitosan-BSA 
complexation as fewer chitosan amino groups were available for interaction. Subsequently, 
the TG-chitosan xerogel released more BSA than the chitosan xerogel though the difference 
was not statistically significant (p > 0.05). The disulphide bond results in a stronger and stable 
swollen gel (maintained physical integrity) that displayed excellent cohesive properties. The 
cohesion and stability of a drug delivery system over the intended duration of drug dissolution 
helps in controlling drug release. The non-covalent complex however, gradually dissolves in 
the presence of NaCl (Boeris et al. 2010) present in PBS to support the higher % release of 
BSA observed in both xerogels. The usefulness of TG-chitosan as a carrier matrix for 
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controlled drug release has been demonstrated with model drugs such as metronidazole and 
clotrimazole (Saboktakin et al., 2011; Kast et al., 2002).  
 
5.3.3 In vitro release of BSA and INS using Franz-type diffusion cell 
 The use of the Franz-type diffusion cell to investigate the in vitro release of the model 
protein drugs stems from the fact that it offers an opportunity to simulate the buccal 
epithelium by the presence of a barrier system between the donor and the receiver 
compartments. Although the barrier used in this work seems extremely porous compared with 
the buccal epithelium, it represents an efficient system to estimate the release profile of the 
model protein drugs and to predict the release mechanisms as well as the kinetics using 
various kinetic models. 
 Figure 5.6 shows the release profiles of BSA from TG-chitosan xerogels with varying 
concentrations of GSH as EI. The optimum concentration of GSH for the formulation was 
determined by the mucoadhesive performance and the release profiles. The presence of GSH  
 
Figure 5.6: Cumulative percent BSA release from TG-chitosan xerogels containing varying 
amounts of GSH as EI from 0.01M PBS at 37 ± 0.1 °C using Franz-type diffusion cell (n=4 
mean ± SD). 
 
had a considerable effect on the release of BSA with statistically significant differences in the 
mean cumulative percent release after 7 hours observed between the control formulation with 
no EI and the formulations containing 5 % and 10 % GSH as EIs (p < 0.05). The slow 
controlled diffusion of entrapped BSA from the hydrated xerogels was the result of the 
complex interactions between BSA, TG-chitosan matrix and the GSH added. BSA adsorption 
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at pH 6.8 (Vallee et al., 2008) and limitation of disulphide bond formation from free thiol 
groups in thiolated xerogels by GSH may have been responsible for the lower BSA percent 
cumulative release from the xerogels containing EI.   
 However, the effect of EI on BSA release was not concentration dependent throughout 
the experimental period as was observed in the mucoadhesion studies (see chapter 4). The 
difference in mean cumulative percent after 7 hours between the xerogels with 5 % and 10 % 
GSH was not statistically significant (p > 0.5) though some differences were observed 
between the release profiles up to the fourth hour. Based on mucoadhesive performance and 
release profiles, the xerogel with 10 % GSH was considered for further development and 
characterisation. 
 The release of another model protein drug from the TG-chitosan xerogel was also 
studied by loading with recombinant human INS and different EIs (5 % APR and 10 % GSH). 
Figure 5.7 shows the biphasic cumulative percent release profiles of INS from the various 
formulations with initial burst release resulting from drug adsorbed on the polymer surface. 
INS with an isoelectric point of 5.4 and a net negative charge around pH 6.8 (Brange et al., 
1990; Gursky et al., 1992; cited in Thomsen et al., 2008) exhibited slow release in the second 
phase due to INS-TG-chitosan complexation. Furthermore, possible interaction between GSH 
and INS led to statistically significant difference (p < 0.05) between the total cumulative 
release from formulations with 10 % GSH and the control formulation with no EI. The 
percent release of INS from the formulation containing APR was also found to be statistically 
different from that of the control formulation (p < 0.05). However, the release of INS was 
affected to different extents by the two different EIs employed. The release from APR 
containing xerogels showed a higher release than that from the GSH loaded xerogels, which 
was statistically significant (p < 0.05). This suggests that the EIs may have different 
interactive mechanisms with the thiolated polymer as well as the model protein drug, and may 
explain the differences observed in the effect of the EIs on the INS release from the xerogels. 
  
 
Figure 5.7: Cummulative percent INS release from TG-chitosan xerogels showing the effect 
of different EIs on release profiles in 0.01M PBS at 37 ± 0.1 °C (n=4 mean ± SD) using 
Franz-type diffusion cell. 
 
5.3.4 Evaluation of drug release kinetics from chitosan and TG-chitosan xerogels 
 Model dependent methods based on mathematical functions were used to describe the 
dissolution profiles of BSA and INS released from the chitosan and TG-chitosan xerogels. 
These included zero order, first order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas 
models which have been represented by the plots in Figure 5.8 (a-e) based on the initial 
linear portions of the release profiles and for the Korsmeyer ± Peppas model, initial 60 % 
of cumulative drug release. Release parameters obtained from fitting experimental 
dissolution release data to the different kinetic equations have been summarised in Tables 
5.4-5.6.  
 The in-vitro release profiles of BSA from the chitosan/TG-chitosan xerogels could 
best be described by first order kinetic model as the plots showed highest linearity (R2 = 
0.9791 ± 0.9957) (Table 5.4). This indicates that the amount of drug released is dependent 
on the matrix drug loading irrespective of formulation process. First order kinetics has 
been proposed as the most appropriate model for dosage forms containing water-soluble 
drugs in porous matrices (Narashimhan et al., 1999; Silvina et al., 2002, cited in Dash et 
al., 2010). The release of BSA from all formulations also displayed close fitting with 
Hixson-Crowell cube root model (R2 = 0.9743 ± 0.9919) (Table 5.4) which suggests that 
the drug release mechanism was by dissolution and changes in the surface area and 
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dimensions of the xerogel (Rahman et al., 2011). The Higuchi plots however showed less 
linearity (R2 = 0.7050 ± 0.9751) compared with the other models an indication that 
diffusion was not the major driving force for the release of BSA from the xerogels.  
 
Figure 5.8: Representative plots of experimental release data of protein drug loaded 
chitosan/TG-chitosan xerogels fitted into different kinetic models, showing  (a) Zero order (b) 
First order (c) Higuchi (d) Hixson-Crowell cube root law and (e) Korsmeyer-Peppas. 
 
To confirm the release mechanism, the release data were fitted into Korsmeyer-Peppas 
equation. Good linearity (R2 = 0.9796 ± 0.9847) (Table 5.4) was observed for all formulations 
except chitosan-BSA (dialysed/annealed) (R2 = 0.9369) (Table 5.4). The slope (n) values 
which characterises the release mechanism of drugs from cylindrical matrices as described in 
Table 5.2, ranged from 0.4855 ± 1.6348. The undialysed chitosan-BSA xerogel showed an 
anomalous or non-Fickian diffusion (0.45 < n <0.89) release mechanism which was similar to 
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that of non-annealed dialysed chitosan-BSA xerogel. This is consistent with the results 
obtained by Chavda and Patel (2010) for a chitosan superporous composite hydrogel-based 
floating drug delivery system. Furthermore, the thiolated (annealed/non-annealed) as well as 
the dialysed annealed chitosan xerogels displayed n > 0.89 values, an indication of a super 
case-II transport mechanism where drug release rate is controlled by more than one process 
(erosion and diffusion) (Shoaib et al., 2010). None of the formulations could fit a zero order 
model (R2 = 0.8750 ± 0.9705) as the release mechanism is concentration dependent and the 
drug under investigation is not a poorly soluble drug (Narashimhan et al., 1999, cited in Dash 
et al., 2010).  
Formulations containing GSH as EI in TG-chitosan xerogels displayed release 
mechanisms closely related to first order, Hixson-Crowell and Korsmeyer-Peppas kinetic 
models (Table 5.5) as described above. The mechanisms observed were concentration and 
dissolution controlled for all the formulations. TG-chitosan-BSA and TG-chitosan-GSH-BSA 
10 % showed diffusional exponent values 0.45 < n < 0.89 which confirms the non-Fickian 
diffusion or anomalous release mechanism. The mechanism for the TG-chitosan-GSH-BSA 5 
% was a super case-II transport. Again Higuchi linearity was low for all formulations (R2 = 
0.7283 ± 0.9611) (Table 5.5), indicating that release was not predominantly by diffusion. The 
addition of GSH did not considerably affect the mechanism of release of BSA from the TG-
chitosan xerogels. 
The release parameters of INS loaded TG-chitosan xerogels with different EIs are 
shown in Table 5.6. Higher linearity was observed with first order and Hixson-Crowell 
models for the control TG-chitosan-INS and the TG-chitosan-INS-APR (5 %) formulations, 
which is consistent with data obtained from other TG-chitosan xerogels loaded with BSA. 
The introduction of 10 % GSH to the INS loaded TG-chitosan xerogel however, gave release 
parameters that showed higher linearity with Korsmeyer-Peppas model (R2 = 0.9565) (Table 
5.6) followed by first order (R2 = 0.9340) and Hixson-Crowell (R2 = 0.0.9336). In addition to 
evaluating the INS loaded xerogels with different EIs, TG-chitosan loaded with BSA was 
further examined with APR as an EI. The release parameters similarly showed better linearity 
with first order, Hixson-Crowell and Korsmeyer-Peppas models (Table 5.6). These further 
support the suggestion that more than one mechanism was responsible for the release which 
could include concentration, xerogel morphology and diffusion. The diffusional coefficients 
(n > 0.89) for all formulations indicated a super case II transport which confirms the 
involvement of more than one mechanism of drug release. 
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Table 5.4: Release parameters obtained from fitting experimental drug dissolution (release) data to different kinetic equations for chitosan and 
TG-chitosan xerogels loaded with BSA.   
Xerogel Zero order First order Higuchi Hixson-Crowell Korsmeyer-Peppas  
KO 
(% min-1) 
R2 K1 
(min-1) 
R2 KH 
(% min-1/2) 
R2 KHC 
(% min-1/3) 
R2 KP 
(% min-n) 
n R2 
Chitosan 
(dialysed/annealed) 
1.009 0.9308 0.0182 0.9838 6.5917 0.7050 -0.0250 0.9743 0.0907 1.6348 0.9369 
Chitosan 
(undialysed) 
0.2505 0.8687 0.0020 0.9906 1.6851 0.9225 -0.0031 0.9907 0.9380 0.6551 0.9796 
Chitosan 
 (Non-annealed) 
1.2626 0.1503 0.0140 0.9791 8.6505 0.9751 -0.0171 0.9692 9.1517 0.4855 0.9815 
TG-chitosan 
(annealed) 
0.8028 0.9584 0.0104 0.9880 5.3437 0.8478 -0.0142 0.9834 1.0032 0.9461 0.9844 
TG-chitosan  
(non-annealed) 
0.8668 0.9671 0.0117 0.9957 5.7670 0.8505 -0.0158 0.9919 1.0967 0.9427 0.9847 
 
K0, K1, KH,  KHC  and KP  are the release rate constants for zero order, first order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas models 
respectively, R2 is the correlation coefficient and n is the release exponent. 
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Table 5.5: Release parameters obtained from fitting experimental drug dissolution (release) data to different kinetic equations for TG-chitosan 
xerogels loaded with BSA containing GSH using Franz-type diffusion cell.  
Xerogel Zero order First order Higuchi Hixson-Crowell Korsmeyer-Peppas  
KO 
(% h-1) 
R2 K1 
(h-1) 
R2 KH 
(% h-1/2) 
R2 KHC 
(% h-1/3) 
R2 KP 
(% h-n) 
n R2 
TG-chitosan-BSA 17.356 0.7109 0.2195 0.9703 30.3570 0.9528 -0.2758 0.9663 26.6563 0.6271 0.9863 
TG-chitosan-BSA-
GSH 5 % 
12.262 0.9843 0.2019 9873 20.6610 0.7283 -0.2739 0.9924 9.9129 1.1809 0.9990 
TG-chitosan-BSA-
GSH 10 % 
14.264 0.7864 0.1626 0.9961 24.8900 0.9611 -0.2145 0.9926 21.2520 0.6547 0.9955 
 
K0, K1, KH,  KHC  and KP  are the release rate constants for zero order, first order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas models 
respectively, R2 is the correlation coefficient and n is the release exponent. 
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Table 5.6: Release parameters obtained from fitting experimental drug dissolution (release) data to different kinetic equations for TG-chitosan 
xerogels loaded with INS and BSA containing different EIs.   
Xerogel Zero order First order Higuchi Hixson-Crowell Korsmeyer-Peppas  
KO 
(% min-1) 
R2 K1 
(min-1) 
R2 KH 
(% min-1/2) 
R2 KHC 
(% min-1/3) 
R2 KP 
(% min-n) 
n R2 
TG-chitosan-INS 0.5336 0.8932 0.0087 0.9751 3.4312 0.6254 -0.0125 0.9715 0.0002 3.0443 0.8786 
TG-chitosan-INS-
APR (5 %) 
0.4536 0.9705 0.0062 0.9942 2.9606 0.7260 -0.0090 0.9923 0.0946 1.4121 0.9702 
TG-chitosan-INS-
GSH (10 %) 
0.3144 0.8750 0.0046 0.9340 2.0268 0.6183 -0.0068 0.9336 0.0066 2.0069 0.9565 
TG-chitosan-BSA-
APR (5 %) 
0.6387 0.8925 0.0106 0.9397 4.1171 0.6190 -0.0149 0.9397 0.1606 1.3461 0.9325 
 
K0, K1, KH,  KHC  and KP  are the release rate constants for zero order, first order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas models 
respectively, R2 is the correlation coefficient and n is the release exponent.
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 The effect of formulation processes such as annealing, dialysis and thiolation on drug 
release were further evaluated by comparing the dissolution profiles using the model 
independent difference (f1) and similarity (f2) factors. Chitosan-BSA (annealed/dialysed) was 
chosen as the reference for the dissolution profile comparisons between the various 
formulations as it is the pre-change formulation and the others are the post-change 
formulations (Test formulations). Table 5.7 shows the calculated (f1) and (f2) values for all 
formulations. Similarity was observed only in the annealed TG-chitosan-BSA xerogels and 
the reference annealed/dialysed chitosan-BSA xerogels (f2 = 53.4, f1 = 2.7). This is consistent 
with the statistical student t-test discussed earlier in this section.  
Table 5.7: Model independent difference (f1) and similarity (f2) factors for release profiles of 
BSA (determining the effect of membrane dialysis, annealing and thiolation on formulations) 
with annealed/dialysed chitosan-BSA and annealed TG-Chitosan-BSA xerogels as reference 
(Rj) formulations.  
Formulations (Tj) Reference (Rj): Chitosan-BSA (annealed/dialysed) 
Difference factor (f1) Similarity factor (f2) 
Chitosan-BSA                  
(non-annealed) 
12.5 39.4 
Chitosan-BSA 
 (undialysed) 
67.2 40.4 
TG-Chitosan-BSA 
(annealed) 
2.7 53.4 
 Reference (Rj): TG-Chitosan-BSA (annealed) 
TG-chitosan-BSA  
(non-annealed) 
10.6 46.4 
 
 The dissolution profiles of the non-annealed and undialysed chitosan-BSA xerogels 
were found not to be similar to that of the reference formulation with (f2) values less than 50 
(Table 5.7). The difference factors for the undialysed xerogel (f1 = 67.2) and the non-annealed 
xerogels (f1 = 12.5) were far from zero signifying the difference between the release profiles. 
Using annealed TG-chitosan-BSA as the reference formulation, the difference (f1 = 10.6) and 
similarity factors (f2 = 46.4) for non-annealed TG-chitosan-BSA (test) was also determined 
(Table 5.7). Based on the FDA guidelines, the dissolution profiles were found to be different 
with f2 < 50. Annealing and dialysis therefore led to changes in dissolution profile while 
thiolation did not affect the dissolution profile of the chitosan based lyophilised xerogels. 
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 The effect of an EI concentration on dissolution profile of the thiolated xerogel was 
determined using TG-chitosan-BSA as the reference against TG-chitosan-BSA containing 5 
% and 10 % GSH as the EI. Whereas the dissolution profile of the xerogel with 10 % GSH 
was found to be similar (f2 = 65.4) to the reference, the xerogel with 5 % was not similar (f2 = 
49.8) though the f1 values were similar (Table 5.8). With the 5 % GSH xerogel as the 
reference and the 10 % GSH as the test formulation, the two were found to be similar, having 
f1 and f2 values of 1.3 and 55.2 respectively.  
Table 5.8: Model independent difference (f1) and similarity (f2) factors for release profiles of 
BSA (determining the effect of EI concentration on release) with TG-Chitosan-BSA and TG-
Chitosan-GSH-BSA (5 %) xerogels as reference (Rj) formulations.  
Formulations (Tj) Reference (Rj) : TG-Chitosan-BSA 
Difference factor (F1) Similarity factor (F2) 
TG-Chitosan-GSH-
BSA (5 %) 
11.2 49.8 
TG-Chitosan-GSH-
BSA- (10 %) 
10.1 65.4 
 Reference (Rj): TG-Chitosan-GSH-BSA (5 %) 
TG-Chitosan-GSH-
BSA (10 %) 
1.3 55.2 
 
The dissolution profiles of thiolated chitosan loaded with INS and incorporated with 
different EIs (5 % APR and 10 % GSH) were also evaluated with the model independent 
approach and the difference and similar factors are as shown in Table 5.9. The difference 
factors (f1) were far above 15 for both formulations using TG-chitosan-INS as the reference 
formulation which indicates a highly significant difference. However, the similarity factors 
(f2) were above 50 for both formulations indicating that all the INS containing formulations 
have similar dissolution profiles. Shah et al., (1998) have however argued that f2 comparison 
has been the focus in Agency guidance since it assures similarity in product performance and 
it gives a measure as to which is more sensitive to large differences at any particular time 
point. The comparison between TG-chitosan-APR-INS and TG-chitosan-APR-BSA were also 
found to be similar with an f2 value of 54.1. The different EIs in the INS loaded xerogels did 
not affect the dissolution profile as all formulations were found to be similar. 
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Table 5.9: Model independent difference (f1) and similarity (f2) factors for release profiles of 
INS and BSA (determining the effect of different EIs on release) with TG-Chitosan-INS 
xerogels and TG-Chitosan-APR-INS (5 %) as reference (Rj) formulations.  
Formulations (Tj) Reference (Rj): TG-Chitosan-INS 
Difference factor (F1) Similarity factor (F2) 
TG-Chitosan-APR- 
INS 
25.5 62.0 
TG-Chitosan-GSH-
INS 
53.2 52.0 
 Reference (Rj): TG-Chitosan-APR-INS 
TG-chitosan-APR-
BSA 
28.3 54.1 
 
5.4 Conclusions 
 The effects of formulation processes including membrane dialysis, annealing and 
thiolation on in vitro drug release profiles from chitosan based lyophilised xerogels have been 
studied. Dialysed and annealed chitosan-BSA xerogels exhibited an initial burst release of 
BSA due to high drug loading and a subsequent controlled release phase from chitosan-BSA 
complex. The presence of crystalline NaAc in the undialysed chitosan-BSA xerogel, however, 
resulted in a three-fold reduction in BSA release due to decreased surface area of dispersed 
drug and changes in pH of release media. The 7 hr total cumulative percentage drug release of 
91.5% and 80.1% observed for the annealed and non-annealed chitosan-BSA xerogels 
respectively was due to the annealing process, enabling a porous network which led to ease of 
hydration and consequent improved drug release. Furthermore, annealed TG-chitosan-BSA 
demonstrated higher BSA release compared to non-annealed TG-chitosan-BSA xerogels. The 
reduced total percent release of BSA could be attributed to the reduced cohesiveness of the 
non-annealed xerogels. Although the process of thiolation has been associated with enhanced 
mucoadhesion characteristics, its effect on drug release was not significant as unmodified 
chitosan-BSA and TG-chitosan-BSA xerogels showed no difference in drug release profiles. 
 Adsorption of BSA by GSH, as EI in the TG-chitosan-BSA xerogel caused a 
significant reduction in BSA release and this was not concentration dependent. Similarly, the 
presence of different EIs (5 % APR and 10 % GSH) in INS loaded TG-chitosan xerogels led 
to reduced INS release. However, the influence of GSH with respect to reduction in INS 
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release was much pronounced, indicating the involvement of different mechanisms of 
inhibition by the different enzyme inhibitors. 
 The model dependent mathematical functions used in describing the release profiles of 
BSA from the xerogels showed that first order, Hixson-Crowell and Korsmeyer-Peppas 
equations fitted the dissolution data best, suggesting the complex nature of release based on 
drug concentration, dissolution and polymer characteristics from all the chitosan based 
formulations. The presence of EI did not alter the release mechanism in the TG-chitosan 
xerogel loaded with either BSA or INS which involved more than one process. This was 
confirmed by the release exponents displaying non-Fickian diffusion and super case-II 
transport release mechanisms for all the formulations under investigation.  
 Based on the model independent difference (f1) and similarity (f2) factors, the release 
profiles of annealed and dialysed chitosan-BSA and annealed TG-chitosan-BSA xerogels 
were found to be similar compared to non-annealed chitosan-BSA and non-annealed TG-
chitosan-BSA xerogels. The release profiles of TG-chitosan-BSA and TG-chitosan-GSH-
BSA 10 % were similar against that of TG-chitosan-GSH-BSA 5 %. However, with TG-
chitosan-GSH-BSA 5 % as the reference, the release profile was similar to that of TG-
chitosan-GSH-BSA 10 %. The different EIs in the INS loaded xerogels did not affect the 
release profile of INS from all formulation. Release profiles of BSA and INS xerogels 
containing APR were also similar. 
The principal implication of these findings is the potential application of the novel 
lyophilised system for the delivery of proteins via the buccal mucosa. These in vitro 
characterisations can help to predict the in vivo performance of the various formulations 
which would be expected to impact on the drug release rate and duration based on the varied 
physical properties of the xerogels.  
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CHAPTER SIX 
PERMEATION STUDIES USING EPIORALTM BUCCAL TISSUE AND SHEEP 
BUCCAL TISSUE  
6.1 Introduction  
Buccal drug delivery involves the direct exposure and subsequent permeation of drugs 
through the mucosal tissues for systemic or local effect. The advantages and limitations of 
buccal drug delivery have been reviewed in chapter 1 section 1.5.1.  The diffusion of drugs 
across the buccal mucosa has been studied in controlled environments such as temperature, 
pH and osmolarity using drug permeability models to determine the barrier properties of 
different biological tissues (Nicolazzo & Finnin, 2008, cited in Patel et al., 2012). Generally, 
animal tissues are employed but are however limited compared to human buccal tissue 
because the oral mucosa of animals such as rats and hamsters are keratinised as opposed to 
the non-keratinised human buccal mucosa (Tsutsumi et al., 1999, cited in Patel et al., 2012). 
Results obtained from rabbit buccal mucosa which is partly non-keratinised can be unreliable 
due to identification and isolation of limited tissue (Squier, & Wertz, 1996). Animal species 
such as dogs and monkeys with non-keratinised buccal tissues but thinner mucosal epithelium 
exhibit greater permeability compared to human buccal tissue (Mehta et al., 1991, cited in 
Patel et al., 2012). Researchers have therefore frequently used pig buccal tissue as it 
demonstrates greater correlation to that of humans (Squier, & Wertz, 1996). Recently, 
permeability studies for venlafaxine have also been carried out using sheep buccal mucosa 
(Kumar et al., 2011). Maintaining buccal tissue integrity and viability during isolation and 
storage before experimental testing is crucial to obtaining reliable permeation results (Patel et 
al., 2012). For example, the storage of porcine buccal mucosa in Krebs bicarbonate Ringer 
solution helped to retain its integrity whiles storage in other solutions such as PBS at 4 °C for 
24 h led to loss of epithelial integrity (Kulkarni et al., 2010).  
Buccal epithelial cell culture models grown from hamster cheek pouch did not 
completely differentiate to form a keratinised surface and therefore displayed greater 
permeability to drugs compared to the original tissue. The hamster cell culture model 
therefore mimics the human buccal mucosa and has been deemed suitable for predicting 
human buccal mucosa permeability (Tavakoli-Saberi & Audus, 1989 cited in Patel et al., 
2012). The TR146 cell line, originally from human buccal carcinoma, has also been used as a 
human buccal mucosa model since it shows differentiation patterns closely resembling the 
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human non-keratinised epithelium. It however displays greater permeability compared to 
native human or porcine buccal tissue (Nielsen, & Rassing, 2000).   
The recent development and commercialisation of EpiOralTM buccal construct 
(MatTek, Ashland, MA, USA) has paved the way for better permeation experimental controls. 
In addition, advantages such as cell homogeneity, reasonable cost, availability and ease of use 
have been reported (Sohi et al., 2010). The multilayered buccal tissue model (Figure 6.1) is 
cultured in serum-free medium on the surface of collagen-coated inserts to form three-
dimensional differentiated tissues consisting of an organised basal layer and multiple non-
cornified layers which are histologically and morphologically similar to native human buccal 
tissue (www.mattek.com).  
 
Figure 6.1: Histology of EpiOralTM (buccal phenotype) Formalin fixed, Paraffin embedded, 
Haematoxylin and Eosin (H&E) stained. Available at< http://www.mattek.com/pages/ > 
Accessed [08/07/2012] 
 
The 8 ± 11 cell layered in vitro tissue model has the characteristics of native buccal tissue 
differentiated from human primary oral keratinocytes (Koschier et al, 2011). The naturally 
occurring antimicrobial peptides human beta defensins (HBD-1 and HDB-3) are 
constitutively expressed by the tissue (www.mattek.com). 
The current chapter investigates the permeation of the protein model drugs; BSA and 
INS released from optimised chitosan based xerogels using human equivalent EpiOralTM 
buccal tissue construct. Further, the effect of EIs on the permeation of INS released from TG-
chitosan xerogels was examined with sheep buccal tissues and the cumulative amounts of INS 
permeating correlated with data from the EpiOralTM experiment. 
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6.2 Materials and Methods  
6.2.1 Materials 
Table 6.1: Details of materials used in permeation studies 
Material  Description  Supplier 
EpiOralTM Buccal Tissue Kit ORL-200 MatTek, Ashland MA, USA 
PBS tablets pH 7.4 Sigma-Aldrich, (Gillingham, UK) 
%UDGIRUG¶VUHDJHQW B6916-500ML Sigma-Aldrich, (Gillingham, UK) 
BSA powder A7906-100 G Sigma-Aldrich, (Gillingham, UK) 
Human INS 12643-50MG Sigma-Aldrich, (Gillingham, UK) 
3-[4,5-dimethylthiazol-2-yl] 
2,5-diphenyltetrazolium 
bromide (MTT) 
M5655-500MG 
 
Sigma-Aldrich, (Gillingham, UK) 
Isopropanol I9030-500ML Sigma-Aldrich, (Gillingham, UK) 
Krebs-Ringer Bicarbonate 
Buffer 
K4002-10X1L Sigma-Aldrich, (Gillingham, UK) 
 
6.2.2 EpiOralSHUPHDWLRQVWXGLHV 
 0.3 mL of EpiOralTM assay media (MatTek, Ashland, MA) warmed to 37 °C, was 
pipetted into 4 wells of 24 well plates and labelled 1 hr equilibration. The remaining wells 
were filled with sterilised 0.01M PBS (pH 7.4) as the receiver fluid and labelled as 0.5, 1.0, 
2.0, 3.0 and 4.0 hrs. The EpiOralTM constructs cultured on the surface of tissue inserts with 
diffusional surface area of 0.6 cm2 were transferred aseptically into the EpiOralTM assay media 
filled 24 well plates. The tissues were then placed in a 37 ± 1 °C, 5 ± 1% CO2 incubator for 1 
hr to equilibrate. The EpiOralTM tissue inserts were then transferred into the 0.5 hr labelled 
receiver fluid,  treated with 0.5 mL of donor solution (0.01M PBS, pH 6.8, simulating salivary 
fluid) into which was added 15 mg of drug loaded laminated  xerogels (test materials) with 
the mucoadhesion layer in contact with the apical surface of the EpiOralTM tissue and returned 
to the incubator. The tissues were moved to the 1 hr wells after 0.5 hrs of elapsed permeation 
time. Similarly the tissues were moved after 2.0, 3.0 and 4.0 hrs of total elapsed time. ȝ/
of the receiver fluid was sampled at the predetermined time intervals, treated with 1 mL 
%UDGIRUG¶V UHDJHQWDQG WKHDEVRUEDQFHPHDVXUHGDWQPDQGQPIRU OLQHDULVDWLRQRI
absorbance using a Multiskan EX microplate photometer equipped with Ascent software 
(Thermo Scientific, Hampshire UK). A graphical representation of the full procedure is 
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shown in Figure 6.2. The concentration of the BSA released from the xerogels was 
determined by interpolation from the linearized calibration curve (r 2 > 0.99) (chapter 3, 
Figure 3.28) and permeation parameters such as the flux (J), apparent permeability coefficient 
(Papp) and enhancement factor (EF) were  determined using equations 6.1, 6.2 and 6.3 
respectively.   
 
J =  dQ/dt .1/A                                           equation 6.1 
Papp =  dQ/dt.1/A .1/C                                equation 6.2 
EF = Papp (formulation)/ Papp (pure drug)  equation 6.3 
 
where J is the steady state flux, dQ/dt is the amount of drug permeated, A is the effective 
diffusion area, C is the initial drug concentration and Papp is the apparent permeability 
coefficient (Fetih et al., 2011).  
 
 
 
Figure 6.2: Graphical representation of the EpiOralTM experimental procedure 
 
 
1 hr equilibration of EpiOralTM
buccal tissue in assay medium in a 
37 ± 1 °C, 5 ± 1% CO2 incubator. 
EpiOralTM buccal tissues transferred 
into well plates containing receiver 
fluid and treated with donor solution 
and drug loaded xerogel  
EpiOralTM buccal tissues are moved 
into new receiver fluids (0.01M PBS 
pH, 6.8) after elapsed specified 
permeation time (up to 4hrs)
Receiver fluid sampled at 
predetermined time intervals and 
analysed for amount of drug 
permeated using microplate
photometer.
EpiOralTM on 
tissue insert
EpiOralTM
assay medium
Drug loaded 
xerogel 
Well plate
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Permeation studies were conducted for the following optimised xerogels in Table 6.2. Non-
treated EpiOralTM tissue was used as the negative control while 10 mg/mL and 4 mg/mL 
solutions of BSA and INS respectively were used as positive controls for BSA and INS 
containing xerogels. 
 
Table 6.2 Optimised drug loaded xerogels used for permeability studies 
BSA loaded xerogels INS loaded xerogels 
Chitosan-BSA TG-chitosan-INS 
TG-chitosan-BSA TG-chitosan-GSH-INS 
TG-chitosan-GSH-BSA TG-chitosan-APR-INS 
 
6.2.3 Tissue integrity (MTT assay) 
After 4 hrs of permeation experiment, the EpiOralTM tissue inserts were transferred into 24 
well plates pre-filled with MTT solution (0.3 mL) dissolved in PBS (5 mg/mL), incubated for 
3 hrs and the MTT medium was gently aspirated from all wells. After the incubation, the 
cultures were extracted in 2 mL of acidified isopropanol for 2 hrs with gentle shaking (120 
rpm). Two, 200 µL aliquots of extract were placed into 96 well plates and the absorbance of 
the extracted (purple coloured) formazan was determined using a Multiskan EX microplate 
photometer equipped with Ascent software (Thermo Scientific, Hampshire UK) at 570 nm. 
Viable cells had the greatest amount of MTT reduction and hence the highest absorbance 
values. Relative cell viability was calculated for each tissue as % of the mean of the negative 
control tissues. Data was processed from three replicates for the mean percentage viability. 
 
6.2.4 In vitro buccal permeation studies (sheep buccal tissue)  
 In vitro INS permeation through sheep buccal mucosa was carried out using Franz-
type diffusion cell with diffusional surface area 0.6 cm2. Fresh sheep buccal mucosa obtained 
from a local slaughterhouse was immediately kept in Krebs-Ringer bicarbonate buffer 
(modified with sodium carbonate) and used within 2 hrs of slaughter (Patel et al., 2007). The 
underlying fat and loose tissues were removed and the mucosal membrane was washed with 
physiological PBS (pH 6.8) at 37 °C. The obtained buccal mucosa membrane was mounted 
between the donor and receiver compartments of the Franz-type diffusion cell, with the 
epithelial side facing the donor compartment (Attia et al., 2004). The receiver chamber was 
filled with 8 mL of 0.01 M PBS (pH 7.4) at 37 °C and uniform mixing was provided by 
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magnetic stirring at 150 rev/min. After an equilibration period of 30 minutes, 0.5 mL of 0.01 
M PBS (pH 6.8) was placed in the donor compartment and 15 mg of the INS loaded 
laminated xerogels were placed in the donor chamber with the mucoadhesion layer in contact 
with the epithelial surface. The chambers were held together by cell clamp and sealed with 
parafilm to limit evaporation. At predetermined time intervals, samples (1 mL) were 
withdrawn from the sampling port of the receiver compartment and replaced with the same 
amount of PBS to maintain a constant volume for 4 hrs. 50 ȝ/RIWKHVDPSOHGPHGLXPZDV
treated with 1 mL of Bradford¶VUHDJHQWDQGSHUPHDWLRQSDUDPHWHUVGHWHUPLQed as described 
in section 6.2.2. 
 
6.2.5 Permeation correlation between EpiOralTM and sheep buccal tissues. 
 The effect of the EI aprotinin (APR) on the permeation of INS via the tissue 
engineered buccal epithelium and the sheep buccal tissue was further investigated by 
constructing a correlation curve for EpiOralTM cumulative permeation against cumulative 
permeation of TG-chitosan-INS through sheep buccal tissue. The linear regression (R2) 
coefficient obtained from the curve was compared with that obtained from TG-chitosan ±
APR-INS curve.  
 
6.3 Results and discussion 
6.3.1 EpiOralTM permeation studies 
The generally low flux across the buccal mucosa poses a significant challenge for 
buccal drug delivery (Langoth et al., 2005).  The intercellular links in the buccal tissue is 
characterised by desmosomes and tight junctions, however the permeation of peptide drugs 
across the buccal epithelium is believed to be mediated via the paracellular route by passive 
diffusion (Rathbone et al., 1994, cited in Langoth et al., 2005).  The cumulative permeation 
curves of BSA released from the chitosan based xerogels is shown in Figure 6.3. Table 6.3 
shows the permeation parameters of BSA and INS for all the chitosan based xerogels used in 
this study. A lag-time of 30 minutes was generally observed for the BSA and INS permeation 
for all the xerogels examined using the EpiOralTM buccal tissue construct. For BSA 
permeation studies, the highest permeation enhancement was observed for the TG-chitosan 
followed by TG-chitosan-GSH and then unmodified chitosan xerogels. Ranaldi et al., (2002, 
cited in Langoth et al., 2005) have demonstrated the ability of unmodified chitosan to enhance 
paracellular absorption across the buccal membrane. The enhancement factor showed a 12.3-
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fold increase in transport of BSA from the unmodified chitosan xerogels across the EpiOralTM 
buccal tissue construct compared to the BSA control. This increase seems to be dependent on 
the ability of the cationic polymer to interact with the negatively charged membrane, resulting 
in structural reorganisation of the tight junction associated proteins (Schipper et al, 1997; 
Senel, & +ÕQFDO, 2001). This is consistent with the results obtained by Schipper et al., (1999) 
in which chitosan produced a 10- to 15-fold permeation enhancement of atenolol through 
mucus-free Caco-2 layers.  
 
 
Figure 6.3: Cumulative permeation curves of BSA released from chitosan based xerogels 
 
Table 6.3: Permeation parameters of xerogels from EpiOralTM buccal construct 
Formulation Flux 
ȝJFP2 /hr) 
(n=3, mean ± SD) 
Apparent permeability 
coefficient (x 10-2 cm2 /hr) 
(n=3, mean ± SD) 
Enhancement 
factor 
Chitosan-BSA 4.2 ± 1.0 4.2 ± 0.9 12.3 
TG-chitosan ±BSA 4.0 ± 0.8 4.6 ± 0.6  13.7 
TG-chitosan-GSH-BSA 3.7 ± 0.7 4.2 ± 1.1 12.6 
TG-chitosan-INS 1.3 ± 0.2 3.1 ± 0.7 1.8 
TG-chitosan-GSH-INS 0.3 ± 0.1 1.3 ± 0.2 0.6 
TG-chitosan-APR-INS 1.2 ± 0.3 3.8 ± 0.5  1.8 
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The slight improvement in permeation for the thiolated chitosans over that of 
unmodified chitosan (13.7-fold) could have stemmed from their enhanced bioadhesive 
properties (see chapter 3) that allowed the polymer to act as a penetration enhancer due to the 
covalent attachment of thioglycolic acid. Free thiol groups have been shown to reduce 
oxidised glutathione found on the surface of buccal mucosa. The reduced glutathione inhibits 
the enzyme protein-tyrosine-phosphatase which subsequently leads to the phosphorylation of 
occludin resulting in the opening of tight junctions, therefore, allowing the transport of 
macromolecules across the membrane (Barrett et al., 1999). It must however, be added that 
the presence of tight junctions in the human equivalent buccal tissue (EpiOralTM) could not be 
confirmed in this study and this requires further investigation. That notwithstanding, the 
evidence of tight junctions in a similar human equivalent tissue EpiAirwayTM by the same 
manufacturer (MatTek Corporation, www.mattek.com) has been confirmed. Drug 
permeability may also have been increased by the improved drug availability (Figueiras et al., 
2009) at the apical surface of the EpiOralTM due to high drug release from the chitosan based 
xerogels which allows a higher concentration diffusion gradient in the direction of absorption 
across the membrane. 
The addition of reduced GSH which has a dual action as a permeation enhancer as 
well as enzyme inhibitor to TG-chitosan ostensively increases the amount of reduced GSH on 
the membrane. A synergistic effect to further improve the permeation enhancing effect of TG-
chitosan ±GSH xerogel was therefore expected. Furthermore, GSH in combination with 
thiolated polycarbophil was observed to have increased the permeation of sodium fluorescein 
across guinea pig small intestinal mucosa by 2.9-fold (Clausen et al., 2002, cited in Langoth 
et al., 2005). However, this expected improvement in permeation was not achieved in the 
current study as the observed permeation parameters for TG-chitosan-GSH shown in Table 
6.3 were slightly lower than those of TG-chitosan. This could be attributed to the interaction 
between GSH and BSA (Vallee et al., 2008) which may have limited the permeation of BSA 
through the Epi-oralTM buccal tissue construct as was observed in the drug release studies (see 
chapter 5). In addition, the large size of BSA (67 kDa) could have limited its permeability 
through the EpiOralTM buccal tissue however, this will require further investigation. 
The cumulative permeation curve of INS loaded TG-chitosan xerogels with different 
EIs is shown in Figure 6.4. Similar permeation curves were observed for TG-chitosan and 
TG-chitosan-APR xerogels which showed no significant differences (p > 0.05) in the flux and 
enhancement factor (Table 6.3).  
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Figure 6.4: Cumulative permeation curves of INS released from TG-chitosan xerogels 
showing the effect different EI on permeation through EpiOralTM buccal tissue. 
 
The apparent permeability was slightly higher for the TG-chitosan-APR xerogel but 
the difference was not statistically significant (p > 0.05). APR therefore had no significant 
effect on the permeability of INS from the TG-chitosan-APR xerogel through Epi-oralTM. No 
report on expression of enzymatic activities in Epi-oralTM was found in the literature and that 
might possibly explain the insignificant effect of the EI on the permeation of INS through 
Epi-oralTM. A significant reduction in the permeation of INS, approximately half that of pure 
INS solution (control), was however, obtained for the TG-chitosan-GSH xerogel. The 
significant effect of GSH on INS permeation, confirms the apparent chemical interaction of 
the two resulting in the reduced release of INS from the TG-chitosan-GSH xerogel in the 
release studies (see chapter 5). GSH may have had a greater affinity for INS thus its effect on 
inhibiting disulphide bond formation in the thiomer was absent (see chapter 4). The formation 
of disulphide bonds has a limiting effect on xerogel hydration which resulted in poor INS 
release and subsequent reduced permeation through the EpiOralTM buccal tissue construct. 
The permeation enhancing effect of the thiolated chitosan was therefore diminished by the 
presence of GSH-INS interaction. The choice of an EI for a particular protein formulation 
intended for buccal deliver plays a significant role in the permeability of the protein. Based on 
these results, APR appears to be a better EI for the delivery of INS via the buccal mucosa and 
was therefore considered for further evaluation using sheep buccal membrane. 
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6.3.2 Tissue integrity (MTT assay) 
Tissue viability was assessed using the 3-[4,5-dimethylthiazol-2-yl] 2,5-diphenyltetrazolium 
bromide (MTT) reduction assay where yellow MTT is reduced to purple formazan primaril y 
by enzymes located in the mitochondria of viable cells (Koschier et al., 2011). )LJXUHµ$¶
DQGµ%¶VKRZVWKHUHVSHFWLYHFHOOYLDELOLW\GDWDIRU%6$DQG,16FRQWDLQLQJ[HURJHOVH[SRVHG
to the EpiOralTM buccal tissue construct as measured by the MTT assay. 
 
Figure 6.5: EpiOralTM WLVVXHYLDELOLW\VKRZLQJµ$¶%6$FRQWDLQLQJFKLWRVDQEDVHG[HURJHOV
with negative (non-WUHDWHGDQGSRVLWLYH%6$VROXWLRQFRQWUROVµ%¶VKRZVWKHWLVVXH
viability of INS containing xerogels along with negative (non-treated) and positive (INS 
solution) controls.  
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Average percentage viability was plotted for the different test conditions using non-treated 
control as the 100% viable tissue. The cell viability was measured after 4 hrs exposure, to 
measure the toxicity of the chitosan based xerogels. All test conditions maintained > 95 % 
viability as measured by the MTT reduction assay, indicating that the excipient as well as 
model protein drugs had no toxic effect on the cells of the EpiOralTM buccal tissue construct. 
 
6.3.3 In vitro buccal permeation studies (sheep buccal tissue)  
The effect of EI on INS permeation was further investigated using sheep buccal 
membrane (Figure 6.6). The amount of INS permeating was approximately 450-fold higher 
(1700 - 2900 µg/cm2) than was observed from the EpiOralTM studies (4.9 ± 5.2 µg/ cm2). This 
suggests that the sheep buccal membrane is more permeable than the human equivalent buccal 
tissue (EpiOralTM). Linearity was observed for both samples up to 2 hours of permeation (R2 > 
0.98) and followed a first order kinetic release which is concentration dependent but the 
curves levelled off due to a possible change in release kinetics. 30 minutes lag-time was 
observed for INS permeation via the sheep buccal tissue. The permeation parameters (Table 
6.5) indicated that TG-chitosan-APR-INS xerogel had an effect on the biological membrane, 
leading to a 1.7-fold increase in INS permeation compared to TG-chitosan-INS and control 
INS solution. Higher flux and apparent permeability coefficients were obtained for the 
xerogel containing APR. The protease inhibitor (APR) may have minimized the degradation 
of the INS on the sheep buccal mucosa and with a resultant increase in INS permeation.   
 
Figure 6.6:  Cumulative permeation curves of INS released from TG-chitosan xerogels 
showing the effect different EI on permeation through sheep buccal tissue. 
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The enhancement factor (EF = 1) observed for the TG-chitosan-INS xerogel suggests 
that the TG-chitosan had no permeation enhancing effect on the biological membrane 
compared to the control. The results also indicate that TG-chitosan did not limit the release of 
INS from the xerogel. However, due to poor physical contact with the sheep buccal epithelial 
surface or possibly absence (or very little) of mucosal fluid (mucin) on the membrane, no 
significant covalent or electrostatic bond (mucoadhesion) could be established. This is 
plausible as the membrane was initially washed in a physiological fluid during preparation 
before mounting on the donor compartment of the Franz-type diffusion cell, which was later 
filled with 0.01 M PBS without mucin, before data acquisition. Further investigation with 
different physiological fluids will be an interesting to compare with the results obtained. 
 
Table 6.4: Permeation parameters of xerogels from sheep buccal tissue 
Formulation Flux 
(mg/cm2 /hr) 
(n=4, mean ± SD) 
Apparent permeability 
coefficient  (cm2 /hr) 
(n=4, mean ± SD) 
Enhancement 
factor 
TG-chitosan-INS 0.43 ± 0.07 0.19 ± 0.01 1.00 
TG-chitosan-APR-INS 0.72 ± 0.05 0.33 ± 0.03 1.70 
 
6.3.4 Permeation correlation between EpiOralTM and sheep buccal tissues. 
The study has shown that there is good correlation during the in vitro permeation of 
INS between the human equivalent buccal tissue (EpiOralTM) and ex vivo sheep buccal 
membrane (Figures 6.7). It was however, interesting to observe that xerogels with EI 
demonstrated better linear correlation (R2 = 0.9953) than xerogels without EI (R2 = 0.9124). 
This could be due to the lack of interaction between the TG-chitosan and the sheep buccal 
membrane discussed in section 6.3.3 above. In the EpiOralTM study, there were no significant 
differences between the permeability parameters (Table 6.4) however, the experiments with 
sheep buccal membrane showed statistically significant differences between the mean flux (p 
< 0.05) and apparent permeability (p < 0.05) data of the TG-chitosan-INS and the TG-
chitosan-APR-INS xerogels. It is quite clear that the presence of the EI was important in 
enhancing INS permeation through the sheep buccal mucosa but this effect was not significant 
in the EpiOralTM study.  
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Figure 6.7:  Correlation curves RIµ$¶ TG-chitosan-,16DQGµ%¶7*-chitosan-APR-INS 
xerogels using data from EpiOralTM and sheep buccal tissue permeation experiments. 
 
6.3 Conclusions 
 This study has investigated the permeation of BSA and INS released from 
chitosan based xerogels using a commercially available model human equivalent buccal tissue 
(EpiOralTM) and sheep buccal membrane. Permeation parameters obtained for the BSA 
containing xerogels showed significant improvement of 12- to 14-fold increase in permeation 
enhancement compared to control. TG-chitosan xerogels demonstrated slightly higher 
apparent permeability coefficient and enhancement factor over unmodified chitosan. 
However, the addition of GSH as an EI to the TG-chitosan xerogel led to reduced permeation 
parameters due to possible adsorption of BSA by GSH. The presence of GSH in INS 
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containing xerogels further confirmed the effect of the EI on drug permeation through 
EpiOralTM by causing a reduction in the flux, apparent permeability coefficient and 
enhancement factor of TG-chitosan-GSH-INS xerogel compared to those of TG-chitosan-INS 
and TG-chitosan-APR-INS. This study has established that GSH containing xerogels actually 
caused inhibition rather than enhancement of INS permeation. Cells in the tissue engineered 
buccal membrane were however found viable by MTT reduction assay after 4 hrs in contact 
with all the test and control samples.   
INS permeation via the sheep buccal membrane was significantly improved by 
employing APR as an EI in the TG-chitosan xerogel. Thiolated chitosan showed no increase 
in INS permeation relative to control INS permeation due possibly to the reduced mucosal 
fluid as a result of the initial wash-off or absence of mucin on the epithelial surface of the 
sheep buccal membrane for covalent attachment. Good linear correlations were obtained for 
the permeation curves of INS in both the EpiOralTM and sheep buccal membrane experiments 
with the APR containing xerogels showing higher correlation coefficient.  
The need for the presence of an EI in formulations intended for buccal delivery of 
therapeutic proteins has been underscored by this study. The foregoing discussion suggests 
the possibility of predicting experimental in vivo trends for INS permeation through sheep 
buccal membrane with EI containing chitosan based xerogels since a good linear correlation 
between in vitro and ex vivo experiments has been achieved.  
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CHAPTER SEVEN 
SUMMARY CONCLUSIONS AND FUTURE WORK 
7.1 Summary conclusions 
The aim of this project was to develop, formulate, characterise and optimise novel 
lyophilised formulations (xerogels) that will deliver therapeutically relevant protein-based 
drugs via the buccal mucosa route. In this section, a summary of the conclusions on  the 
formulation design, optimisation, analytical characterisation and determination of physico-
chemical properties including hydration, mucoadhesion, release profile and kinetics and 
permeation characteristics of lyophilised chitosan and thiolated chitosan xerogels as potential 
protein drug delivery systems to the buccal mucosa membrane is presented. 
Mucoadhesive lyophilised systems from chitosan and TG-chitosan were developed as 
potential protein drug delivery systems via the buccal mucosa, by lyophilising aqueous gels of 
the polymers. Annealing, plasticisation and cryoprotection procedures were critical in 
obtaining porous and flexible dialysed xerogels. DSC was used to determine an appropriate 
lyophilisation cycle by evaluating thermal events before lyophilisation to select a suitable 
annealing temperature. The annealing step in the lyophilisation cycle helped to obtain the 
desired porous structure for the final optimised formulations. The non drug-loaded xerogel 
formulation containing 10 % (per polymer weight) each of plasticizer (GLY) and 
cryoprotectant (D-MANN) was deemed optimum for drug loading and further development. 
Improved flexibility was obtained by incorporating GLY while the presence of D-MANN in 
the xerogels was critical in preventing protein instability due to perturbation by freezing. The 
removal of NaAc formed as a result of neutralisation of excess acetic by sodium hydroxide in 
the preliminary formulation development stage by membrane dialysis, was essential for 
obtaining optimised xerogels with excellent characteristics for application to the buccal 
mucosa surface. Stable TG-chitosan xerogels were also developed by covalently attaching 
thioglycolic acid to chitosan via amidation using water soluble carbodiimide (EDAC) as 
coupling agent. The optimised xerogels were drug loaded with 50 % and 20 % (per polymer 
weight) of BSA and INS respectively. The final lyophilised xerogel was backed with an 
impervious EC laminate which is expected to ensure uni-directional drug release at the 
mucosal surface. In addition, enzyme inhibitors (reduced GSH and APR) and permeation 
enhancer (Brij 35) were incorporated in the xerogels to offer improved permeability of the 
buccal mucosa. 
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Analytical characterisation of the chitosan based xerogels was carried out using 
various analytical techniques. Structural information on chitosan and TG-chitosan were 
confirmed from 1HNMR and ATR-FT-IR spectra.  89VSHFWURVFRS\XVLQJ(OOPDQ¶VUHDFWLRQ
was employed to quantify the amount of thiol groups immobilised covalently on chitosan to 
obtain TG-chitosan. The difference in polymer molecular weight between chitosan and TG-
chitosan was monitored by GPC, which confirmed the covalent attachment.  ATR-FT-IR and 
CD spectroscopic analyses of the secondary structures of the loaded model protein drugs BSA 
and INS indicated the conformational stability of the proteins. With respect to protein 
physical stability, no multiple glass-transition temperatures were detected by DSC after 
lyophilisation for all formulations except for the undialysed chitosan xerogel. The XRPD 
analysis of the formulated xerogels indicated amorphous structures, however the presence of 
NaAc crystals identified by ATR-FT-IR spectra and XRPD diffractogram and confirmed with 
SEM microscopy resulted in thick walled xerogels for the undialysed chitosan samples. 
Furthermore, the SEM micrographs displayed highly porous xerogels due to annealing which 
allowed for high drug loading capacities of the dialysed and annealed xerogels which also 
exhibited optimal moisture content for maintaining protein stability. Storage of xerogels at 25 
°C/ 60 % RH for six months resulted in protein chemical instability while storage at 5 °C 
maintained protein stability up to six month as per HPLC determination.  
Annealed chitosan xerogel showed significantly higher hydration capacity compared 
to non-annealed xerogel. Membrane dialysis did not have any significant effect on the 
hydration capacity however the presence of process impurity NaAc resulted in xerogels with 
poor structural stability. Annealed TG-chitosan xerogel similarly showed higher hydration 
capacity compared to non-annealed TG-chitosan xerogel however, disulphide bond formation 
in the thiolated xerogel limited the hydration capacity. DTT was used to confirm that the 
hydration capacity is driven by the cross-linked disulphide bond formation. The hydration 
capacity of the xerogels had a direct impact on xerogel mucoadhesion properties. The 
annealed chitosan xerogels showed better mucoadhesion properties compared to non-annealed 
chitosan xerogels. However, undialysed chitosan xerogel demonstrated reduced 
mucoadhesion characteristics due to the presence of NaAc. Improved mucoadhesion 
properties were obtained for the annealed thiolated xerogels compared to non-annealed 
thiolated and unmodified chitosan xerogels. The results also indicated that the effect of EI on 
mucoadhesion was concentration dependent as well as inhibitor specific.  
Formulation processes such as membrane dialysis, annealing and thiolation had 
significantly varying effects on the in vitro drug release profiles from the chitosan based 
lyophilised xerogels using 0.01 M PBS as dissolution medium. An initial burst release of BSA 
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was observed for dialysed and annealed chitosan-BSA xerogels followed by a controlled 
release phase due to chitosan-BSA complexation. Enhanced porosity led to ease of hydration 
and consequent improved drug release in annealed xerogels. A three-fold reduction in BSA 
release was however obtained for the undialysed chitosan-BSA xerogel. Thiolation effect on 
drug release was not significant as unmodified chitosan-BSA and TG-chitosan-BSA xerogels 
showed no difference in drug release profiles. A significant reduction in protein release was 
caused by the presence of EIs in both the BSA and INS containing xerogels to different 
extents.  The release kinetics described by model dependent mathematical functions indicated 
a complex nature of drug release based on drug concentration, dissolution and polymer 
characteristics since the dissolution data from all xerogels best fitted First order, Hixson-
Crowell and Korsmeyer-Peppas equations. The release exponents also displayed non-Fickian 
diffusion and super case-II transport release mechanisms for all the formulations. The 
presence of EI did not alter the release mechanism in the TG-chitosan xerogel loaded with 
either BSA or INS. Similarities in BSA release profiles were found between annealed 
xerogels based on analysis from model independent difference (f1) and similarity (f2) factors. 
The release profiles of TG-chitosan-BSA and TG-chitosan-GSH-BSA 10 % were also similar. 
The different EIs in the INS loaded xerogels did not show any difference in the release profile 
of INS from all formulations. 
The permeation parameters obtained using a commercially available model human 
equivalent buccal tissue (EpiOralTM) for BSA containing xerogels showed significant 
improvement of 12- to 14-fold increase in permeation enhancement compared to control.  
Slightly higher apparent permeability coefficient and enhancement factor were demonstrated 
by TG-chitosan xerogels over unmodified chitosan. However, the addition of GSH as an EI to 
the TG-chitosan xerogels led to reduced permeation parameters. Similarly, GSH in INS 
xerogels caused a reduction in the permeation parameters of TG-chitosan-GSH-INS xerogel 
compared to those of TG-chitosan-INS and TG-chitosan-APR-INS. This study has established 
that GSH containing xerogels actually caused inhibition rather than enhancement of INS 
permeation. On the other hand, APR in the TG-chitosan xerogel significantly improved INS 
permeation via sheep buccal membrane while showing a better linear correlation with 
permeation curve of INS from the EpiOralTM experiment compared to TG-chitosan xerogel 
without APR. 
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7.2 Key research findings 
x Novel chitosan based lyophilised xerogels with excellent mucoadhesion, 
penetration enhancing, enzyme inhibitor and drug release properties have been 
developed. Membrane dialysis was determined to be essential for obtaining 
xerogels with excellent physical characteristics.  
x The research has established that it is essential that the development of 
chitosan based delivery systems for controlled release of therapeutic proteins 
takes into consideration the stability of the protein drug upon storage. In 
addition, to improving stability of proteins within chitosan based systems, 
formulations must be protected from potentially extreme hydrolysing 
conditions to ensure maintenance of protein native structure.  
x The hydration capacity of the developed thiolated xerogels is controlled by the 
presence of disulphide linkages. Thiolation was confirmed to be responsible 
for enhanced mucoadhesion characteristics however the type and concentration 
of EI employed significantly affects the mucoadhesion properties.  These in 
vitro characterisations can help to predict the in vivo performance of the 
various formulations which would be expected to impact on the drug release 
rate and duration, based on the varied physical properties of the xerogels.  
x The need for the presence of an EI in formulations intended for buccal delivery 
of therapeutic proteins has been underscored by this study. The foregoing 
results indicate the possibility of predicting experimental in vivo trends for INS 
permeation through sheep buccal membrane with EI containing chitosan based 
xerogels since a good linear correlation between in vitro and ex vivo 
experiments has been achieved.  
x The foremost implication of these findings is the potential application of the 
novel lyophilised system for the delivery of proteins via the buccal mucosa 
 
7.3 Future work 
1. Mucoadhesion properties of the xerogels could be studied by using animal buccal 
tissue model and the results compared with that obtained in this project. However, 
recent research using hydrogels as substitutes for animal studies is gaining attention 
(Khutoryanskiy, 2011). An investigation of the mucoadhesive characteristics of the 
chitosan based xerogels using hydrogel substitutes will be a useful evaluation tool. 
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2. The long-term stability evaluation for xerogels stored at 5 ± 3 °C would require 
continuity to obtain data to fully establish the stability of xerogels stored at that 
temperature. 
3. Analytical evaluation of protein conformational stability using CD, DSC and FT-IR 
techniques to determine the extent of secondary structural changes after storage of the 
xerogels at ICH conditions of 25 °C/60 % RH is suggested. Possible studies to 
determine the mechanism of degradation will be an interesting research. The 
molecular weight of the chemically degraded proteins could be determined by the use 
of sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
mass spectrometry. 
4. Final product packaging material needs to be investigated and the stability re-
evaluated based on the ICH conditions. 
5. Characterisation of the chitosan based xerogels after loading with other model 
biotechnologically produced protein drugs to compare with INS.   
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APPENDIX B: Manuscripts in preparation 
1. Development characterisation of laminated thiolated chitosan-based lyophilised 
xerogels for potential buccal delivery of macromolecules. 
 
2. Effect of protease enzyme inhibitors on mucoadhesion and release kinetics of 
macromolecules from laminated thiolated-chitosan freeze-dried xerogels. 
 
3. In-vitro permeation studies of insulin using sheep buccal tissue and EpiOralTM buccal 
tissue construct. 
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APPENDIX C: Abstracts and posters from conference proceedings  
1. Accepted abstract for poster presentation - AAPS 2012 
Abstract I.D. AM-12-01660 
 
 
 
Evaluation of enzyme inhibitors on laminated thiolated chitosan xerogels for buccal 
delivery of insulin 
I. Ayensu1, J.C. Mitchell1, J.S. Boateng1                                                                 
     1
 School of Science, University of Greenwich, Central Avenue, Chatham Maritime, 
Kent, UK, ME4 4TB 
 j.s.boateng@gre.ac.uk 
Purpose: This research aims to evaluate the effect of different enzyme inhibitors (EI) on the 
physical characteristics of lyophilised chitosan-thioglycolic acid (TG-chitosan) based 
xerogels as a novel system for buccal mucosa delivery of insulin (INS).  
Method: TG-chitosan was prepared via amide conjugation of chitosan and thioglycolic acid, 
FKDUDFWHULVHG E\ (OOPDQ¶V UHDFWLRQ DQG WKH PROHFXODU ZHLJKW 0: PRQLWRUHG E\ JHO
permeation chromatography (GPC). 1g each of formulated TG-chitosan gels (Table 1) was 
added onto already dried impervious ethylcellulose (EC) films (laminate) in moulds and 
lyophilised. The laminated lyophilised xerogels were characterised by attenuated total 
reflectance-Fourier transform infra red spectroscopy (ATR-FT-IR), circular dichroism (CD), 
in-vitro drug release in 0.1M PBS (pH 7.4) using Franz-type diffusion cell and mucoadhesion 
with a texture analyser. The effect of different EI (aprotinin and glutathione) on 
mucoadhesion and release characteristics, were investigated. 
Results: Lyophilised TG-chitosan xerogels attached onto EC films contained Brij 35 which 
acted as a permeation enhancer while mannitol and glycerol served as cryoprotectant and 
plasticizer respectively. The EC backing was to ensure one directional release of INS. The 
released INS was conformationally stable by ATR-FT-IR and CD analyses. 10 mg of 
glutathione was deemed optimum from preliminary evaluation with varying amounts of 
glutathione. Statistically significant difference (p < 0.01) was observed between the stickiness 
of formulations B and C (Fig.1). There was however, no statistically significant differences (p 
> 0.05), in work of adhesion and cohesion between all the formulations. Formulation B 
showed improved mucoadhesion properties compared to formulations A and C. Fig. 2 shows 
the biphasic % release profiles of INS from the various formulations with initial burst release 
resulting from drug adsorbed on polymer surface. Slow release of INS in the second phase 
was due to INS-TG-chitosan interaction. Furthermore, possible interaction between 
glutathione and INS led to statistical significant difference (p =  0.01) between the % release 
from formulations B and C. Release of INS from formulation A containing aprotinin was not 
significantly different from that of control formulation, C. 
 
Conclusion: Aprotinin showed no significant effect on characteristics of TG-chitosan 
xerogels while glutathione improved in vitro mucoadhesion but with limited INS release.   
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2. Accepted abstract for podium and poster presentation - APS 2012 (UKPHARMSCI) 
Abstract number: 42 
 
 
INTRODUCTION 
Mucosal routes including the buccal membrane offer a 
potential for the delivery of proteins. However, due to 
size exclusion at epithelial barriers, salivary washout and 
peptidase activity, the buccal route may still be limited in 
its potential for protein delivery. This project is aimed at 
preparing a delivery system using chitosan thioglycolic 
acid (TG-chitosan) as the polymer matrix for potential 
buccal mucosa delivery of protein macromolecules. The 
effect of glutathione (GSH) as an enzyme inhibitor on 
xerogel characteristics was also evaluated. 
 
MATERIALS AND METHOD 
 
Conjugation and characterisation of chitosan and 
thioglycolic acid to obtain TG-chitosan were performed 
as previously described [1]. 2g each of formulated gels 
(Table 1) were added unto dried hydrophobic ethyl 
cellulose (EC) films (backing membrane) in moulds and 
lyophilised [2]. 
 
Table 1. Formulation components 
Component Formulations (mg) 
Formulation A Formulation B 
TG-chitosan 100 100 
Mannitol 10 10 
Glycerol 10 10 
Brij 35 10 10 
Glutathione  0 10 
BSA 50 50 
  
The laminated lyophilised xerogels were characterised 
for surface morphology by SEM, swelling capacity (%) 
with or without reducing agent dithiothreitol (DTT), 
mucoadhesion using texture analysis (TA) and  in-vitro 
drug release in 0.1M PBS (pH 6.8) using Franz-type 
diffusion cell. 
 
RESULTS AND DISCUSSION  
 
Flexible and tough xerogels with mannitol as 
cryoprotectant, glycerol as plasticizer and Brij 35 as 
permeation enhancer have been prepared. Statistically 
significant differences (p < 0.05) were observed between 
the % swelling capacity with or without DTT in 
formulation A. This indicates that disulphide formation 
drives the swelling capacity of formulation A but not B 
(Table 2).  
 
Table 2. Formulations % swelling capacities and TA properties 
Samples Swelling capacity  
(%) 
With           Without  
      DTT            DTT 
Texture Analysis 
(In vitro mucoadhesion )  
PAF 
 (N) 
TWA 
(mJ) 
Cohesiveness 
(mm) 
Formulation A 
 
1086.8 ± 5.1 480.0 ±18.2 3.8 ± 0.5 13.2 ± 3.0 9.6 ± 3.3 
Formulation B 
 
849.3 ± 32.6 912.5 ±25.1 5.7 ± 0.9 19.4 ± 3.7   10.4 ± 3.2 
 
 
Improved mucoadhesion properties were achieved with 
the use of GSH (Table 2). To ensure unidirectional 
release of BSA, an impervious backing membrane (EC 
film) was employed (Fig 1). Drug release was facilitated 
by the porous polymeric network of the xerogels (Fig 
1) due to the increased surface area of dispersed drug. 
 A
B
 
Fig. 1 SEM image of xerogel (A) on EC backing membrane (B) 
 
The initial BSA burst release (Fig. 2) was due to drug 
molecules adsorbed on the xerogel surface and high 
initial loading of BSA.  
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Fig. 2. BSA release from formulations (A) and (B). 
A subsequent prolonged release period ensued due to 
BSA-TG-chitosan complexation. A slow diffusion of 
entrapped protein from hydrated xerogels therefore 
occurred. At pH 6.8, however, BSA (isoelectric point 
around 5) is adsorbed by GSH and disulphide formation 
in TG-chitosan limits TG-chitosan-BSA complexation 
leading to higher release of BSA from the TG-chitosan 
xerogels containing no GSH. 
 
CONCLUSION 
 
Laminated lyophilised TG-chitosan based xerogel for 
potential protein delivery via buccal mucosa has been 
developed that incorporates improved mucoadhesion, 
permeation enhancing and enzyme inhibition properties.  
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INTRODUCTION 
Protein drug delivery presents a number of challenges 
including cost, injection site injury, patient non-
compliance and GIT enzyme degradation. Alternate non-
invasive routes of delivery such as the buccal membrane 
have been investigated to overcome these challenges. The 
route may still be limited in its potential for protein 
delivery and mucoadhesive polymers, permeation 
enhancers and enzyme inhibitors (EI) have been 
employed to improve drug permeation. This study 
evaluates the permeability of insulin through lamb buccal 
tissue and EpiOralTM buccal tissue construct. The effect 
of an EI (aprotinin) on permeation using chitosan 
thioglycolic acid (TG-chitosan) as the polymer matrix 
was investigated. 
 
MATERIALS AND METHODS 
TG-chitosan was synthesized via amidation, purified and 
sulfhydryl groups immobilised on chitosan was estimated 
as previously described [1]. The average molecular 
weights (Mw) of chitosan and TG-chitosan were 
monitored with gel permeation chromatography (GPC). 
1g each of formulation gels (Table 1) was overlaid on 
dried impervious ethyl cellulose (EC) films in moulds 
and lyophilised [2].  
 
Table 1. Formulation components 
Component Formulations (mg) 
Formulation A Formulation B 
TG-chitosan 100 100 
Mannitol 10 10 
Glycerol 10 10 
Brij 35 10 10 
Aprotinin 5 0 
Insulin  15 15 
 
 
 
Conformational stability of insulin in the xerogels was 
determined by far-UV circular dichroism (CD). In-vitro 
insulin permeability studies was carried using freshly 
excised lamb buccal tissue mounted on a Franz-type 
diffusion cell and (SL2UDO buccal tissue constructs, 
cultured on the surface of tissue inserts. Tissue viability 
was examined by 3-[4,5-dimethylthiazol-2-yl] 2,5-
diphenyltetrazolium bromide (MTT). The effect of 
aprotinin on permeation was evaluated. 
 
RESULTS AND DISCUSSION  
 
Stable TG-chitosan xerogels containing insulin, glycerol 
(plasticizer) and mannitol (cryoprotectant) with enhanced 
mucoadhesion characteristics, enzyme inhibition 
(aprotinin) and permeation enhancing (Brij 35) properties 
have been prepared. Hydrophilic EC laminate ensured 
unidirectional release of insulin unto mucosal surface. 
The released insulin was conformationally stable via CD 
determination. 
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Fig 1. Permeation of insulin released from formulations A and B.   
Enhanced permeation was observed with formulation A, 
containing aprotinin as EI in lamb buccal tissue (Fig.1) 
with a permeation coefficient of 0.33 cm2/hr compared to 
0.19 cm2/hr for formulation B. No significant difference 
in permeation coefficient of formulations was observed 
with EpiOralTM tissue (Table 2) 
Table 2. Permeation coefficients of insulin through both tissues 
 
 
Buccal tissue 
 Lamb 
 
Epi-oral 
 A B A B 
Permeation coefficient (cm2 /hr) 0.33 0.19 0.04 0.04 
 
 
Permeation correlation between lamb and EpiOralTM 
tissues was however, better in the formulation containing 
aprotinin (Fig. 2) compared to formulation without the 
EI.  
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2.5
3
3.5
4
4.5
5
5.5
0 0.5 1 1.5 2
F
o
rm
u
la
ti
o
n
 B
 p
e
rm
e
a
ti
o
n
 (
E
p
i-
o
ra
l)
Formulation B permeation (Lamb)
R² = 0.9953
3.5
4
4.5
5
0 0.5 1 1.5 2 2.5 3
fo
rm
u
la
ti
o
n
 A
 p
e
rm
e
a
ti
o
n
 (
E
p
i-
o
ra
l)
Formulation A permeation (Lamb)
 
Fig 2.  Permeation correlation between lamb and EpiOralTM buccal 
tissues.   
Tissues were deemed viable at the end of the permeation 
studies. 
 
CONCLUSION 
 
The inclusion of aprotinin in TG-chitosan xerogels 
improved insulin permeation in lamb buccal tissue and 
correlated with permeation through the EpiOralTM buccal 
tissue construct. 
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